Document:

EX-10.28

 Exhibit 10.28 

EXECUTION VERSION 
 LICENSE
AGREEMENT 
 by and between 

DICERNA PHARMACEUTICALS, INC., 

on the one hand, 
 and 

PROTIVA BIOTHERAPEUTICS INC. 
 and

 TEKMIRA PHARMACEUTICALS CORPORATION 

on the other hand 
 Dated:
November 16, 2014 
 THE COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 406
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE
INDICATED IN THIS EXHIBIT WITH “*****”. 

 TABLE OF CONTENTS 

 

							
	 	    	 	  	Page	 
		
	 ARTICLE I – DEFINITIONS
	  	 	2	  
			
	 1.1
	    	 General
	  	 	2	  
			
	 1.2
	    	 Interpretation
	  	 	9	  
		
	 ARTICLE II – LICENSE GRANTS AND RELATED RIGHTS
	  	 	10	  
			
	 2.1
	    	 License Grants to Dicerna
	  	 	10	  
			
	 2.2
	    	 Sublicensing
	  	 	10	  
			
	 2.3
	    	 Grant Back
	  	 	11	  
			
	 2.4
	    	 Retained Rights
	  	 	11	  
			
	 2.5
	    	 Rights in Bankruptcy
	  	 	11	  
			
	 2.6
	    	 Contractors
	  	 	11	  
		
	 ARTICLE III – FINANCIAL PROVISIONS
	  	 	12	  
			
	 3.1
	    	 Upfront Payment and Milestone Payments
	  	 	12	  
			
	 3.2
	    	 Royalty Payments
	  	 	13	  
			
	 3.3
	    	 Royalty Reports; Expense Reports; Records and Audits
	  	 	13	  
			
	 3.4
	    	 Payment Procedure
	  	 	14	  
			
	 3.5
	    	 Term of Payments
	  	 	15	  
		
	 ARTICLE IV – ADDITIONAL OBLIGATIONS
	  	 	15	  
			
	 4.1
	    	 Obligations of Protiva
	  	 	15	  
			
	 4.2
	    	 Obligations of Dicerna
	  	 	15	  
			
	 4.3
	    	 Other Obligations and Agreements of the Parties
	  	 	15	  
		
	 ARTICLE V – INTELLECTUAL PROPERTY
	  	 	16	  
			
	 5.1
	    	 Ownership
	  	 	16	  
			
	 5.2
	    	 Prosecution and Maintenance of Patents
	  	 	16	  
			
	 5.3
	    	 Third-Party Infringement of Protiva Patents and Tekmira Patents
	  	 	16	  
			
	 5.4
	    	 Defense of Claims Brought by Third Parties
	  	 	18	  
		
	 ARTICLE VI – CONFIDENTIAL INFORMATION AND PUBLICITY
	  	 	18	  
			
	 6.1
	    	 Limitation of Disclosure
	  	 	18	  
			
	 6.2
	    	 Non-Disclosure of Confidential Information
	  	 	18	  
			
	 6.3
	    	 Exceptions
	  	 	19	  
			
	 6.4
	    	 Permitted Uses; Protection
	  	 	19	  

  
 -i- 

 TABLE OF CONTENTS 

(continued) 
  

							
	 	    	 	  	Page	 
			
	 6.5
	    	 Permitted Disclosures
	  	 	20	  
			
	 6.6
	    	 Press Release
	  	 	20	  
		
	 ARTICLE VII – INDEMNIFICATION AND INSURANCE
	  	 	20	  
			
	 7.1
	    	 Protiva Indemnification
	  	 	20	  
			
	 7.2
	    	 Dicerna Indemnification
	  	 	21	  
			
	 7.3
	    	 Tender of Defense; Counsel
	  	 	21	  
			
	 7.4
	    	 Insurance
	  	 	22	  
		
	 ARTICLE VIII – TERM AND TERMINATION
	  	 	22	  
			
	 8.1
	    	 Term
	  	 	22	  
			
	 8.2
	    	 Termination for Material Breach
	  	 	22	  
			
	 8.3
	    	 Termination for Failure to Actively Develop or Commercialize
	  	 	23	  
			
	 8.4
	    	 Challenges of Protiva’s Patents or Tekmira Patents
	  	 	23	  
			
	 8.5
	    	 Rights in Bankruptcy
	  	 	23	  
			
	 8.6
	    	 Consequences of Termination; Survival
	  	 	24	  
			
	 8.7
	    	 Remedies
	  	 	24	  
		
	 ARTICLE IX – MISCELLANEOUS
	  	 	24	  
			
	 9.1
	    	 Representations and Warranties
	  	 	24	  
			
	 9.2
	    	 Force Majeure
	  	 	27	  
			
	 9.3
	    	 Consequential Damages
	  	 	28	  
			
	 9.4
	    	 Assignment
	  	 	28	  
			
	 9.5
	    	 Notices
	  	 	28	  
			
	 9.6
	    	 Independent Contractors
	  	 	29	  
			
	 9.7
	    	 Governing Law; Dispute Resolution; Arbitration
	  	 	29	  
			
	 9.8
	    	 Severability
	  	 	31	  
			
	 9.9
	    	 No Implied Waivers
	  	 	31	  
			
	 9.10
	    	 Headings
	  	 	31	  
			
	 9.11
	    	 Entire Agreement; Amendment
	  	 	31	  
			
	 9.12
	    	 Waiver of Rule of Construction
	  	 	31	  
			
	 9.13
	    	 No Third-Party Beneficiaries
	  	 	31	  

  
 -ii- 

 TABLE OF CONTENTS 

(continued) 
  

							
	 	    	 	  	Page	 
			
	 9.14
	    	 Further Assurances
	  	 	32	  
			
	 9.15
	    	 Performance by Affiliates
	  	 	32	  
			
	 9.16
	    	 Counterparts
	  	 	32	  

  
 -iii- 

 LICENSE AGREEMENT 

This LICENSE AGREEMENT (this “Agreement”) is entered into as of November 16, 2014 (the “Effective
Date”), by and between Dicerna Pharmaceuticals, Inc., a Delaware corporation with offices at 480 Arsenal Street, Building 1, Suite 120, Watertown, MA 02472 USA and its Affiliates (“Dicerna”), on the one hand, and Protiva
Biotherapeutics Inc., a British Columbia corporation with a principal place of business at 100-8900 Glenlyon Parkway, Burnaby, B.C., Canada V5J 5J8 (“Protiva”), and Tekmira
Pharmaceuticals Corporation, a British Columbia corporation with a principal place of business at 100-8900 Glenlyon Parkway, Burnaby, B.C., Canada V5J 5J8 (“Tekmira”), on the other hand.

 RECITALS 
 WHEREAS,
Protiva and its Affiliates (as defined below) possess, and develop and improve from time to time Protiva Patents and LNP Technology (each as defined below); 

WHEREAS, Dicerna possesses and develops and improves from time to time intellectual property relating to Dicerna Material (as defined below);

 WHEREAS, pursuant to a Material Transfer Agreement, dated August 13, 2014, among Dicerna, Protiva and Tekmira (the
“MTA”), the parties performed certain studies in order to determine the potential utility of the Licensed Intellectual Property (as defined below) as it relates to the Product (as defined below) as the basis of this Agreement, with
the intent to provide for further studies and activities to formulate, develop for regulatory approval, and commercialize one or more products; 

WHEREAS, the Parties are, contemporaneously herewith, entering into a Supply Agreement, pursuant to which Protiva shall Manufacture and supply
to Dicerna the Product for certain purposes in accordance with the terms set forth therein; 
 WHEREAS, Protiva desires to grant Dicerna
licenses to the Protiva Intellectual Property (as defined below) to Develop, Manufacture and Commercialize (each as defined below) Products directed to treatment of PH1 upon the terms and subject to the conditions set forth in this Agreement; 

WHEREAS, Tekmira desires to grant Dicerna licenses to the Tekmira Patents (as defined below) to Develop, Manufacture and Commercialize
Products directed to treatment of PH1 upon the terms and subject to the conditions set forth in this Agreement; and 
 WHEREAS, Tekmira is
the parent of Protiva and is willing to guarantee Protiva’s performance under this Agreement, upon the terms and subject to the conditions set forth in this Agreement. 

NOW, THEREFORE, in consideration of the mutual covenants contained herein, and other good and valuable consideration, the receipt of which is
hereby acknowledged, Dicerna and Protiva enter into this Agreement effective as of the Effective Date: 

 ARTICLE I – DEFINITIONS 

1.1 General. When used in this Agreement, each of the following terms, whether used in the singular or plural, shall have the meanings
set forth in this Article I. 
 “Affiliate” means, with respect to a Person, any corporation, company, partnership, joint
venture or firm which controls, is controlled by, or is under common control with such Person. For purposes of the foregoing sentence, “control” means (a) in the case of corporate entities, direct or indirect ownership of at least
fifty percent (50%) of the stock or shares having the right to vote for the election of directors, or (b) in the case of non-corporate entities, direct or indirect ownership of at least fifty percent (50%) of the equity interest with
the power to direct the management and policies of such non-corporate entities. 
 “Agreement” has the meaning set forth in
the introductory paragraph. 
 “Applicable Laws” means all applicable laws, statutes, rules, regulations, guidelines,
guidances, ordinances, orders, decrees, writs, judicial or administrative decisions and the like of any nation or government, any state or other political subdivision thereof, any entity exercising executive, judicial, regulatory or administrative
functions of or pertaining to government (including any Governmental Authority), any tribunal or arbitrator of competent jurisdiction, and any trade organization whose regulations have the force of law. 

“Arbitrators” has the meaning set forth in Section 9.7(b). 

“CMO” means a contract manufacturing organization. 

“Code” has the meaning set forth in Section 2.4(b). 

“Commercialize” or “Commercialization” means, excluding Manufacturing, any and all activities directed to
marketing, promoting, distributing, importing, having imported, exporting, having exported, selling and having sold products and services, including, subject to the terms of this Agreement, having Third Parties conduct such activities on behalf of
the Person receiving the rights to Commercialize. 
 “Commercially Reasonable Efforts” means the efforts and resources that
would reasonably be used (including the promptness with which such efforts and resources would be applied) by a similarly sized company within the biopharmaceutical industry for the pharmaceutical or clinical development, manufacture or
commercialization of a pharmaceutical product of similar market and profit potential and at a similar stage in development or product life as compared to the Product or for the other activities to which this term applies. 

“Confidential Information” means all confidential information and confidential materials, patentable or otherwise, of a Party
disclosed by or on behalf of such Party to the other Party before, on or after the Effective Date in connection with the discussions and negotiations pertaining to, or in the course of performing, this Agreement, the Supply Agreement or the Quality
Agreement, including the terms of such agreements, including chemical substances, equipment, data, reports, Know-How, sources of supply, patent positioning, business plans, and also each Party’s proprietary and confidential information of Third
Parties in possession of such Party under an obligation of confidentiality, whether or not related to making, using or selling the Product. 

  
 2 

 “Control,” “Controls” or “Controlled by”
means, with respect to Licensed Intellectual Property, the possession of (whether by ownership or license, other than pursuant to this Agreement), or the ability of Protiva or Tekmira, as applicable, to grant access to, or a license or sublicense
of, the Licensed Intellectual Property as provided for herein. 
 “Cover,” “Covers” or “Covered
by” means, with respect to the Product, that, but for ownership of or a license or sublicense granted under a Valid Claim of a Protiva Patent, the Development, Manufacture, or Commercialization with respect to the Product would infringe
such Patent (or, if such Patent is a patent application, would infringe a patent issued from such patent application based on the claims pending in the patent application as of the moment the determination of “Cover,” “Covers,”
or “Covered by” is being made). 
 “CTA” means a Clinical Trial Application filed with the national competent
authority in an EU member state for regulatory approval of a clinical trial of the Product, including all amendments and supplements to the application. 

“Develop,” “Developing” or “Development” means Manufacturing and any and all activities and
studies required to develop products and services for Regulatory Approval or for Commercialization, including, subject to the terms of this Agreement, having Third Parties conduct such activities and studies on behalf of the Person receiving the
rights to Develop. 
 “Dicerna” has the meaning set forth in the Preamble. 

“Dicerna Indemnitees” has the meaning set forth in Section 7.1. 

“Directed to” means, in respect of any Product, the initial Development Program, the initial IND and the initial NDA
submitted with a Regulatory Authority for Regulatory Approval in respect of such Product are intended for the treatment of PH1. 

“Disclosing Party” means the Party that discloses its Confidential Information. 

“Discover”, “Discovering” or “Discovery” means any and all research or discovery activities
in respect of products and services, including, subject to the terms of this Agreement, having Third Parties conduct such activities on behalf of the Person receiving the rights to Discover. 

“Dispute” has the meaning set forth in Section 9.7(b). 

“DMF” means Protiva’s Drug Master File(s) filed with any Regulatory Authority covering the Manufacture of Product. 

“Effective Date” has the meaning set forth in the introductory paragraph. 

  
 3 

 “EMA” means the European Medicines Agency, a body of the European Union and
established by Regulation (EC) No 726/2004 of the European Parliament and of the Council of March 31, 2004, or any successor agency(ies) thereof performing similar functions. 

“Enforcement Costs” has the meaning set forth in Section 5.3(c)(ii)(a). 

“Enforcing Party” has the meaning set forth in Section 5.3(c)(i). 

“European Union” or “EU” means the European Union which, following the entry into force of the Treaty of
Lisbon on December 1, 2009, replaced and succeeded the European Community established by the Treaty of Rome signed on March 15, 1957. 

“Excluded Target” means *****. 

“FDA” means The Food and Drug Administration of the United States Department of Health and Human Services, or any successor
agency(ies) thereof performing similar functions. 
 “Field” means treatment, prevention or diagnosis of (i) human
disease or other medical disorder and (ii) animal (excluding fish and arthropods) disease or other medical disorder; provided, however, that the term “Field” shall not include any Product directed to any Excluded Target. 

“Final Inventory” has the meaning set forth in Section 8.6(b). 

“First Commercial Sale” means the first bona fide sale of the Product to a non-Sublicensee Third Party in an
arm’s length transaction after Regulatory Approval in response to a submission of an NDA. 
 “GAAP” means United
States generally accepted accounting principles as in effect from time to time, consistently applied. 
 “Governmental
Authority” means any United States or supra-national, foreign, federal, state, local, provincial, or municipal government, governmental, regulatory or administrative authority, agency, body, branch, bureau, instrumentality or commission or
any court, tribunal, or judicial or arbitral body having relevant jurisdiction over a subject matter, including any Regulatory Authority. 

“HAO1” means Hydroxyacid Oxidase (Glycolate Oxidase) 1, a gene transcribing for the protein 2-hydroxyacid oxidase 1. 

“IND” means, with respect to the Product, an Investigational New Drug Application filed with respect to the Product, as
described in the FDA regulations, including all amendments and supplements to the application, and any equivalent filing with any Regulatory Authority outside the United States. 

“Indemnified Party” has the meaning set forth in Section 7.3. 

“Indemnifying Party” has the meaning set forth in Section 7.3. 

  
 4 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

 “Insolvent Party” has the meaning set forth in Section 8.5. 

“Joint Patent” has the meaning set forth in the Supply Agreement. 

“Know-How” means biological materials and other tangible materials, information, data, inventions, practices, methods,
methodologies, protocols, formulas, formulations, oligonucleotide sequences, knowledge, trade secrets, processes, assays, skills, experience, techniques and results of experimentation and testing, patentable or otherwise. 

“Licensed Intellectual Property” means the Protiva Intellectual Property and the Tekmira Patents. 

“Lipid Nanoparticles” means lipid particles (plus or minus encapsulated drug), lipid components of lipid particles,
formulations comprising lipid particles and methods of manufacturing lipid particles. 
 “LNP Technology” means the
intellectual property (other than Protiva Patents) covering nucleic acid delivery technology directed to (i) the composition of matter of Lipid Nanoparticles, (ii) the method of use of Lipid Nanoparticles, or (iii) the method of
manufacturing Lipid Nanoparticles (plus or minus encapsulated drug), in each case, Controlled by Protiva. 
 “Losses” has
the meaning set forth in Section 7.1. 
 “MAA” means a Marketing Authorization Application and all amendments and
supplements thereto for the Product filed with the EMA or a national competent authority in an EU member state, including all documents, data, and other information concerning the Product that are necessary for obtaining Regulatory Approval to place
the Product on the market in the EU or in an EU member state. 
 “Manufacture” or “Manufacturing” means,
with respect to a Lipid Nanoparticle or product, all activities associated with the production, manufacture, testing, fill/finish, packaging, labeling, releasing or processing of such raw material or product, including having Third Parties conduct
such activities on behalf of the Person having the rights to Manufacture. 
 “MTA” has the meaning set forth in the
recitals. 
 “Milestone Payment” has the meaning set forth in Section 3.1(b). 

“NDA” means the New Drug Application and all amendments and supplements thereto for the Product filed with the FDA, including
all documents, data, and other information concerning the Product that are necessary for gaining Regulatory Approval to market and sell the Product in the United States. 

“Net Sales” ***** 

  
 5 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

 ***** 

“New York Courts” has the meaning set forth in Section 9.7(c). 

“Non-PH1 Patent Infringement Action” has the meaning set forth in Section 5.3(b). 

“Party” means either Dicerna or Protiva (or, where specified, Tekmira); “Parties” means Dicerna and Protiva
(and, where specified, Tekmira). 
 “Patent” means any patent (including any reissue, extension, substitution,
confirmation, re-registrations, re-examination, revival, supplementary protection certificate, patents of addition, continuation, continuation-in-part, or divisional) or patent application (including any provisional application, non-provisional
patent application, continuation, continuation-in-part, divisional, PCT international applications or national phase applications), in each case whether in the U.S. or any foreign country. 

“Patent Infringement Action” has the meaning set forth in Section 5.3(c). 

“Permitted Contractor” means a Third Party (e.g. a contractor or consultant) that performs the activities assigned to
Protiva under this Agreement or the Supply Agreement under a bona fide contract services arrangement for which Protiva has received Dicerna’s prior written consent (such consent not to be unreasonably withheld, conditioned or delayed) as
to the identity of the Third Party and the scope of activities to be performed by such Third Party. 

  
 6 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

 “Person” means an individual, corporation, limited liability company, syndicate,
association, trust, partnership, joint venture, unincorporated organization, government agency or any agency, instrumentality or political subdivision thereof, or other entity. 

“PH1” means Primary Hyperoxaluria 1. 

“PH1 Patent Infringement Action” has the meaning set forth in Section 5.3(c). 

“Pivotal Trial” means a (a) clinical trial that is designed to study the safety and efficacy of the Product (and to help
evaluate its overall risks and benefits) and is intended to form the primary basis for Regulatory Approval for Commercialization of the Product in one or more countries in the Territory, (b) clinical trial that Dicerna or its Affiliate
expressly refers to in a press release as a “pivotal” trial or study, or (c) clinical trial that satisfies either of the following: (i) the protocol for that clinical trial shall have been reviewed by the FDA or other relevant
Regulatory Authority under its procedures for reaching agreement on the design and size of clinical trials intended to form the primary basis of Regulatory Approval for Commercialization of the Product, such as the FDA Guidance for Industry: Special
Protocol Assessment (May 2002) (or equivalent guidance issued in the future), and any comments from the FDA or other relevant Regulatory Authority on that protocol shall have been incorporated in the final protocol for that clinical trial or
resolved to the satisfaction of the FDA or other relevant Regulatory Authority as evidenced by further written communications from the FDA or other relevant Regulatory Authority; or (ii) the FDA or other relevant Regulatory Authority has
determined in writing that the clinical trial can be considered as the primary basis for Regulatory Approval for Commercialization of the Product. For the avoidance of doubt, a clinical trial satisfying any of the requirements sufficient to render
it a Pivotal Trial under this definition shall be considered a Pivotal Trial even if more than one such trial is required by the FDA or other Regulatory Authority for Regulatory Approval for Commercialization of the Product. Such a trial shall be
considered initiated on the later of: (1) the date that it first satisfied the requirements of this definition; or (2) the date of the first dosage of a patient in such trial. 

“Proceeds” has the meaning set forth in Section 5.3(c)(ii). 

“Product” means one or more formulations using Licensed Intellectual Property formulated with one or more nucleic acid
compositions (including oligonucleotide constructs that are designed to function using RNA interference) for the treatment of PH1. 

“Product Composition Patent” has the meaning set forth in the Supply Agreement. 

“Protiva” has the meaning set forth in the Preamble. 

“Protiva Indemnitees” has the meaning set forth in Section 7.2. 

“Protiva Intellectual Property” means, collectively, the Protiva Patents, LNP Technology and Confidential Information of
Protiva. 
 “Protiva Materials” means all materials not supplied by or on behalf of Dicerna, its Affiliates or their
Sublicensee that Protiva uses for the performance of the Studies and the Services. 

  
 7 

 “Protiva Patents” means all Patents Controlled by Protiva that include claims
that Cover (i) the composition of matter of Lipid Nanoparticles, (ii) the method of use of Lipid Nanoparticles, or (iii) the method of Manufacturing Lipid Nanoparticles (plus or minus encapsulated drug), in each case that are useful
or necessary for the Development, Manufacture or Commercialization of the Product, or otherwise Cover any Product, including the Patents listed on Exhibit A, but excluding the Patents listed on Exhibit C and all Joint Patents. 

“Quality Agreement” means the quality agreement dated as of the date hereof between the Parties. 

“Receiving Party” means the Party that receives Confidential Information of the other Party. 

“Record Retention Period” has the meaning set forth in Section 3.3(b). 

“Regulatory Approval” means any registration, license, approval or authorization from any Regulatory Authority required for
the Development, Manufacture or Commercialization of the Product in a regulatory jurisdiction anywhere in the world. 
 “Regulatory
Authority” means any federal, national, multinational, state, provincial or local regulatory agency, department, bureau or other governmental entity anywhere in the world with authority over the Development, Manufacture or Commercialization
of the Product under this Agreement. The term “Regulatory Authority” includes the FDA, the EMA, the European Commission and relevant national competent authorities in the EU member states. 

“Royalty” has the meaning set forth in Section 3.2(a). 

“Royalty Payment Term” means, for any Product on a country-by-country basis, the term beginning on the Effective Date and
ending on the later of (i) the last to expire Valid Claim of a Royalty Term Patent infringed by such Product in such country, (ii) the expiration of the data exclusivity granted by the Regulatory Authority in such country in respect of
such Product, and (iii) the tenth (10th) anniversary of the First Commercial Sale of such Product in such country. 

“Royalty Term Patents” means (i) any Protiva Patents or Tekmira Patents provided such Patents have been identified to
Dicerna in writing at any time during the Term and Protiva has provided Dicerna with a copy thereof, and (ii) subject to Section 7.3(e) of the Supply Agreement, the Product Composition Patent, if any. 

“Services” has the meaning set forth in the Supply Agreement. 

“Solvent Party” has the meaning set forth in Section 8.5. 

“Studies” has the meaning set forth in the MTA. 

“Sublicense Agreement” has the meaning set forth in Section 2.2(a). 

“Sublicensee” means a Third Party to whom Dicerna has granted a sublicense in a Sublicense Agreement pursuant to the terms
hereof. 

  
 8 

 “Supply Agreement” means the Development and Supply Agreement dated as of the
date hereof between the Parties. 
 “Tekmira Patents” means all Patents Controlled by Tekmira that include claims that
Cover (i) the composition of matter of Lipid Nanoparticles, (ii) the method of use of Lipid Nanoparticles that are useful or necessary for the Development, Manufacture or Commercialization of the Product, or otherwise Cover any Product,
including the Patents listed on Exhibit B, but excluding the Patents listed on Exhibit C, or (iii) the method of manufacturing Lipid Nanoparticles (plus or minus encapsulated drug). 

“Term” means the term described in Section 8.1. 

“Territory” means worldwide. 

“Third Party” means any Person other than Protiva, Dicerna or any of their respective Affiliates. 

“Third Party Claim” has the meaning set forth in Section 7.3. 

“Valid Claim” means a claim of: (a) an issued and unexpired Protiva Patent, Tekmira Patent or Product Composition
Patent, which claim has not been revoked or held unenforceable, unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction, which is not appealable or has not been appealed within the time allowed for
appeal, and which has not been abandoned, disclaimed, denied, or admitted to be invalid or unenforceable through reissue, re-examination or disclaimer or otherwise; or (b) a patent application that is a Protiva Patent, Tekmira Patent or Product
Composition Patent that has not been pending for more than ***** years after the original priority date for said application, and that has not been cancelled, withdrawn or abandoned, or finally rejected by an administrative agency action, and
which is not appealable or has not been appealed within the time allowed for appeal. 
 1.2 Interpretation. 

(a) Words such as “herein”, “hereinafter”, “hereof” and “hereunder” refer to this Agreement as a whole
and not merely to a section, paragraph or clause in which such words appear, unless the context otherwise requires. Enumerative references to sections, paragraphs or clauses, or exhibits, without reference to an explicit agreement, document or
exhibit, refer to this Agreement or exhibits attached to this Agreement, as applicable. The singular shall include the plural, and each masculine, feminine and neuter reference shall include and refer also to the others, unless the context otherwise
requires. The words “include”, “includes” and “including” are deemed to be followed by “without limitation” or words of similar import. Except where the context otherwise requires, the word “or” is
used in the inclusive sense (and/or). All dollar amounts are expressed in U.S. dollars. 
 (b) In the event of any direct conflict between
this Agreement and the Supply Agreement, the provisions of this Agreement shall prevail; provided, however, that if either this Agreement or the Supply Agreement expressly contemplates such conflict, the terms of such agreement shall
control. 

  
 9 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

 ARTICLE II – LICENSE GRANTS AND RELATED RIGHTS 

2.1 License Grants to Dicerna. 

(a) Protiva hereby grants to Dicerna, and Dicerna hereby accepts, a worldwide, sublicensable (subject to Section 2.2), irrevocable
(except as set forth in Article VIII), perpetual (subject to Article VIII) right and license under Protiva Intellectual Property (including the Patents listed on Exhibit A) to Develop, Manufacture and Commercialize Products that both
(i) are Directed to treatment of PH1, and (ii) are for use in the Field. 
 (b) Tekmira hereby grants to Dicerna, and Dicerna
hereby accepts, a worldwide, sublicensable (subject to Section 2.2), irrevocable (except as set forth in Article VIII), perpetual (subject to Article VIII) right and license under Tekmira Patents (including the Patents listed on Exhibit
B) to Develop, Manufacture and Commercialize Products that both (i) are Directed to treatment of PH1, and (ii) are for use in the Field. 

(c) The licenses in Sections 2.1(a) and 2.1(b) are exclusive (even as to Protiva and Tekmira), except with respect to the license rights
granted by Protiva or Tekmira to the Licensed Intellectual Property prior to the Effective Date set forth on Exhibit D. 
 2.2
Sublicensing. 
 (a) Dicerna may grant written sublicenses (each, a “Sublicense Agreement”) to the Licensed
Intellectual Property (subject to Section 2.4(b)) solely to Develop, Manufacture and Commercialize Products are solely directed to the treatment of PH1 for use in the Field, including to CMOs; provided, however, that any
sublicense granted by Dicerna shall be subject and, except as set forth below, subordinate to the terms and conditions of this Agreement and shall contain terms and conditions consistent with those in this Agreement. Dicerna shall assume full
responsibility for the performance of all obligations and observance of all terms herein under the licenses granted to it. If Dicerna becomes aware of a material breach of any Sublicense Agreement by a Sublicensee, Dicerna shall promptly notify
Protiva of the particulars of same and take Commercially Reasonable Efforts to enforce the terms of such Sublicense Agreement. All Sublicense Agreements shall provide that the Sublicensee may only use the Confidential Information of Protiva in
accordance with terms of this Agreement applicable to Dicerna’s use of such Confidential Information and subject to provisions at least as stringent as those set forth in Article VI. Dicerna shall use Commercially Reasonable Efforts to make
Protiva an express third-party beneficiary of each CMO Agreement (as defined in the Supply Agreement), and Protiva shall be an express third-party beneficiary of any other Sublicense Agreement, including the provisions related to use and disclosure
of Protiva’s Confidential Information. Upon expiration or termination of this Agreement, and provided any Sublicensee is in good standing and has not contributed to the breach or other circumstance that led to any termination, such Sublicense
Agreement will remain in full force and effect and Dicerna will be required, until the expiration or termination of each Sublicense Agreement, to: (i) remit to Protiva all royalties or other payments Dicerna receives from any Sublicensee
regarding the sale or other disposition of any Products; and (ii) enforce the terms of the Sublicense Agreement at the direction and expense of Protiva. 

  
 10 

 (b) Unless otherwise provided in this Agreement, Dicerna shall notify Protiva within
***** days after execution of a Sublicense Agreement and provide a copy of the fully executed Sublicense Agreement to Protiva within the same time, which shall be treated as Confidential Information of Dicerna under Article VI. Dicerna may
redact any financial or other competitively sensitive information from any Sublicense Agreement prior to disclosure to Protiva. 
 2.3
Grant Back. Dicerna agrees to grant and hereby grants (a) to Protiva a non-exclusive, non-royalty-bearing, sublicensable right and license under the Licensed Intellectual Property solely for purposes of performing its obligations under
this Agreement, the Supply Agreement and the Quality Agreement and (b) to Tekmira a non-exclusive, non-royalty-bearing, sublicensable right and license under the Tekmira Patents solely for purposes of performing its obligations under this
Agreement, the Supply Agreement and the Quality Agreement. 
 2.4 Retained Rights. 

(a) Each of Protiva and Tekmira expressly retains any rights not expressly granted to Dicerna under this Article II (or otherwise under this
Agreement) or under the Supply Agreement. Nothing in Section 2.1 limits Protiva’s ability to perform its obligations under this Agreement or the Supply Agreement. 

(b) Notwithstanding anything to the contrary contained herein but subject to terms set forth in the Supply Agreement, including
Section 7.2 of the Supply Agreement, (i) neither Tekmira nor Protiva is granting to Dicerna a license to Research, Develop or otherwise improve upon the Lipid Nanoparticles based on Tekmira Patents or Protiva Intellectual Property or
Confidential Information it has received from Tekmira or Protiva (but, for clarity, Dicerna may otherwise Research, Develop and improve upon Lipid Nanoparticles without the use of Tekmira Patents, Protiva Intellectual Property or Confidential
Information it has received from Tekmira or Protiva); and (ii) no license is provided from either Party to the other to use its Know-How, except as may be necessary or useful for a Party to fulfill its obligations to any Regulatory Authority
(subject to the penultimate sentence in Section 6.3) or necessary for a Party to perform the activities required or expressly permitted under this Agreement, the Supply Agreement or the Quality Agreement and with respect to the Product. 

2.5 Rights in Bankruptcy. All licenses and rights to licenses granted under or pursuant to this Agreement by Protiva to Dicerna are,
and shall otherwise be deemed to be, for purposes of Section 365(n) of the United States Bankruptcy Code (the “Code”), licenses of rights to “intellectual property” as defined under Section 101(35A) of the Code.
Dicerna, as a licensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the Code, and that upon commencement of a bankruptcy proceeding by or against Protiva (or any Affiliate of Protiva
that owns or Controls Protiva Intellectual Property or Tekmira Patents) under the Code, Dicerna shall be entitled to a complete duplicate of, or complete access to (as Dicerna deems appropriate), any such intellectual property and all embodiments of
such intellectual property. 
 2.6 Contractors. Notwithstanding Sections 2.1 and 2.2, Protiva may utilize Permitted Contractors to
perform its obligations in accordance with this Agreement or the Supply 

  
 11 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

 
Agreement provided that Protiva shall not share Dicerna’s Confidential Information with any Permitted Contractor unless Protiva and its Permitted Contractor shall have executed a binding
agreement which contains (i) obligations of confidentiality, non-use, and invention assignment consistent with and at least as protective of Dicerna’s rights as the provisions of this Agreement, and (ii) other reasonable and customary
terms and conditions, so as to enable Protiva to comply with its obligations under this Agreement and the Supply Agreement. 
 ARTICLE III
– FINANCIAL PROVISIONS 
 3.1 Upfront Payment and Milestone Payments. 

(a) On or before the third (3rd) day following the Effective Date, Dicerna shall
make a one-time fully-earned, non-refundable and non-creditable payment to Protiva in the amount of US $2,500,000 as partial consideration for the rights granted under this Agreement. 

(b) Subject to the terms and conditions of this Agreement, Dicerna shall make the following fully-earned, non-refundable and non-creditable
milestone payments upon the achievement of the specified milestones with respect to a Product (each a “Milestone Payment”): 
  

					
	 Milestone Event
	  	Milestone Fee	 
	 *****
	  	 	*****	  
		
	 *****
	  	 	*****	  
		
	 *****
	  	 	*****	  

 (c) If there is more than one Product in Development or Commercialization at the same time, Dicerna shall be
obligated to make each Milestone Payment for every Product that achieves the milestone set forth above (i.e., if there is more than one Product that satisfies the applicable milestone event, more than one Milestone Payment for the milestone event
shall be owed by Dicerna to Protiva); provided, however, that if the first milestone event in Section 3.1(b) has been reached for a Product (i.e., initiation of a first Pivotal Trial) and the Milestone Payment made, but such Product does not
ultimately obtain Regulatory Approval in the United States, any EU market or the market of any EU member state, then on any subsequent Product there will not by any Milestone Payment due upon the initiation of a first Pivotal Trial for that
subsequent Product. 
 (d) Dicerna shall act in good faith in determining whether to designate its clinical trials for Products as
“pivotal trials” and shall not manipulate the structure of its clinical trials for Products that would otherwise meet the definition of a Pivotal Trial in such a manner as to avoid meeting such definition for purposes of delaying payment
of the applicable Milestone Payment. 

  
 12 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

 3.2 Royalty Payments. 

(a) In addition to the payments set forth in Section 3.1, during the Royalty Payment Term, Dicerna shall pay to Protiva the following
royalty amounts with respect to the Net Sales of Products (the “Royalty”): 
  

					
	 Royalty Table
	 
	 Net Sales
	  	Royalty
(Percent of Net Sales)	 
	 For all cumulative, worldwide Net Sales less than *****
	  	 	*****	  
		
	 For cumulative, worldwide Net Sales equal to or exceeding ***** but less than *****
	  	 	*****	  
		
	 For cumulative, worldwide Net Sales equal to or exceeding *****
	  	 	*****	  

 (b) For clarity, the application of the Royalty tiers in the above Royalty Table will be progressive, meaning
that the Royalty percentage in each tier only applies to Net Sales in that tier and not retroactively to prior Net Sales in a lower tier. 

(c) No royalty offsets shall apply for Third Parties owed royalties by Dicerna for DCR-PH1 or any adjuvant or additional active substance. The
Royalties are inclusive of royalties, if any, owed by Protiva to Third Parties for any intellectual property licensed to Dicerna under this Agreement, which third-party royalties are exclusively the obligation of Protiva. 

3.3 Royalty Reports; Expense Reports; Records and Audits. 

(a) Within ***** days after the end of each calendar quarter during the Royalty Payment Term until the calendar quarter after which Dicerna or
any of its Affiliates or Sublicensees is no longer selling any Products, Dicerna shall provide to Protiva a written report (in electronic form) that includes, for each calendar quarter, (i) the gross invoiced sales of the Product sold during
such quarter, (ii) the Net Sales of the Products, and (ii) the calculated amount of the Royalty owed by Dicerna pursuant to Section 3.2 in respect of the sale of the Products. If reasonably requested by Protiva, Dicerna will also
provide non-binding estimates for Net Sales and Royalties after the calendar quarter end but prior to delivery of the written report. 
 (b)
Until the fifth (5th) anniversary of the date any book or record is created or such longer period required by Applicable Law (the “Record Retention Period”), Dicerna shall

  
 13 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

 
maintain and retain complete and accurate books of account and records covering all transactions relating to payment of amounts that may be due under Section 3.2 of this Agreement. Upon the
reasonable advance notice of Protiva (of at least ***** days), Dicerna shall make such books and records available for inspection and audit by Protiva’s authorized representative (which shall be a national certified public accounting firm
designated by Protiva), subject to reasonable precautions to protect the confidential information of Dicerna. Protiva may not audit Dicerna’s books and records more than once in any *****-month period. All audits must be conducted during normal
business hours of Dicerna and conducted in a manner so as to minimize the impact on the normal operations of Dicerna. The accounting firm conducting any such audit must provide a report of its findings of any audit to both Parties, may only identify
in such report whether the amount of Royalties paid was correct and the actual amount of Royalties payable and may not disclose any other Confidential Information of Dicerna. The auditor’s report and all other information disclosed to the
auditor or generated by the auditor in such audit will be the Confidential Information of Dicerna. Protiva shall pay the cost of such audits unless it discovers that Dicerna has underreported aggregate Net Sales during any year in the Record
Retention Period by an amount of ***** or more, in which case the costs of such audit shall be borne by Dicerna. If an audit reveals an underpayment or overpayment, the Party responsible for making payment shall promptly pay to the other Party
the amount of the underpayment or overpayment discovered unpaid under this Section 3.3(b), subject to Section 3.4(d). 
 3.4
Payment Procedure. 
 (a) Remittance of payments under this Article III shall be made by means of wire transfer of immediately
available funds to a bank account designated in advance in writing by Protiva. All amounts payable to Protiva under this Agreement shall be paid in United States Dollars. In those cases in which the amounts due in United States Dollars is calculated
based on one or more currencies other than United States Dollars, such amounts shall be converted into United States Dollars using the spot exchange rate for the relevant currency on the date of the applicable transaction, as such exchange rate is
published by the Wall Street Journal (or comparable publication if not available). 
 (b) Any Milestone Payment owed pursuant to
Section 3.1(b) shall be paid by Dicerna to Protiva within ***** days after the occurrence of the event triggering the payment of such Milestone Payment. 

(c) Any Royalty shall accrue in accordance with Section 3.2 during the applicable Royalty Payment Term. Royalty obligations that accrue
during a calendar quarter shall be paid within ***** days after the end of such quarter. 
 (d) Any payments due from one Party to the other
Party under this Article III that are not paid by the date such payments are due shall bear interest from the date such unpaid payments are due until paid in full at the lesser of: (i) ***** per month; or (ii) the highest amount of
interest permitted by Applicable Law. The foregoing interest shall be in addition to any other remedies that either Party may have pursuant to this Agreement. 

(e) Protiva is solely responsible for any sales, use, excise, value-added, services, consumption, or other similar tax that is assessed in
connection with any payment due hereunder 

  
 14 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

 
and shall either pay such payment directly or reimburse Dicerna for the same. Any withholding or other taxes that Dicerna or its Affiliates are required by Applicable Law to withhold or pay on
behalf of Protiva may be deducted from such payments and paid to the appropriate tax authority contemporaneously with the remittance to Protiva, provided that (i) Dicerna promptly furnishes to Protiva proper evidence of the taxes so paid and
(ii) Dicerna cooperates with and furnishes to Protiva appropriate documents to secure application of the most favorable rate of withholding tax under Applicable Law (or exemption from such withholding tax payments, as applicable). Dicerna and
Protiva shall use Commercially Reasonable Efforts to cooperate to minimize any such taxes, assessments and fees to the extent permitted by Applicable Law. 

3.5 Term of Payments. Following expiry of the Royalty Payment Term in respect of any country (a) the licenses granted to Dicerna
with respect to such country become fully paid-up, sublicensable, royalty-free, exclusive (subject to Section 2.1(b)), transferable, perpetual and irrevocable licenses continuing indefinitely and (b) the obligation of Dicerna to pay any
Royalties with respect to sales of Products in such country terminates. 
 ARTICLE IV – ADDITIONAL OBLIGATIONS 

4.1 Obligations of Protiva. Protiva shall, itself or through its Affiliates or Permitted Contractors upon Dicerna’s reasonable
request, use Commercially Reasonable Efforts to assist Dicerna in obtaining any license from any Third Party needed for Dicerna or its Affiliates to exploit the LNP Technology as contemplated by this Agreement (provided that such efforts would not
require Protiva to make any payment to any such Third Party). 
 4.2 Obligations of Dicerna. 

(a) Dicerna shall, itself or through its Affiliates or Sublicensees, use Commercially Reasonable Efforts to Develop and Commercialize the
Product, provided that Protiva’s sole remedy for Dicerna’s breach of this Section 4.2(a) is as set forth in Section 8.3. 

(b) Until the earlier of (i) termination of this Agreement or (ii) the First Commercial Sale of the Product, Dicerna shall not,
directly or indirectly, in-license from any Third Party for use with the Product a drug delivery system competitive with (A) the composition of matter of Lipid Nanoparticles, (B) the method of use of Lipid Nanoparticles or (C) the
method of manufacturing Lipid Nanoparticles (plus or minus encapsulated drug), in each case, Controlled by Protiva or Tekmira and licensed to Dicerna hereunder; provided, however, that if, after such period, Dicerna in-licenses from a
Third Party such drug delivery system, then, as the sole remedy to Protiva, the license grant by Protiva in Section 2.1 shall thereafter be on a non-exclusive basis. The foregoing does not prohibit Dicerna from licensing any Third Party
technology or intellectual property necessary to Develop, Manufacture, or Commercialize the Products. 
 4.3 Other Obligations and
Agreements of the Parties. 
 (a) Each Party agrees that from the Effective Date until the expiration of one (1) year after the
expiration of the Term of this Agreement, it shall not, except upon the express prior written consent of the other Party in each instance, directly or indirectly employ in any capacity (whether as a full or part time employee or as a consultant or
contractor) any individual who is 

  
 15 

 
then employed by such other Party and has worked in any capacity related to this Agreement, the Supply Agreement or the Quality Agreement. This provision shall not apply to or prohibit general
solicitations, such as job postings though public media, not focused on or directed specifically to the personnel of the other Party or hiring or employing any individual who is hired by a Party in response to those general solicitations. 

(b) The Parties acknowledge and agree that, in respect of the Product, all regulatory dossiers filed by Dicerna with the Regulatory
Authorities and Regulatory Approvals granted (excluding in either case any content directed exclusively to Licensed Intellectual Property), are the sole and exclusively property of Dicerna. 

(c) The Parties shall cooperate with each other to provide all reasonable assistance and take all actions that are necessary to comply with
any Applicable Laws in connection with their respective Regulatory Authority obligations in relation to the Product under this Agreement. In addition, the Parties shall work together in good faith to develop such necessary regulatory strategies
which may be required for purposes of this Agreement. 
 ARTICLE V – INTELLECTUAL PROPERTY 

5.1 Ownership. 
 (a)
Subject to the licenses granted by Protiva herein, Protiva is and shall at all times remain the sole and exclusive owner of the Protiva Intellectual Property. 

(b) Subject to the licenses granted by Tekmira herein, Tekmira is and shall at all times remain the sole and exclusive owner of the Tekmira
Patents, including, for the avoidance of doubt, the Excluded Patents. 
 (c) Dicerna is and shall at all times remain the sole and exclusive
owner of Dicerna’s Confidential Information. 
 5.2 Prosecution and Maintenance of Patents. Protiva shall have the sole right
and responsibility, in its sole discretion and at its sole cost and expense, to file, prosecute, maintain or abandon patent protection in the Territory for Protiva Patents. Tekmira shall have the sole right and responsibility, in its sole discretion
and at its sole cost and expense, to file, prosecute, maintain or abandon patent protection in the Territory for Tekmira Patents. 
 5.3
Third-Party Infringement of Protiva Patents and Tekmira Patents. 
 (a) Each Party shall use Commercially Reasonable Efforts to
promptly report in writing to the other Party during the Term any known or suspected commercially relevant infringement by a Third Party of any of the Protiva Patents or Tekmira Patents Covering the Product of which such Party becomes aware and
provide the other Party with all evidence supporting or relating to such infringement in its possession. 
 (b) Protiva shall have the sole
and exclusive right to initiate an infringement or other appropriate suit with respect to infringements or suspected infringements of any of the Protiva Patents and Tekmira shall have the sole and exclusive right to initiate an infringement or other

  
 16 

 
appropriate suit with respect to infringements or suspected infringements of any of the Tekmira Patents, in each case, in respect of infringing activity that is not directed to the treatment of
PH1 with a Product (each such suit or other action, a “Non-PH1 Patent Infringement Action”), or to take such other actions as Protiva or Tekmira, in its sole discretion, deems appropriate with respect to such infringements or
suspected infringements, all at Protiva’s or Tekmira’s sole cost and expense, as applicable. Protiva and Tekmira shall notify Dicerna promptly after initiating any such Non-PH1 Patent Infringement Action that has a reasonable possibility
of harming or damaging Dicerna’s rights or licenses to the Licensed Intellectual Property. 
 (c) Protiva shall have the first right to
initiate an infringement or other appropriate suit with respect to infringements or suspected infringements of any of the Protiva Patents and Tekmira shall have the first right to initiate an infringement or other appropriate suit with respect to
infringements or suspected infringements of any of the Tekmira Patents, in each case, by Products that are directed to the treatment of PH1 (each such suit or other action, a “PH1 Patent Infringement Action”; and, together with the
Non-PH1 Patent Infringement Action, a “Patent Infringement Action”), all at Protiva’s sole cost and expense. Protiva shall: (A) notify Dicerna promptly after initiating any such PH1 Patent Infringement Action and
(B) consult closely with Dicerna regarding all aspects of such PH1 Patent Infringement Action and permit Dicerna to have an attorney of its own choosing participate in such PH1 Patent Infringement Action. Protiva shall not enter into any
settlement or compromise in connection with an PH1 Patent Infringement Action that would materially eliminate, diminish, or otherwise modify any right, title, or interest of Dicerna in any Licensed Intellectual Property or that would require any
payments, concessions, or otherwise bind Dicerna, without Dicerna’s prior written consent, which consent shall not be unreasonably withheld, delayed or conditioned. If Protiva elects not to initiate, pursue or maintain any such PH1 Patent
Infringement Action, Protiva shall provide Dicerna with prompt written notice of the same and, thereafter, Dicerna will have the right, but not the obligation, to initiate, pursue or maintain any PH1 Patent Infringement Action Dicerna deems
appropriate with respect to such infringements or suspected infringements, all at Dicerna’s sole cost and expense. Thereafter, Dicerna shall consult closely with Protiva regarding all aspects of such PH1 Patent Infringement Action and permit
Protiva to have an attorney of its own choosing participate in such PH1 Patent Infringement Action. Dicerna shall not enter into any settlement or compromise in connection with a PH1 Patent Infringement Action that would materially eliminate,
diminish, or otherwise modify any right, title, or interest of Protiva or Tekmira in any Licensed Intellectual Property or that would require any payments, concessions, or otherwise bind Protiva, without Protiva’s prior written consent, which
consent shall not be unreasonably withheld, delayed or conditioned. 
 (i) Upon the request of the Party bringing a PH1 Patent Infringement
Action under this Section 5.3(c) (the “Enforcing Party”), the other Party shall cooperate with the Enforcing Party in such PH1 Patent Infringement Action, including joining such PH1 Patent Infringement Action as a party with
the Enforcing Party if necessary or required by Applicable Law. If the non-Enforcing Party is requested to join as a party to a PH1 Patent Infringement Action it may be represented, at the cost of the Enforcing Party, by counsel mutually agreed by
the Parties. 
 (ii) The Parties shall share in the proceeds from any PH1 Patent Infringement Action under this Section 5.3(c),
including settlements thereof (the “Proceeds”), as follows: 
 (a) First, for the costs and expenses, including legal
fees, that are incurred by the Enforcing Party as part of or in preparation of the PH1 Patent Infringement Action, including the costs and expenses of the non-Enforcing Party reimbursed by the Enforcing Party in accordance with this Section (the
“Enforcement Costs”); and 
 (b) The remainder of the Proceeds will be treated as Net Sales, with Protiva receiving
Royalties on such remainder of the Proceeds in accordance with Section 3.2 and Dicerna receiving the rest of the remainder of the Proceeds. 

  
 17 

 (d) With respect to any infringement or suspected infringements of any of the Protiva Patents or
Tekmira Patents that would result in action that could reasonably be considered both an PH1 Patent Infringement Action and a Non-PH1 Patent Infringement Action, Protiva shall have the first right to initiate an infringement or other appropriate
suit, subject to Section 5.3(c). If Protiva elects not to initiate, pursue or maintain any such Patent Infringement Action, Protiva shall provide Dicerna with prompt written notice of the same and, thereafter, Dicerna will have the right, but
not the obligation, to initiate, pursue or maintain only the claims that would form the basis of an PH1 Patent Infringement Action, all at Dicerna’s sole cost and expense, subject to Section 5.3(c). The Parties will share in any Proceeds
from any such Patent Infringement Action consistent with Section 5.3(b) and 5.3(c) above (i.e., after reimbursement of each Party’s Enforcement Costs, Protiva retains all Proceeds resulting from infringing activity not directed to the
treatment of PH1 with a Product and Proceeds resulting from infringing activity related to Products directed to the treatment of PH1 will be shared in accordance with Section 5.3(c)(ii)). 

5.4 Defense of Brought by Third Parties. Each Party shall promptly notify the other Party if it becomes aware of any claim that
Dicerna’s actual use, sale or practice of Product in connection with its exercise of its license under Section 2.1 infringes, misappropriates, or otherwise violates the intellectual property rights of any Third Party. 

ARTICLE VI – CONFIDENTIAL INFORMATION AND PUBLICITY 

6.1 Limitation of Disclosure. With the exception of information essential for Regulatory Authority filings and documentation not
fulfilled by use of the DMF, neither Party shall be obligated to disclose to the other Party confidential information related to its technology. Protiva shall disclose specific information regarding the chemical composition of a formulation in Lipid
Nanoparticles used in the Product for purposes of filings with the Regulatory Authorities; provided, however, that (i) Protiva shall not be obligated to disclose to Dicerna the details related to any process in which such
formulation was selected, nor the chemistry of any other lipids not used in the formulation and (ii) subject to Section 6.3, if Protiva discloses Confidential Information to Dicerna for use with Regulatory Authorities, Dicerna shall not
disclose such Confidential Information without Protiva’s prior written consent. 
 6.2 Non-Disclosure of Confidential
Information. Each Party agrees that, for itself and its Affiliates, until the tenth (10th) anniversary of the termination or expiration of this Agreement, a Receiving Party shall maintain all Confidential Information of the Disclosing Party
in strict confidence and shall not (a) disclose Confidential Information to any Third Party without the prior written consent of the Disclosing Party, except for disclosures expressly permitted below and to the Receiving Party’s and its
Affiliates’ Sublicensees and each of their employees 

  
 18 

 
who have a need to know such Confidential Information for purposes of exploiting the licenses granted herein or otherwise conducting their activities under this Agreement or (b) use
Confidential Information for any purpose except those explicitly licensed or otherwise authorized or permitted by this Agreement; provided that the foregoing obligations shall survive with respect to any Confidential Information that is receiving
protection as a trade secret under Applicable Law for so long as such Confidential Information continues to receive such protection. 
 6.3
Exceptions. The obligations in this Article VI shall not apply with respect to any portion of the Confidential Information that the Receiving Party can show by competent documented proof: (i) was known to the Receiving Party or its
Affiliates, without any obligation to keep it confidential or any restriction on its use, prior to disclosure by the Disclosing Party; (ii) is subsequently disclosed to the Receiving Party or its Affiliates by a Third Party lawfully in
possession thereof and without any obligation to keep it confidential or any restriction on its use; (iii) is or otherwise becomes generally available to the public or enters the public domain, either before or after it is disclosed to the
Receiving Party and such public availability is not the result, directly or indirectly, of any fault of, or improper taking, use or disclosure by, the Receiving Party or its Affiliates or anyone working in concert or participation with the Receiving
Party or its Affiliates; or (iv) has been independently developed by employees or contractors of the Receiving Party or its Affiliates without the aid, application or use of Confidential Information of the Disclosing Party. Notwithstanding the
foregoing, (A) specific Confidential Information disclosed by a Disclosing Party shall not be deemed to be within any exceptions set forth in (i), (ii), or (iii) above merely because it is embraced by more general information to which one
or more of those exceptions may apply, (B) no combination of information shall be deemed to be within any such exceptions unless the combination itself and its principle of operation are within the public domain and (C) disclosure of
Confidential Information to Regulatory Authorities shall not constitute a public disclosure (i.e., it shall remain Confidential Information after such disclosure). Even though Confidential Information may be within one of the exceptions described in
the preceding sentence, the Receiving Party shall not disclose to Third Parties that the excepted Confidential Information was received from the Disclosing Party. 

6.4 Permitted Uses; Protection. Confidential Information of a Disclosing Party may be used by the Receiving Party in the performance of
its obligations under this Agreement, the Supply Agreement and the Quality Agreement, including disclosures to Permitted Contractors who are bound by enforceable confidentiality agreements with terms consistent with and at least as protective as
this Article VI, as otherwise expressly authorized in this Agreement or as expressly authorized by the Disclosing Party in writing. Confidential Information that is Licensed Intellectual Property may be used by Dicerna subject to and in accordance
with the provisions of this Agreement, the Supply Agreement and the Quality Agreement, to the extent applicable to Dicerna’s license to Licensed Intellectual Property. Each Receiving Party shall take steps to maintain the confidentiality of the
Disclosing Party’s Confidential Information that are consistent with the steps it takes to maintain the confidentiality of its own confidential information of a similar value, but in no event less than commercially reasonable steps;
provided, however, that nothing in this Agreement shall be deemed to eliminate, restrict, or otherwise limit Dicerna’s license to use such Confidential Information in accordance with the terms and conditions of this Agreement,
even if such use may result, directly or indirectly, in the disclosure of such Confidential Information, so long as such disclosures are made in a manner than complies with Section 6.5 below. 

  
 19 

 6.5 Permitted Disclosures. The Receiving Party may disclose Confidential Information
belonging to the Disclosing Party to the extent (and only to the extent) such disclosure is reasonably necessary in the following instances: (i) subject to the proviso below, by either Party hereto, in order to comply with non-patent Applicable
Law (including any securities Applicable Law or the rules of a securities exchange in a relevant jurisdiction) and with judicial process, if based on the reasonable advice of the Receiving Party’s counsel, such disclosure is necessary for such
compliance; (ii) subject to the proviso below, by either Party hereto, in connection with prosecuting or defending litigation; and (iii) subject to the proviso below, by Dicerna, its Sublicensees, or their sublicensees in connection with
any legal or regulatory requirements related to the Development, Manufacture or Commercialization of Product that use or employ Licensed Intellectual Property, such as labeling requirements, disclosures in connection with obtaining Regulatory
Approvals, and the like, so long as the Development, Manufacture or Commercialization of Product has been and is performed in a manner that complies with the terms and conditions of Dicerna’s license to such Licensed Intellectual Property and
reasonable steps are taken to maintain the confidentiality of said Confidential Information even when disclosed for legal or regulatory purposes; provided, however, that with respect to clause (i), (ii) and (iii) where
legally permissible, (a) the Receiving Party shall notify the Disclosing Party of the Receiving Party’s intent to make any disclosure pursuant thereto sufficiently prior to making such disclosure so as to allow the Disclosing Party
adequate time to take whatever action it may deem appropriate to protect the confidentiality of the information to be disclosed, including seeking protective orders or injunctive relief, and (b) consistent with Applicable Law, the Disclosing
Party shall have the right to suggest reasonable changes to the disclosure to protect its interests, and the Receiving Party shall not unreasonably refuse to include such changes in its disclosure. 

6.6 Press Release. Each Party shall publicize the execution of this Agreement by issuing its respective press release attached hereto
as Exhibit E. After such initial press release, neither Party shall issue a press release or public announcement relating to the other Party or the collaboration activities undertaken pursuant this Agreement or the Supply Agreement without
the prior written approval of the other Party, which approval shall not be unreasonably withheld, delayed or conditioned; provided, however, that (a) either Party may issue a press release or public announcement as required
by Applicable Law; and (b) nothing in the foregoing will prevent Dicerna from issuing press releases and public announcements regarding the Product that do not reference Protiva, Tekmira or the LNP Technology, except that Dicerna shall (without
Protiva’s consent) acknowledge that Protiva licensed to Dicerna the LNP Technology and Protiva Patents in respect of such Product. Except as otherwise provided herein, each Party agrees not to use the name, trademark, service mark, or design
registered to the other Party or its Affiliates in any publicity, promotional, or advertising material, without prior written approval of the other Party. 

ARTICLE VII – INDEMNIFICATION AND INSURANCE 

7.1 Protiva Indemnification. Protiva agrees to indemnify Dicerna and its Affiliates, and their respective agents, directors, officers,
employees, representatives, successors and 

  
 20 

 
permitted assigns (the “Dicerna Indemnitees”) against and to hold each of them harmless from any and all losses, costs, damages, fees or expenses (“Losses”)
actually incurred or suffered by a Dicerna Indemnitee to the extent arising out of or in connection with any claim, suit, demand, investigation or proceeding brought by a Third Party based on: (a) any breach of any representation, warranty or
covenant by Protiva under this Agreement; or (b) Protiva’s, its Affiliates’ or its Permitted Contractors’ gross negligence, willful misconduct or violation of Applicable Law. The foregoing indemnification shall not apply to the
extent that any Losses are due to Dicerna’s, its Affiliates’ or its Sublicensees’ gross negligence or willful misconduct. 

7.2 Dicerna Indemnification. Dicerna agrees to indemnify Protiva and its Affiliates, and their respective agents, directors, officers,
employees, representatives, successors and permitted assigns (the “Protiva Indemnitees”) against and to hold each of them harmless from any and all Losses actually incurred or suffered by a Protiva Indemnitee to the extent arising
out of or in connection with any claim, suit, demand, investigation or proceeding brought by a Third Party based on: (a) any breach of any representation, warranty or covenant by Dicerna under this Agreement; (b) Dicerna’s, its
Affiliates’ or its Sublicensees’ gross negligence, willful misconduct or violation of Applicable Law; or (c) product recall, products’ liability or similar claims based on the Development or Commercialization of the Product
(except to the extent that Protiva is required to indemnify the Dicerna Indemnitees for such Losses pursuant to the Supply Agreement). The foregoing indemnification obligations shall not apply to the extent that any Losses are due to Protiva’s,
its Affiliates’ or its Permitted Contractors’ gross negligence or willful misconduct. 
 7.3 Tender of Defense; Counsel.
Any Person (the “Indemnified Party”) seeking indemnification under this Article VII agrees to give prompt notice in writing to the other Party (the “Indemnifying Party”) of the assertion of any claim or the
commencement of any action by any Third Party (a “Third Party Claim”) in respect of which indemnity may be sought under this Article. Such notice shall set forth in reasonable detail such Third Party Claim and the basis for
indemnification (taking into account the information then available to the Indemnified Party). The failure to so notify the Indemnifying Party shall not relieve the Indemnifying Party of its indemnification and hold harmless obligations hereunder,
except to the extent such failure shall have materially and adversely prejudiced the Indemnifying Party. The Indemnifying Party shall be entitled to participate in the defense of any Third Party Claim and shall be entitled to control and appoint
lead counsel reasonably satisfactory to the Indemnified Party for such defense by written notice to the Indemnified Party within ***** calendar days after the Indemnifying Party has received notice of the Third Party Claim, in each case at its
own expense; provided, however, that the Indemnifying Party must use Commercially Reasonable Efforts to conduct the defense of the Third Party Claim in a manner designed to protect the rights of the Indemnified Parties, and otherwise
conduct such defense actively and diligently, thereafter in order to preserve its rights in this regard. The Indemnifying Party shall not be entitled to assume or maintain control of the defense of any Third Party Claim and shall pay the fees and
expenses of one counsel retained by the Indemnified Party if: (a) the Third Party Claim relates to or arises in connection with any criminal proceeding, action, indictment or allegation; (b) the Third Party Claim seeks an injunction or
equitable relief against a Indemnified Party or any of its Affiliates; or (c) the Indemnifying Party has failed or is failing to prosecute or defend vigorously the Third Party Claim. Each Indemnified Party shall obtain the prior written consent
of the Indemnifying Party, such consent not to be unreasonably withheld, delayed or conditioned, before entering into 

  
 21 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

 
any settlement of a Third Party Claim. Notwithstanding the foregoing, the Indemnifying Party shall not be entitled to enter into or approve any settlement of a Third Party Claim without the
consent of the Indemnified Party (which may be withheld in its sole discretion), if the settlement (i) does not expressly unconditionally release all applicable Indemnified Parties and their Affiliates from all Losses with respect to such Third
Party Claim, (ii) imposes injunctive or other equitable relief against the Indemnified Party or any of its Affiliates, (iii) involves any admission of criminal or similar liability, or (iv) involves any monetary damages that may not
be fully covered by the Indemnifying Party. In the event that the Indemnifying Party fails to assume the defense of the Third Party Claim in accordance with this Section 7.3, (1) the Indemnified Party may defend against the Third Party
Claim in any manner it reasonably may deem appropriate, and (2) the Indemnifying Party shall remain responsible for any Losses of the Indemnified Party as a result of such Third Party Claim. In circumstances where the Indemnifying Party is
controlling the defense of a Third Party Claim in accordance with this Section 7.3, the Indemnified Party shall be entitled to participate in the defense of any Third Party Claim and to employ separate counsel of its choice for such purpose, in
which case the fees and expenses of such separate counsel shall be borne by such Indemnified Party. Notwithstanding anything herein to the contrary, in circumstances where there is a conflict of interest that would reasonably make it inappropriate
under applicable standards of professional conduct to have common counsel for the Indemnifying Party and the Indemnified Party, the Indemnified Party shall be entitled to employ separate counsel, that is reasonably acceptable to the Indemnifying
Party, and the Indemnifying Party shall pay the reasonable fees and expenses of such separate counsel. Each Party shall cooperate, and cause their respective Affiliates to cooperate in all reasonable respects, in the defense or prosecution of any
Third Party Claim and shall furnish or cause to be furnished such records, information and testimony, and attend such conferences, discovery proceedings, hearings, trials or appeals, as may be reasonably requested in connection therewith, all at the
expense of the Indemnifying Party. 
 7.4 Insurance. Each Party shall maintain insurance, including product liability insurance, with
respect to its activities under this Agreement regarding the Product in such amount as such Party customarily maintains with respect to similar activities for its other products. Each Party shall maintain such insurance for so long as it continues
its activities under this Agreement, the Supply Agreement or the Quality Agreement, and thereafter for so long as such Party customarily maintains insurance for itself covering similar activities for its other products. Notwithstanding the
foregoing, the Parties agree that during such time that Tekmira is an Affiliate of Protiva, Protiva shall have satisfied its obligations under this Section 7.4 provided it is covered by Tekmira’s existing insurance policies that also
satisfy the obligations under this Section 7.4. 
 ARTICLE VIII – TERM AND TERMINATION 

8.1 Term. The term of this Agreement (the “Term”) shall begin on the Effective Date and, unless terminated earlier as
provided herein, shall continue in perpetuity. 
 8.2 Termination for Material Breach. If either Party commits a material breach or
material default in the performance or observance of any of its obligations under this Agreement, and such breach or default continues without cure for a period of ***** days after delivery by the other Party of written notice reasonably detailing
such breach or default, then the 

  
 22 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

 
non-breaching or non-defaulting Party shall have the right to terminate this Agreement, with immediate effect, by giving written notice to the breaching or defaulting Party. The Parties shall
retain all rights and remedies (at law or in equity) in respect of any breach hereof. 
 8.3 Termination for Failure to Actively Develop
or Commercialize. If Protiva reasonably concludes that Dicerna is failing to use Commercially Reasonable Efforts to actively Develop or Commercialize the Product, Protiva can request from Dicerna written confirmation that Dicerna or its
Affiliates or Sublicensees are actively Developing and Commercializing the Product. Following receipt of such request, if Dicerna either: (a) fails to deliver such written confirmation to Protiva within ***** days of Protiva’s
delivery of such request; or (b) provides such written confirmation but does not thereafter, in a timely and diligent manner, actually use Commercially Reasonable Efforts to actively Develop or Commercialize the Product, Protiva may terminate
this Agreement immediately on written notice to Dicerna. 
 8.4 Challenges of Protiva’s Patents or Tekmira Patents. If Dicerna
or any of its Affiliates or Sublicensees directly and voluntarily commences or participates in any action or proceeding (including any patent opposition or re-examination proceeding), or otherwise asserts in writing (to Protiva or any of its
Affiliates or to the U.S. Patent and Trademark Office) any claim, challenging or denying the validity of any of the Protiva Patents or Tekmira Patents, Protiva or Tekmira, as applicable, shall have the right to give notice to Dicerna (which notice
must be given, if at all, within ***** days after Protiva’s CEO or General Counsel first learns of the foregoing) that the licenses granted by Protiva to Dicerna hereunder to such Protiva Patent(s) or by Tekmira to Dicerna hereunder to
such Tekmira Patent(s) shall terminate ***** days following Dicerna’s receipt of such notice, and, unless Dicerna or its Affiliate or Sublicensees, as applicable, withdraws or causes to be withdrawn all such challenge(s) within such *****
period, such licenses to such Protiva Patent or Tekmira Patent, as applicable, shall so terminate; provided that if such action, proceeding or assertion is made by a Sublicensee the license shall only terminate with respect to the sublicense granted
to such Sublicensee. Neither Dicerna’s, its Affiliates’, a Sublicensee, or any of their employees’ participating in or appearing in any such action, proceeding or claim as a result of receiving a subpoena or other court order
requiring such participation or appearance will give rise to a right for Protiva to terminate as set forth in this Section 8.4. 
 8.5
Rights in Bankruptcy. Each Party (the “Insolvent Party”) shall promptly notify the other Party (the “Solvent Party”) in writing upon the initiation of any proceeding in bankruptcy, reorganization,
dissolution, liquidation or arrangement for the appointment of a receiver or trustee to take possession of the assets of the Insolvent Party or similar proceeding under law for release of creditors by or against the Insolvent Party or if the
Insolvent Party shall make a general assignment for the benefit of its creditors. To the extent permitted by Applicable Law, if the applicable circumstances described above shall have continued for ***** days undismissed, unstayed, unbonded and
undischarged, the Solvent Party may terminate this Agreement upon written notice to the Insolvent Party at any time. If Protiva is the Insolvent Party, the rights and remedies granted to Dicerna (as the Solvent Party) pursuant to this
Section 8.5 shall be in addition to, and not in lieu of, Dicerna’s rights and remedies under Section 2.4(b) above. 

  
 23 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

 8.6 Consequences of Termination; Survival. 

(a) In the event this Agreement is properly terminated in accordance with its terms, then Dicerna’s rights and licenses under the
Licensed Intellectual Property shall terminate upon the effective date of such termination, except as set forth in Sections 2.2(a) and 8.6(b). Termination of this Agreement shall not relieve the Parties of any obligation accruing prior to or upon
such expiration or termination and the provisions of this Section 8.6, Section 3.3(b), Section 4.3(a) and ARTICLE I – (Definitions), ARTICLE V – (Intellectual Property), ARTICLE VI – (Confidential Information and
Publicity), ARTICLE VII – (Indemnification and Insurance), and ARTICLE IX – (Miscellaneous) shall survive any expiration or termination of this Agreement. 

(b) On the effective date of termination of this Agreement, the Supply Agreement and Quality Agreement between the Parties, shall each
automatically terminate, subject to the survival obligations of each such agreement; provided, however, that (i) within ***** days after expiration or termination of this Agreement, Dicerna will provide Protiva with an inventory of all
Products in Protiva’s, its Affiliates’ and their Sublicensees’ (including CMO’s) possession or control, including finished products and works-in-process (“Final Inventory”) and (ii) for a period of
***** months after such expiration or termination Dicerna will have the right to have its CMOs complete the Manufacture of all works-in-process in the Final Inventory and to sell off all Final Inventory (including Product created from completed
works-in-process) in accordance with the terms of this Agreement (including Section 3.2). 
 (c) After the expiration or termination of
this Agreement, Dicerna shall have no further obligations of payment to Protiva under this Agreement (including for Milestone Payments), except for the Royalty payment obligations in accordance with Section 3.2 related to Dicerna’s sale of
Products sold prior to the date of termination and sales of the Final Inventory in accordance with Section 8.6(b). 
 8.7
Remedies. The Parties acknowledge and agree that, in the event of a breach or a threatened breach by either Party of this Agreement for which it shall have no adequate remedy at law, the other Party may suffer irreparable damage and,
accordingly, may be entitled to injunctive and other equitable remedies to prevent or restrain such breach or threatened breach, in addition to any other remedy they might have at law or at equity. In the event of a breach or threatened breach by a
Party of any such provision, the other Party shall be authorized and entitled to seek from any court of competent jurisdiction injunctive relief, whether preliminary or permanent, arising from such breach, which rights shall be cumulative and in
addition to any other rights or remedies to which the other Party may be entitled in law or equity. 
 ARTICLE IX – MISCELLANEOUS

 9.1 Representations and Warranties. 

(a) Mutual Representations and Warranties by Protiva and Dicerna. 

(i) Each Party hereby represents and warrants to the other Party as of the Effective Date that: 

(a) it is duly organized and validly existing under the laws of the jurisdiction of its incorporation or formation, and has all necessary
power and authority to conduct its business in the manner in which it is currently being conducted, to own and use its assets in the manner in which its assets are currently owned and used, and to enter into and perform its obligations under this
Agreement; 

  
 24 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

 (b) the execution, delivery and performance of this Agreement has been duly authorized by all
necessary action on the part of such Party and its Board of Directors or other governing body and no consent, approval, order or authorization of, or registration, declaration or filing with any Third Party or Governmental Authority is necessary for
the execution, delivery or performance of this Agreement; 
 (c) this Agreement constitutes the legal, valid and binding obligation of such
Party, enforceable against it in accordance with its terms, subject to (A) Applicable Laws of general application relating to bankruptcy, insolvency and the relief of debtors, and (B) Applicable Laws governing specific performance,
injunctive relief and other equitable remedies; and 
 (d) neither it nor any of its Affiliates or their employees have ever been
(i) convicted of a crime for which a Person can be debarred under Section 306(a) or 306(b) of the Generic Drug Enforcement Act of 1992 or under 42 U.S.C. Section 1320-7 or (ii) sanctioned by, suspended, excluded or otherwise
ineligible to participate in any federal health care program, including Medicare and Medicaid or in federal procurement or non-procurement programs. If at any time this representation and warranty is no longer accurate, Protiva or Dicerna, as the
case may be, shall immediately notify the other of such fact. 
 (b) Protiva Representations, Warranties, and Covenants. Protiva
hereby represents, warrants, and covenants to Dicerna that: 
 (i) Protiva shall perform its obligations herein in compliance with all
Applicable Laws; 
 (ii) as of the Effective Date, Protiva has no actual knowledge that the manufacture, use, sale and import of Protiva
Intellectual Property and the LNP Technology, including as used in the Product, infringes, misappropriates or otherwise violates any issued Patent or other intellectual property right of any Third Party anywhere in the Territory; 

(iii) as of the Effective Date, no Affiliate of Protiva or Tekmira (other than Protiva and Tekmira) Controls (including by joint ownership)
any intellectual property rights relevant to or useful to the Development, Manufacture and Commercialization of Products directed to the treatment of PH1; 

(iv) neither Protiva nor any of its Affiliates has assigned, transferred, conveyed or otherwise encumbered, nor during the Term will assign,
transfer, convey or otherwise encumber, its right, title and interest in the Patents, Confidential Information and other intellectual property either owned by or exclusively licensed to Protiva as of the Effective Date in a manner that conflicts
with any rights granted to Dicerna hereunder, subject only to the non-exclusive licenses granted by Protiva prior to the Effective Date as set forth on Exhibit D, and none of the exclusive licenses granted by Protiva prior to the Effective Date as
set forth on Exhibit D conflict with any rights granted to Dicerna hereunder; 

  
 25 

 (v) as of the Effective Date, except for the grant of license rights set forth at
Section 2.1(b), Tekmira is a party to this Agreement and the Supply Agreement for the sole purpose of providing the representations, warranties and covenants set forth in this Section 9.1(c); 

(vi) for each country or jurisdiction in which Protiva Controls any Protiva Patent as of the Effective Date, Exhibit A lists the
Protiva Patent in such country or jurisdiction with the latest twenty year expiration date, calculated from the earliest filed, non-provisional, application from which benefit of priority is claimed, for any Protiva Patent in such country or
jurisdiction; and 
 (vii) Protiva shall not file any new Patent applications in any country or jurisdiction for the predominant purpose of
extending the duration of the Royalty Payment Term. 
 (c) Tekmira Representations, Warranties, and Covenants. Tekmira hereby
represents, warrants, and covenants to Dicerna that: 
 (i) as of the Effective Date, it is duly organized and validly existing under the
laws of the jurisdiction of its incorporation or formation, and has all necessary power and authority to conduct its business in the manner in which it is currently being conducted, to own and use its assets in the manner in which its assets are
currently owned and used, and to enter into and perform its obligations under this Agreement; 
 (ii) as of the Effective Date, the
execution, delivery and performance of this Agreement has been duly authorized by all necessary action on the part of Tekmira and its Board of Directors and no consent, approval, order or authorization of, or registration, declaration or filing with
any Third Party or Governmental Authority is necessary for the execution, delivery or performance of this Agreement; 
 (iii) as of the
Effective Date, Tekmira has no actual knowledge that the manufacture, use, sale and import of Tekmira Patents, including as used in the Product, infringes, misappropriates or otherwise violates any issued Patent or other intellectual property right
of any Third Party anywhere in the Territory; 
 (iv) as of the Effective Date, this Section 9.1(c) constitutes the legal, valid and
binding obligation of Tekmira, enforceable against it in accordance with its terms, subject to (A) Applicable Laws of general application relating to bankruptcy, insolvency and the relief of debtors, and (B) Applicable Law governing
specific performance, injunctive relief and other equitable remedies; 
 (v) as of the Effective Date, neither it nor any of its Affiliates
or their employees have ever been (i) convicted of a crime for which a Person can be debarred under Section 306(a) or 306(b) of the Generic Drug Enforcement Act of 1992 or under 42 U.S.C. Section 1320-7 or (ii) sanctioned by,
suspended, excluded or otherwise ineligible to participate in any federal health care program, including Medicare and Medicaid or in federal procurement or non-procurement programs; 

  
 26 

 (vi) if at any time the representation and warranty in Section 9.1(c)(v) is no longer
accurate, Tekmira shall promptly notify Dicerna of such fact; 
 (vii) neither Tekmira nor any of its Affiliates has assigned, transferred,
conveyed or otherwise encumbered, nor during the Term will assign, transfer, convey or otherwise encumber, its right, title and interest in the Patents owned by or exclusively licensed to Tekmira as of the Effective Date in a manner that conflicts
with any rights granted to Dicerna hereunder, subject only to the non-exclusive licenses granted by Tekmira prior to the Effective Date as set forth on Exhibit D, and none of the exclusive licenses granted by Tekmira prior to the Effective Date as
set forth on Exhibit D conflict with any rights granted to Dicerna hereunder; and 
 (viii) Tekmira shall cause Protiva to perform and to
comply with the provisions of this Agreement, and shall remain responsible for and guarantee the performance of Protiva under this Agreement, and is liable to Dicerna for any breach of this Agreement by Protiva and for the actions and omissions of
Protiva undertaken pursuant to this Agreement as if taken by Tekmira itself. 
 (ix) for each country or jurisdiction in which Tekmira
Controls any Tekmira Patent as of the Effective Date, Exhibit B lists the Tekmira Patent in such country or jurisdiction with the latest twenty year expiration date, calculated from the earliest filed, non-provisional, application from which
benefit of priority is claimed, for any Tekmira Patent in such country or jurisdiction; and 
 (x) Tekmira shall not file any new Patent
applications in any country or jurisdiction for the predominant purpose of extending the duration of the Royalty Payment Term. 
 (d)
Warranty Disclaimer. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTY OR CONDITIONS OF ANY KIND, EITHER EXPRESS OR IMPLIED, TO THE OTHER PARTY WITH RESPECT TO ANY
INTELLECTUAL PROPERTY, PRODUCTS, GOODS, RIGHTS OR OTHER SUBJECT MATTER OF THIS AGREEMENT AND HEREBY DISCLAIMS ALL IMPLIED CONDITIONS, REPRESENTATIONS, AND WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND
NONINFRINGEMENT OR VALIDITY OF PATENT RIGHTS WITH RESPECT TO ANY AND ALL OF THE FOREGOING. EACH PARTY HEREBY DISCLAIMS ANY REPRESENTATION OR WARRANTY THAT THE DEVELOPMENT, MANUFACTURE OR COMMERCIALIZATION OF ANY PRODUCT PURSUANT TO THIS AGREEMENT
SHALL BE SUCCESSFUL OR THAT ANY PARTICULAR SALES LEVEL WITH RESPECT TO ANY SUCH PRODUCT SHALL BE ACHIEVED. 
 9.2 Force Majeure.
Except with respect to payment obligations, a Party shall neither be held liable or responsible to any other Party, nor be deemed to have defaulted under or 

  
 27 

 
breached this Agreement, for failure or delay in fulfilling or performing any term of this Agreement to the extent, and for so long as, such failure or delay is caused by or results from causes
beyond the reasonable control of the affected Party, including fire, floods, embargoes, power shortage or failure, acts of war (whether war be declared or not), insurrections, riots, terrorism, civil commotions, strikes, lockouts or other labor
disturbances, acts of God or any acts, omissions or delays in acting by any Governmental Authority or any other Party, and such affected Party promptly begins performing under this Agreement once such causes have been removed. 

9.3 Consequential Damages. UNDER NO CIRCUMSTANCES WILL ANY PARTY BE LIABLE TO ANY OTHER PARTY WITH RESPECT TO THIS AGREEMENT, AND THE
ACTIVITIES CONTEMPLATED HEREBY, FOR ANY CONSEQUENTIAL, INDIRECT, SPECIAL, PUNITIVE, INCIDENTAL OR SIMILAR DAMAGES, WHETHER FORESEEABLE OR UNFORESEEABLE AND REGARDLESS OF THE CAUSE OF ACTION FROM WHICH THEY ARISE, EVEN IF ADVISED OF THE POSSIBILITY
OF SUCH DAMAGES OCCURRING. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 9.3 IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OF A PARTY OR DAMAGES AVAILABLE FOR A PARTY’S BREACH OF CONFIDENTIALITY OBLIGATIONS IN
ARTICLE VI. 
 9.4 Assignment. Neither Party shall assign any of its rights and obligations hereunder without the prior written
consent of the other Party, except (a) to a purchaser of all or substantially all of the assets or business of such Party to which this Agreement relates, or to the successor resulting from any merger, acquisition, consolidation or similar
transaction with such Party and (b) to an Affiliate; provided, however, that (i) such assignment to an Affiliate shall not relieve such Party of its obligations herein, and (ii) in each case, the assigning Party shall
provide the other Party with written notice of such assignment. Any purported transfer or assignment in contravention of this Section 9.4 shall, at the option of the non-assigning Party, be null and void and of no effect. This Agreement shall
be binding upon and inure to the benefit of the Parties and their permitted successors and assigns. 
 9.5 Notices. 

Notices to Dicerna shall be addressed to: 

Dicerna Pharmaceuticals, Inc. 

480 Arsenal St., #120 
 Watertown,
MA 02472 
 United States 

Attention: CEO and President 

With a copy to: 
 Dicerna
Pharmaceuticals, Inc. 
 480 Arsenal St., #120 

Watertown, MA 02472 
 United
States 
 Attention: Chief Financial Officer 

  
 28 

 Notices to Protiva shall be addressed to: 

Protiva Pharmaceuticals Corporation 

100-8900 Glenlyon Parkway 

Burnaby, B.C. 
 Canada V5J 5J8

 Attention: President & CEO 

Facsimile No.: (604) 630-5103 

Notices to Tekmira shall be addressed to: 

Tekmira Pharmaceuticals Corporation 

100-8900 Glenlyon Parkway 

Burnaby, B.C. 
 Canada V5J 5J8

 Attention: President & CEO 

Facsimile No.: (604) 630-5103 

In each case with copy to: 

Orrick, Herrington & Sutcliffe LLP 

51 West 52nd Street 

New York, NY 10019 
 Attention: R.
King Milling 
 Facsimile No.: (212) 506-5151 

Any party hereto may change their address by giving notice to the other parties in the manner provided in this Section 9.5. Any notice required or
provided for by the terms of this Agreement shall be in writing and shall be (a) sent by certified mail, return receipt requested, postage prepaid, (b) sent via a reputable international express courier service, or (c) sent by
facsimile transmission, with a copy by regular mail. The effective date of the notice shall be the actual date of receipt by the receiving party. 

9.6 Independent Contractors. It is understood and agreed that the relationship between the Parties is that of independent contractors
and that nothing in this Agreement shall be construed as authorization for either Party to act as the agent for the other Party. 
 9.7
Governing Law; Dispute Resolution; Arbitration. This Agreement shall be governed and interpreted in accordance with the substantive laws of the State of New York, excluding its conflicts of laws principles. 

(a) The Parties and Tekmira recognize that a bona fide dispute as to certain matters may from time to time arise during the Term that relate
to a Party or Tekmira’s rights or obligations hereunder. In the event of the occurrence of any Dispute, the Parties and Tekmira shall first have such Dispute referred to their respective executives designated below for

  
 29 

 
attempted resolution by good faith negotiations within ***** calendar days after such notice is received. If either Party or Tekmira desires to pursue arbitration under Section 9.7(b)
below to resolve any such Dispute, unless expressly provided for otherwise herein, a referral to such executives under this Section 9.7(a) shall be a mandatory condition precedent. Said designated executives as of the Effective Date are as
follows. 
  

			
	For Dicerna:		Douglas Fambrough, Ph.D., President and CEO
		
	For Protiva:		Mark Murray, President and CEO
		
	For Tekmira:		Mark Murray, President and CEO

 In the event that they shall be unable to resolve the Dispute by consensus within such *****-day period, the Dispute shall be
finally settled by binding arbitration as provided below. 
 (b) Except as expressly otherwise provided in this Agreement, in the event of
any dispute arising out of or relating to the interpretation of any provision of this Agreement or the failure of either Party or Tekmira to perform or comply with any obligation of such party pursuant to this Agreement or the breach, termination or
validity hereof (a “Dispute”), such Dispute will be finally settled by arbitration in accordance with the commercial arbitration rules of the American Arbitration Association, then in force and the Federal Arbitration Act, 9 U.S.C.
§ 1 et seq., by three (3) arbitrators (the “Arbitrators”); provided that the appointed arbitrators shall have appropriate experience in the pharmaceutical industry. Dicerna shall appoint one Arbitrator and Protiva
and Tekmira, collectively, shall appoint one Arbitrator, and such two Arbitrators shall jointly appoint the third Arbitrator. If any party is not able to appoint its Arbitrator or the two initial Arbitrators are not able to appoint the third
Arbitrator within a reasonable amount of time after the initiation of such process, the applicable Arbitrator or Arbitrators will be appointed in accordance with the above identified commercial arbitration rules. The place of arbitration will be New
York, New York, and the Arbitrators must decide the Dispute in accordance with the substantive laws of the State of New York. The Arbitrators, by accepting their appointment, undertake to conduct the process such that the award is rendered within
***** months of their appointment and is final and binding upon all parties participating in such arbitration. The judgment rendered by the Arbitrators may, at the Arbitrator’s discretion, include costs of arbitration, reasonable
attorneys’ fees and reasonable costs for any expert and other witnesses. Judgment upon the award may be entered in any court having jurisdiction, or application may be made to such court for judicial acceptance of the award or an order of
enforcement as the case may be. Any period of limitations or survival period that would otherwise expire between the initiation of the procedures described in this Section 9.7 and the conclusion of such procedures will be extended until
***** days following the conclusion of such procedures. This Section 9.7 does not prohibit a Party or Tekmira from seeking preliminary injunctive relief in aid of arbitration from a court of competent jurisdiction. 

(c) The Parties and Tekmira consent to (i) the exclusive jurisdiction of the Federal courts and the State courts of the State of New
York, in each case, located in the borough of Manhattan, City of New York (the “New York Courts”) for (A) any action referenced in Section 9.7(d) and (B) any action in aid of arbitration, for provisional relief of the
status quo or to prevent irreparable harm prior to the appointment of the Arbitrators in Section 9.7(b) above, and 

  
 30 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

 
(ii) the non-exclusive jurisdiction of the New York Courts for any action to enter or enforce any arbitral award entered in connection with this Agreement. THE PARTIES AND TEKMIRA HEREBY
IRREVOCABLY WAIVE, AND AGREE TO CAUSE THEIR RESPECTIVE AFFILIATES TO WAIVE, THE RIGHT TO TRIAL BY JURY IN SUCH ACTIONS. 
 (d) Unless agreed
by the Parties, the foregoing alternative dispute resolution procedures shall not be used with respect to any claim by one Party against another regarding the validity, infringement, misappropriation or violation of a Patent, copyright, trade secret
or trademark. 
 9.8 Severability. In the event that any provision of this Agreement is held by a court of competent jurisdiction to
be unenforceable because it is invalid or in conflict with any law of the relevant jurisdiction, the validity of the remaining provisions shall not be affected and the rights and obligations of the Parties and Tekmira shall be construed and enforced
as if the Agreement did not contain the particular provisions held to be unenforceable, provided that the Parties and Tekmira, shall negotiate in good faith a modification of this Agreement with a view to revising this Agreement in a
manner which reflects, as closely as is reasonably practicable, the commercial terms of this Agreement as originally signed. 
 9.9 No
Implied Waivers. The waiver by either Party or Tekmira of a breach or default of any provision of this Agreement by the other Party or Tekmira shall not be construed as a waiver of any succeeding breach of the same or any other provision, nor
shall any delay or omission on the part of either Party or Tekmira to exercise or avail itself of any right, power or privilege that it has or may have hereunder operate as a waiver of any right, power or privilege by such Party or Tekmira. 

9.10 Headings. The headings of articles and sections contained this Agreement are intended solely for convenience and ease of reference
and do not constitute any part of this Agreement, or have any effect on its interpretation or construction. 
 9.11 Entire Agreement;
Amendment. This Agreement (along with the attachments), the Supply Agreement, and the Quality Agreement contain the entire understanding of the Parties and Tekmira with respect to the subject matter hereof and thereof and supersede and replace
any and all previous arrangements and understandings, whether oral or written, between the Parties and Tekmira with respect to the subject matter hereof and thereof. This Agreement (including the attachments hereto) may be amended only by a writing
signed by each of the Parties and Tekmira. 
 9.12 Waiver of Rule of Construction. Each Party and Tekmira has had the opportunity to
consult with counsel in connection with the review, drafting and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting party shall not apply. 

9.13 No Third-Party Beneficiaries. Except as expressly contemplated herein, no Third Party, including any employee of either Party or
Tekmira, shall have or acquire any rights by reason of this Agreement. 

  
 31 

 9.14 Further Assurances. Each Party and Tekmira shall provide such further documents or
instruments required by the other Party or Tekmira as may be reasonably necessary or desirable to give effect to the purpose of this Agreement and carry out its provisions. 

9.15 Performance by Affiliates. Either Party may use one or more of its Affiliates to perform its obligations and duties hereunder, and
Affiliates of a Party are expressly granted certain rights herein; provided that each such Affiliate shall be bound by the corresponding obligations of such Party and the relevant Party shall remain liable hereunder for the prompt
payment and performance of all their respective obligations hereunder. 
 9.16 Counterparts. This Agreement may be executed in any
number of counterparts in original or by facsimile or PDF copy, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument. 

[Signature Page Follows] 

  
 32 

 IN WITNESS WHEREOF, authorized representatives of Dicerna, Protiva and Tekmira have executed and delivered this
License Agreement effective as of the Effective Date. 
  

			
	DICERNA PHARMACEUTICALS, INC.
		
	By:		 /s/ Douglas Fambrough

	Name:		Douglas Fambrough
	Title:		CEO & President
	
	DICERNA PHARMACEUTICALS, INC.
		
	By:		 /s/ James E. Dentzer

	Name:		James E. Dentzer
	Title:		Chief Financial Officer
	
	PROTIVA BIOTHERAPEUTICS INC.
		
	By:		 /s/ B. Cousins

	Name:		B. Cousins
	Title:		EVP & CFO
		
	By:		 /s/ Paul Brennan

	Name:		Paul Brennan
	Title:		SVP Business Development
	
	TEKMIRA PHARMACEUTICALS CORPORATION
		
	By:		 /s/ B. Cousins

	Name:		B. Cousins
	Title:		EVP & CFO
		
	By:		 /s/ Paul Brennan

	Name:		Paul Brennan
	Title:		SVP Business Development

 [Signature Page to License Agreement] 

 Exhibit A 

Protiva Patents 
  

							
	*****						

  
 34 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

 Exhibit B 

Tekmira Patents 
  

			
	*****		

  
 35 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

 Exhibit C 

Excluded Patents 
 ***** 

  
 36 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

 ***** 

  
 37 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

 Exhibit D 

Existing License Grants 
 ***** 

  
 38 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

 Exhibit E 

Press Releases 
 Dicerna Press Release
– See Attachment E-1. 
 Protiva Press Release – See Attachment E-2. 

  
 39 

 Attachment E-1. 

Dicerna Announces License Agreement with Tekmira 

to Advance Dicerna’s PH1 Development Program 

WATERTOWN, Mass., November 17, 2014 – Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of RNA interference (RNAi)
therapeutics, today announced a licensing agreement for Dicerna to use Tekmira’s proprietary lipid nanoparticle (LNP) technology for delivery of DCR-PH1, Dicerna’s investigational product candidate for primary hyperoxaluria type 1 (PH1), a
rare, inherited liver disorder that often results in kidney failure, and for which there are no approved therapies.  
 This announcement follows the
successful testing of DCR-PH1 in combination with Tekmira’s LNP technology in animal models, including mice and non-human primates. Under the agreement, Dicerna will pay Tekmira $2.5 million upfront, as well as $22 million in potential
development milestones, and a mid-single-digit royalty on future PH1 sales. 
 Tekmira’s LNP system has shown in other human clinical studies to
provide potent, safe and effective RNA delivery to hepatocytes (liver cells). Licensing Tekmira’s LNP will streamline the development path for DCR-PH1 and allows Dicerna to focus its LNP efforts on its oncology pipeline. 

“Dicerna is focused on realizing the full clinical potential of our proprietary pipeline of highly targeted RNAi therapies by applying proven
technologies,” said Douglas Fambrough, Ph.D., Chief Executive Officer of Dicerna. “By drawing on Tekmira’s extensive and deep experience with lipid nanoparticle delivery to the liver, the agreement will streamline the development path
for DCR-PH1. We look forward to initiating Phase 1 trials of DCR-PH1 in 2015, aiming to fill a high unmet medical need for patients with PH1.”

“This new agreement validates our leadership position in RNAi delivery and underscores the significant value we can bring to partners who leverage our
LNP technology,” said Dr. Mark J. Murray, President and CEO of Tekmira. “Our LNP technology is enabling the most advanced applications of RNAi therapeutics in the clinic. We are excited to be working with Dicerna in advancing a
needed, investigational therapeutic for the treatment of PH1.” 
 About RNAi 

RNAi therapeutics have the potential to treat a number of human diseases by “silencing” disease-causing genes. The discoverers of RNAi, a gene
silencing mechanism used by all cells, were awarded the 2006 Nobel Prize for Physiology or Medicine. RNAi trigger molecules often require delivery technology to be effective as therapeutics. 

  
 40 

 About Tekmira’s LNP Technology 

Tekmira LNP technology represents the most widely adopted delivery technology for the systemic delivery of RNAi triggers. Tekmira’s LNP platform is being
utilized in multiple clinical trials by Tekmira and its partners. Tekmira’s LNP technology (formerly referred to as stable nucleic acid-lipid particles, or SNALP) encapsulates RNAi triggers with high efficiency in uniform lipid nanoparticles
that are effective in delivering these therapeutic compounds to disease sites. Tekmira’s LNP formulations are manufactured by a proprietary method that is robust, scalable and highly reproducible, and LNP-based products have been reviewed by
multiple regulatory agencies for use in clinical trials. LNP formulations comprise several lipid components that can be adjusted to suit the specific application. 

About Primary Hyperoxaluria Type 1 (PH1) 
 PH1 is a
rare, inherited liver disorder that often results in severe damage to the kidneys. The disease can be fatal unless the patient undergoes a liver-kidney transplant, a major surgical procedure that is often difficult to perform due to the lack of
donors and the threat of organ rejection. In the event of a successful transplant, the patient must live the rest of his or her life on immunosuppressant drugs, which have substantial associated risks. Currently, there are no FDA approved treatments
for PH1. 
 PH1 is characterized by a genetic deficiency of the liver enzyme alanine:glyoxalate-aminotransferase (AGT), which is encoded by the AGXT gene.
AGT deficiency induces overproduction of oxalate by the liver, resulting in the formation of crystals of calcium oxalate in the kidneys. Oxalate crystal formation often leads to chronic and painful cases of kidney stones and subsequent fibrosis
(scarring), which is known as nephrocalcinosis. Many patients progress to end-stage renal disease (ESRD) and require dialysis or transplant. Aside from having to endure frequent dialysis, PH1 patients with ESRD may experience a build-up of oxalate
in the bone, skin, heart and retina, with concomitant debilitating complications. While the true prevalence of primary hyperoxaluria is unknown, it is estimated to be one to three cases per one million people.1 Fifty percent of patients with PH1 reach ESRD by their mid-30s.2 

About DCR-PH1 
 Dicerna is developing DCR-PH1, which is in
preclinical development, for the treatment of PH1. DCR-PH1 is engineered to address the pathology of PH1 by targeting and destroying the messenger RNA (mRNA) produced by HAO1, a gene implicated in the pathogenesis of PH1. HAO1 encodes glycolate
oxidase, a protein involved in producing oxalate. By reducing oxalate production, this approach is designed to prevent the complications of PH1. In preclinical studies, DCR-PH1 has been shown to induce potent and long-term inhibition of HAO1 and to
significantly reduce levels of urinary oxalate, while demonstrating long-term efficacy and tolerability in animal models of PH1. 

  
 41 

 About Dicerna’s Dicer Substrate Technology 

Dicerna’s proprietary RNAi molecules are known as Dicer substrates, or DsiRNAs, so called because they are processed by the Dicer enzyme, which is the
initiation point for RNAi in the human cell cytoplasm. Dicerna’s discovery approach is believed to maximize RNAi potency because the DsiRNAs are structured to be ideal for processing by Dicer. Dicer processing enables the preferential use of
the correct RNA strand of the DsiRNA, which may increase the efficacy of the RNAi mechanism, as well as the potency of the DsiRNA molecules relative to other molecules used to induce RNAi. 

About Tekmira 
 Tekmira Pharmaceuticals Corporation is a
biopharmaceutical company focused on advancing novel RNAi therapeutics and providing its leading lipid nanoparticle (LNP) delivery technology to pharmaceutical partners. Tekmira has been working in the field of nucleic acid delivery for over a
decade, and has broad intellectual property covering its delivery technology. Further information about Tekmira can be found at www.tekmira.com. Tekmira is based in Vancouver, Canada and Seattle, USA. 

About Dicerna 
 Dicerna Pharmaceuticals, Inc., is a
biopharmaceutical company focused on the discovery and development of innovative treatments for rare, inherited diseases involving the liver and for cancers that are genetically defined. The company is using its proprietary RNA interference (RNAi)
technology platform to build a broad pipeline in these therapeutic areas. In both rare diseases and oncology, Dicerna is pursuing targets that have been difficult to address using conventional approaches, but where connections between targets and
diseases are well understood and documented. The company intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. 

Cautionary Note on Forward-Looking Statements 
 This press
release includes forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and
uncertainties include that LNP technology may fail to deliver DCR-PH1 to the liver in human beings or otherwise fail to accelerate clinical development, and that clinical trials may not demonstrate the effectiveness of DCR-PH1. Additional risks,
including those relating to Dicerna’s preclinical research and clinical development and other risks, are identified under the heading “Risk Factors” included in Dicerna’s most recent Form 10-Q filing and in other future filings
with the SEC. The forward-looking statements contained in this press release reflect Dicerna’s current views with respect to future events, and Dicerna does not undertake and specifically disclaims any obligation to update any
forward-looking statements. 

  
 42 

 References 
  

	1 	Cochat, P, Rumsby, G. Primary hyperoxaluria. The New England Journal of Medicine 2013; 369(7): 649-658. 

	2 	Rare Kidney Stone Consortium. Primary Hyperoxaluria. 2010. Available at: http://www.rarekidneystones.org/hyperoxaluria/physicians.html. Accessed October 14, 2014. 

Investor Contacts: 
 Westwicke Partners 

Yolanda Taylor, 617-366-6803 
 yolanda.taylor@westwicke.com

 Media Contacts: 
 SmithSolve 

Alex Van Rees, 973-442-1555 ext. 111 

alex.vanrees@smithsolve.com 

  
 43 

 Attachment E-2. 
  

			
	Not For Immediate Release		November 17, 2014

 Tekmira Announces Licensing and Collaboration Agreement with Dicerna 

Tekmira’s LNP to enable Dicerna’s PH1 Candidate 

Vancouver, B.C. – Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR; TSX:TKM) a leading developer of RNA interference (RNAi) therapeutics, today
announces a licensing and collaboration agreement with Dicerna Pharmaceuticals, Inc. Tekmira has licensed its proprietary lipid nanoparticle (LNP) delivery technology for exclusive use in Dicerna’s primary hyperoxaluria type 1 (PH1) development
program. 
 Under the agreement, Dicerna will pay Tekmira $2.5 million upfront and payments of $22 million in aggregate development milestones, plus a
mid-single-digit royalty on future PH1 sales. This new partnership also includes a supply agreement with Tekmira providing clinical drug supply and regulatory support in the rapid advancement of the product candidate. 

The agreement announced today follows the successful testing and demonstration of positive results combining Tekmira’s LNP technology with DCR-PH1 in
pre-clinical animal models. 
 Dicerna will use Tekmira’s third generation LNP technology for delivery of DCR-PH1, Dicerna’s Dicer substrate RNA
(DsiRNA) molecule, for the treatment of PH1, a rare, inherited liver disorder that often results in kidney failure and for which there are no approved therapies. 

“This new agreement validates our leadership position in RNAi delivery with LNP technology, and it underscores the significant value we can bring to
partners who leverage our technology. Our LNP technology is enabling the most advanced applications of RNAi therapeutics in the clinic, and it continues to do so. We are excited to be working with Dicerna to be able to advance a needed therapeutic
for the treatment of PH1,” said Dr. Mark J. Murray, Tekmira’s President and CEO. 
 “As a core pillar of our business strategy, we
continue to engage in partnerships where our technology improves the risk profile and accelerates the development programs of our collaborators and provides meaningful non-dilutive financing to TKMR,” added Dr. Murray. 

  
 44 

 “Dicerna is focused on realizing the full clinical potential of our proprietary pipeline of highly targeted
RNAi therapies by applying proven technologies,” said Douglas Fambrough, Ph.D., Chief Executive Officer of Dicerna. “By drawing on Tekmira’s extensive and deep experience with lipid nanoparticle delivery to the liver, the agreement
will streamline the development path for DCR-PH1. We look forward to initiating Phase 1 trials of DCR-PH1 in 2015, aiming to fill a high unmet medical need for patients with PH1.”

About RNAi 
 RNAi therapeutics have the potential to treat
a number of human diseases by “silencing” disease-causing genes. The discoverers of RNAi, a gene silencing mechanism used by all cells, were awarded the 2006 Nobel Prize for Physiology or Medicine. RNAi trigger molecules often require
delivery technology to be effective as therapeutics. 
 About Tekmira’s LNP Technology 

Tekmira believes its LNP technology represents the most widely adopted delivery technology for the systemic delivery of RNAi triggers. Tekmira’s LNP
platform is being utilized in multiple clinical trials by Tekmira and its partners. Tekmira’s LNP technology (formerly referred to as stable nucleic acid-lipid particles, or SNALP) encapsulates RNAi triggers with high efficiency in uniform
lipid nanoparticles that are effective in delivering these therapeutic compounds to disease sites. Tekmira’s LNP formulations are manufactured by a proprietary method which is robust, scalable and highly reproducible, and LNP-based products
have been reviewed by multiple regulatory agencies for use in clinical trials. LNP formulations comprise several lipid components that can be adjusted to suit the specific application. 

About Primary Hyperoxaluria Type 1 (PH1) 
 PH1 is a
rare, inherited liver disorder that often results in severe damage to the kidneys. The disease can be fatal unless the patient undergoes a liver-kidney transplant, a major surgical procedure that is often difficult to perform due to the lack of
donors and the threat of organ rejection. In the event of a successful transplant, the patient must live the rest of his or her life on immunosuppressant drugs, which have substantial associated risks. Currently, there are no FDA approved treatments
for PH1. 
 PH1 is characterized by a genetic deficiency of the liver enzyme alanine:glyoxalate-aminotransferase (AGT), which is encoded by the AGXT gene.
AGT deficiency induces overproduction of oxalate by the liver, resulting in the formation of crystals of calcium oxalate in the kidneys. Oxalate crystal formation often leads to chronic and painful cases of kidney stones and subsequent fibrosis
(scarring), which is known as 

  
 45 

 
nephrocalcinosis. Many patients progress to end-stage renal disease (ESRD) and require dialysis or transplant. Aside from having to endure frequent dialysis, PH1 patients with ESRD may experience
a build-up of oxalate in the bone, skin, heart and retina, with concomitant debilitating complications. While the true prevalence of primary hyperoxaluria is unknown, it is estimated to be one to three cases per one million people.1 Fifty percent of patients with PH1 reach ESRD by their mid-30s.2 

About DCR-PH1 
 Dicerna is developing DCR-PH1, which is in
preclinical development, for the treatment of PH1. DCR-PH1 is engineered to address the pathology of PH1 by targeting and destroying the messenger RNA (mRNA) produced by HAO1, a gene implicated in the pathogenesis of PH1. HAO1 encodes glycolate
oxidase, a protein involved in producing oxalate. By reducing oxalate production, this approach is designed to prevent the complications of PH1. In preclinical studies, DCR-PH1 has been shown to induce potent and long-term inhibition of HAO1 and to
significantly reduce levels of urinary oxalate, while demonstrating long-term efficacy and tolerability in animal models of PH1. 
 About Dicerna’s
Dicer Substrate Technology 
 Dicerna’s proprietary RNAi molecules are known as Dicer substrates, or DsiRNAs, so called because they are processed
by the Dicer enzyme, which is the initiation point for RNAi in the human cell cytoplasm. Dicerna’s discovery approach is believed to maximize RNAi potency because the DsiRNAs are structured to be ideal for processing by Dicer. Dicer processing
enables the preferential use of the correct RNA strand of the DsiRNA, which may increase the efficacy of the RNAi mechanism, as well as the potency of the DsiRNA molecules relative to other molecules used to induce RNAi. 

About Tekmira 
 Tekmira Pharmaceuticals Corporation is a
biopharmaceutical company focused on advancing novel RNAi therapeutics and providing its leading lipid nanoparticle (LNP) delivery technology to pharmaceutical partners. Tekmira has been working in the field of nucleic acid delivery for over a
decade, and has broad intellectual property covering its delivery technology. Further information about Tekmira can be found at www.tekmira.com. Tekmira is based in Vancouver, Canada and Seattle, USA. 

About Dicerna 
 Dicerna Pharmaceuticals, Inc., is a
biopharmaceutical company focused on the discovery and development of innovative treatments for rare, inherited diseases involving the liver and for cancers that are genetically defined. The company is using its proprietary RNA interference (RNAi)
technology platform to build a broad pipeline in these therapeutic areas. In both rare diseases and oncology, Dicerna is pursuing 

  
 46 

 
targets that have been difficult to address using conventional approaches, but where connections between targets and diseases are well understood and documented. The company intends to discover,
develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. 
 Forward-Looking Statements and
Information 
 This news release contains “forward-looking statements” or “forward-looking information” within the meaning of
applicable securities laws (collectively, “forward-looking statements”). Forward-looking statements in this news release include statements about Tekmira’s strategy, future operations, clinical trials, prospects and the plans of
management; RNAi (ribonucleic acid interference) product development programs; the licensing and collaboration agreement with Dicerna; the upfront and development milestones, and royalties on future sales payable by Dicerna to Tekmira; the supply
agreement with Dicerna; and initiation of Phase I trials of DCR-PH1 in 2015. 
 With respect to the forward-looking statements contained in this news
release, Tekmira has made numerous assumptions regarding, among other things: LNP’s status as a leading RNAi delivery technology. While Tekmira considers these assumptions to be reasonable, these assumptions are inherently subject to
significant business, economic, competitive, market and social uncertainties and contingencies. 
 Additionally, there are known and unknown risk factors
which could cause Tekmira’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained herein. Known risk factors
include, among others: the use of Tekmira’s LNP delivery technology for delivery of DCR-PH1 may have no positive effect on the treatment of PH1; Tekmira may not receive milestone payments or royalties from Dicerna in the quantum anticipated, or
at all; the initiation of Phase I trials of DCR-PH1 may not occur as currently contemplated, or at all; Tekmira’s products may not prove to be effective or as potent as currently believed; the FDA may refuse to approve Tekmira’s products,
or place restrictions on Tekmira’s ability to commercialize its products; Tekmira may not obtain and protect intellectual property rights, and operate without infringing on the intellectual property rights of others; Tekmira may face
competition from other pharmaceutical or biotechnology companies and the possibility that other organizations have made advancements in RNAi delivery technology that Tekmira is not aware of; anticipated pre-clinical and clinical trials may be more
costly or take longer to complete than anticipated, and may never be initiated or completed, or may not generate results that warrant future development of the tested drug candidate; and economic and capital market conditions. 

  
 47 

 A more complete discussion of the risks and uncertainties facing Tekmira appears in Tekmira’s Annual Report
on Form 10-K and Tekmira’s continuous disclosure filings, which are available at www.sedar.com or at www.sec.gov. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Tekmira disclaims any
obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by
law. 
 ### 
 References 

 

	1 	Cochat, P, Rumsby, G. Primary hyperoxaluria. The New England Journal of Medicine 2013; 369(7): 649-658. 

	2 	Rare Kidney Stone Consortium. Primary Hyperoxaluria. 2010. Available at: http://www.rarekidneystones.org/hyperoxaluria/physicians.html. Accessed October 14, 2014. 

  
 48 

			
	 Investor Contacts:
  

Tekmira:
 Julie P. Rezler

 
 Director, Investor Relations

 
 Phone: 604-419-3200

 
 Email: jrezler@tekmira.com
		 Media Contacts:
  

Tekmira:
 Please direct all media inquiries to
media@tekmira.com

  
 49EX-10.29

 Exhibit 10.29 

Execution Version 
  

 

DEVELOPMENT AND SUPPLY AGREEMENT 

By and Among 

PROTIVA BIOTHERAPEUTICS INC. 

And 

TEKMIRA PHARMACEUTICALS CORPORATION 

ON THE ONE HAND, 

And 

DICERNA PHARMACEUTICALS, INC. 

ON THE OTHER HAND 

 
  

  
 THE COMPANY HAS REQUESTED AN ORDER FROM
THE SECURITIES AND EXCHANGE COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED
FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

 TABLE OF CONTENTS 

 

							
	 Article 1 DEFINITIONS AND INTERPRETATION
		 	1	  
			
	 1.1
		 Definitions.
		 	1	  
			
	 1.2
		 Interpretation.
		 	8	  
			
	 1.3
		 Conflict.
		 	8	  
		
	 Article 2 DEVELOPMENT COLLABORATION
		 	9	  
			
	 2.1
		 Responsibilities of Protiva under the Services.
		 	9	  
			
	 2.2
		 Technical Transfer.
		 	10	  
			
	 2.3
		 Statements of Work.
		 	10	  
			
	 2.4
		 Joint Development Committee.
		 	10	  
			
	 2.5
		 On-Site Participation of Dicerna Personnel at the Facilities.
		 	12	  
			
	 2.6
		 Acceptance of Final Formulated Product.
		 	12	  
		
	 Article 3 FORECASTING
		 	12	  
			
	 3.1
		 Batch Forecasting.
		 	12	  
			
	 3.2
		 Services Forecasting.
		 	13	  
			
	 3.3
		 Lead Times for Manufacturing SOWs.
		 	13	  
			
	 3.4
		 Lead Times for all Other SOWs.
		 	14	  
			
	 3.5
		 Binding SOWs and Change Orders.
		 	15	  
		
	 Article 4 MANUFACTURING
		 	16	  
			
	 4.1
		 Dicerna Materials.
		 	16	  
			
	 4.2
		 Protiva Materials.
		 	17	  
			
	 4.3
		 Specification Changes.
		 	17	  
			
	 4.4
		 Responsibility for Safe Use and Safe Keeping.
		 	18	  
			
	 4.5
		 Manufacture.
		 	18	  
			
	 4.6
		 Testing and Release.
		 	20	  
			
	 4.7
		 Storage, Packaging and Shipment.
		 	20	  
			
	 4.8
		 Inspection Upon Receipt.
		 	20	  
			
	 4.9
		 Disputed Batch.
		 	20	  
			
	 4.10
		 Independent Laboratory.
		 	21	  
			
	 4.11
		 Replacement Batches.
		 	21	  
			
	 4.12
		 Non-GMP Batches.
		 	22	  

							
		
	 Article 5 REGULATORY MATTERS
		 	22	  
			
	 5.1
		 Quality Agreement.
		 	22	  
		
	 Article 6 FINANCIAL PROVISIONS
		 	22	  
			
	 6.1
		 Invoicing.
		 	22	  
			
	 6.2
		 Rescheduling and Cancellation.
		 	23	  
			
	 6.3
		 Payment and Interest.
		 	23	  
			
	 6.4
		 Payment Procedures and Tax.
		 	23	  
			
	 6.5
		 Records and Audit.
		 	24	  
		
	 Article 7 INTELLECTUAL PROPERTY
		 	24	  
			
	 7.1
		 License Agreement.
		 	24	  
			
	 7.2
		 Ownership.
		 	24	  
			
	 7.3
		 Prosecution and Maintenance of Joint Patents and Product Composition Patents.
		 	26	  
			
	 7.4
		 Third-Party Infringement of Joint Patents and Product Composition Patents.
		 	26	  
		
	 Article 8 CONFIDENTIAL INFORMATION AND PUBLICITY
		 	28	  
			
	 8.1
		 Incorporation by Reference.
		 	28	  
		
	 Article 9 INDEMNIFICATION AND INSURANCE
		 	28	  
			
	 9.1
		 Protiva Indemnification.
		 	28	  
			
	 9.2
		 Dicerna Indemnification.
		 	28	  
			
	 9.3
		 Tender of Defense; Counsel.
		 	29	  
			
	 9.4
		 Insurance.
		 	30	  
		
	 Article 10 EXPORT
		 	30	  
			
	 10.1
		 General.
		 	30	  
			
	 10.2
		 Delays and Assistance.
		 	30	  
		
	 Article 11 TERM AND TERMINATION
		 	30	  
			
	 11.1
		 Term.
		 	30	  
			
	 11.2
		 Termination for Material Breach.
		 	31	  
			
	 11.3
		 Rights in Bankruptcy.
		 	31	  
			
	 11.4
		 Termination of License Agreement.
		 	31	  
			
	 11.5
		 Consequences of Termination; Survival.
		 	31	  
			
	 11.6
		 Remedies.
		 	32	  

  
 ii 

							
		
	 Article 12 GENERAL PROVISIONS
		 	32	  
			
	 12.1
		 Representation and Warranties.
		 	32	  
			
	 12.2
		 Force Majeure and Delay Events.
		 	34	  
			
	 12.3
		 Consequential Damages.
		 	35	  
			
	 12.4
		 Assignment.
		 	35	  
			
	 12.5
		 Notices.
		 	36	  
			
	 12.6
		 Independent Contractors.
		 	37	  
			
	 12.7
		 Governing Law; Dispute Resolution Arbitration.
		 	37	  
			
	 12.8
		 Severability.
		 	38	  
			
	 12.9
		 No Implied Waivers.
		 	38	  
			
	 12.10
		 Headings.
		 	39	  
			
	 12.11
		 Entire Agreement; Amendment.
		 	39	  
			
	 12.12
		 Time of the Essence.
		 	39	  
			
	 12.13
		 Waiver of Rule of Construction.
		 	39	  
			
	 12.14
		 No Third Party Beneficiaries.
		 	39	  
			
	 12.15
		 Further Assurances.
		 	39	  
			
	 12.16
		 Performance by Affiliates.
		 	39	  
			
	 12.17
		 Counterparts.
		 	40	  
			
	 12.18
		 Non-Solicitation of Employees.
		 	40	  

 Exhibits 
  

			
	Exhibit A:		Draft SOW # 1
		
	Exhibit B:		Draft SOW # 2
		
	Exhibit C:		Draft SOW # 3
		
	Exhibit D:		Technical Transfer

  
 iii 

 DEVELOPMENT AND SUPPLY AGREEMENT 

THIS DEVELOPMENT AND SUPPLY AGREEMENT (this “Supply Agreement”) is entered into as of November 16, 2014 (the “Effective
Date”), by and among Dicerna Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 480 Arsenal Street, Building 1, Suite 120, Watertown, MA 02472 USA (“Dicerna”), on the one hand,
and Protiva Biotherapeutics Inc. a British Columbia corporation having its principal place of business at 100-8900 Glenlyon Way, Burnaby, B.C.V5J 5J8, Canada (“Protiva”), and (with respect to Section 12.1(c) only)
Tekmira Pharmaceuticals Corporation, a British Columbia corporation having its principal place of business at 100-8900 Glenlyon Way, Burnaby, B.C.V5J 5J8, Canada (“Tekmira”) on the other hand.  

RECITALS 
 WHEREAS, the Parties
entered into a Material Transfer Agreement dated August 13, 2014 and a License Agreement (as defined below) as of the date hereof; 
 WHEREAS,
the Parties desire to enter into this Supply Agreement pursuant to which Protiva shall perform certain development and other services for Dicerna and Manufacture and test Manufactured Product for Dicerna upon the terms and subject to the conditions
set forth in this Supply Agreement (as each term is defined below); 
 WHEREAS, the Parties are, contemporaneously herewith, entering into a License
Agreement, pursuant to which Protiva is licensing Dicerna to develop, have manufactured and commercialize Products (as defined in the License Agreement) directed to treatment of PH1; and 

WHEREAS, Tekmira is the parent of Protiva and is willing to guarantee Protiva’s performance under this Supply Agreement, upon the terms and
subject to the conditions set forth in this Supply Agreement. 
 NOW THEREFORE, in consideration of the mutual covenants and agreements herein
contained, and other good and valuable consideration, the receipt of which is hereby acknowledged, the Parties agree as follows: 

Article 1 DEFINITIONS AND INTERPRETATION 
  

	1.1	Definitions. 

 Unless the context otherwise requires, the terms in this Supply Agreement, the Quality
Agreement, and any SOW, with initial letters capitalized, shall have the meanings set forth below, or the meaning as designated in the indicated places throughout this Supply Agreement. 

 

	(a)	“Additional Formulation” means any formulation (other than a Product) directed to the treatment of PH1 using the LNP Technology and the Dicerna Materials necessary or useful to support Dicerna’s
preclinical studies and clinical trials that is Manufactured by Protiva. 

  

	(b)	“Affiliate” has the meaning set forth in the License Agreement. 

  

	(c)	“Applicable Laws” has the meaning set forth in the License Agreement. 

	(d)	“Applicable Requirements” means, with respect to any task or activity, all Applicable Laws (including GMPs), Specifications and SOPs applicable to such task or activity. 

 

	(e)	“Arbitrators” has the meaning set forth at Section 12.7(b). 

  

	(f)	“Associated Documentation” means, with respect to each Dicerna Material, the material safety data sheet (“MSDS”), Certificate of Analysis, and instructions for proper handling and
storage applicable to such Dicerna Material. 

  

	(g)	“Batch” means a specific quantity of a Manufactured Product having a particular Specification, and that (i) has uniform character and quality within specified limits, and (ii) is produced
according to a single Manufacturing SOW during a single Run. 

  

	(h)	“Batch Forecast” means a non-binding, good faith, ***** rolling forecast of Dicerna’s estimated requirements for GMP Batches and Non-GMP Batches of Manufactured Product, as applicable, during the
***** period covered by such Batch Forecast. 

  

	(i)	“Batch Price” means, with respect to the Manufacture of each Batch of Manufactured Product, the amount, measured in Dollars, to be paid to Protiva as specified in the applicable SOW, which amount shall
be equal to the Reimbursable Expenses. 

  

	(j)	“Business Day” means any day that is not a Saturday, a Sunday, or other day which is a statutory holiday in the Province of British Columbia, Canada or a State or Federal holiday in Massachusetts.

  

	(k)	“Calendar Quarter” means the respective periods of three (3)-consecutive calendar months ending on March 31, June 30, September 30 and December 31. 

 

	(l)	“Certificate of Analysis” or “CoA” means a document signed by an authorized representative of either Party, a Permitted Contractor, or a CMO, as the case may be, describing, with
respect to a particular material or Batch (i) the characteristics of such material or Batch, measured on the basis of the applicable Specifications for, and testing methods applied to, such material or Batch and (ii) certifying the
accuracy of each of the foregoing. 

  

	(m)	“Certificate of Compliance” or “CoC” means, as further specified in the Quality Agreement, for each Batch, a document prepared by Protiva (i) listing the manufacturing date, unique
Batch number, and quantity of Manufactured Product in such Batch, and (ii) certifying that such Batch was manufactured in conformance and in accordance with the warranties set forth in Section 12.1(b). The Parties shall from time to time
agree upon a format or formats for the Certificate of Compliance to be used under this Supply Agreement. 

  

	(n)	“Change Order” has the meaning set forth in Section 3.5(c). 

  

	(o)	“CMO” means a contract manufacturing organization. 

  

	(p)	“CMO Agreement” means a manufacturing or service agreement entered into by Dicerna, one of its Affiliates or one of their Sublicensees with any Designated CMO or Secondary CMO for the Manufacture of
Product. 

  

	(q)	“Commercialize” or “Commercialization” has the meaning set forth in the License Agreement. 

  
 2 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

	(r)	“Commercially Reasonable Efforts” has the meaning set forth in the License Agreement. 

  

	(s)	“Confidential Information” has the meaning set forth in the License Agreement. 

  

	(t)	“CTA” means a Clinical Trial Application filed with the national competent authority in an EU member state for regulatory approval of a clinical trial of the Product, including all amendments and
supplements to the application. 

  

	(u)	“Delay Event” means any event resulting in the delay or interruption of the performance of the Services arising out of or in connection with any act or omission of Dicerna, its Affiliate, their
Sublicensee, or any Designated CMO or Secondary CMO, including any failure to provide required Dicerna Materials to Protiva and any interruption to the performance of an SOW arising out a visit to the Facilities by Dicerna, its Affiliate, their
Sublicensee or any Designated CMO or Secondary CMO. 

  

	(v)	“Delivery Joint Patent” has the meaning set forth in Section 7.3(a). 

  

	(w)	“Designated CMO” means any CMO selected by Dicerna, its Affiliate or their Sublicensees as its primary manufacturer of Product for commercial sales. 

 

	(x)	“Develop,” “Developing” or “Development” has the meaning set forth in the License Agreement. 

 

	(y)	“Dicerna” has the meaning set forth in the Preamble. 

  

	(z)	“Dicerna Indemnitees” has the meaning set forth in Section 9.1. 

  

	(aa)	“Dicerna Materials” means all double stranded siRNA molecules targeting HAO1 and any other nucleic acid constructs, biological materials or active substance(s) related to the Product, which in each case
are to be provided by Dicerna, its Affiliates or their Sublicensees to Protiva for use in the performance of the Services. 

  

	(bb)	“Dicerna Rights and Technology” means Patents, rights to Patents, Know-How, Inventions and other intellectual property (including methods, processes, or compositions of matter) directed to Dicer
Substrates or Products directed to treatment of PH1. 

  

	(cc)	“Dicer Substrates” means double stranded siRNA molecules. 

  

	(dd)	“Dispute” has the meaning set forth at Section 12.7(b). 

  

	(ee)	“Disputed Batch” has the meaning set forth at Section 4.9. 

  

	(ff)	“DMF” means Protiva’s Drug Master File filed with any Regulatory Authority covering the Manufacture of Manufactured Product. 

 

	(gg)	“Dollars” and “$” mean the lawful currency of the United States of America. 

  

	(hh)	“Effective Date” has the meaning set forth in the introductory paragraph. 

  

	(ii)	“EMA” means the European Medicines Agency, a body of the European Union and established by Regulation (EC) No 726/2004 of the European Parliament and of the Council of March 31, 2004, or any
successor agency(ies) thereof performing similar functions. 

  
 3 

	(jj)	“Equipment” means any part or whole of the manufacturing or testing equipment designed by or for Protiva, and used by Protiva, Dicerna or any Designated CMO or Secondary CMO in connection with the
Services or the Technical Transfer. 

  

	(kk)	“Executed Batch Record” means a compilation of records containing the Manufacturing history and control of a specific Batch. These records are generated by the Manufacturing and Quality Control
personnel and reviewed and approved by the Quality Assurance personnel of the Manufacturing Party or its Affiliate, Sublicensee, Designated CMO or Secondary CMO, as applicable. 

 

	(ll)	“Facilities” means, Protiva’s facilities at 100 – 8900 Glenlyon Parkway, Burnaby, B.C. V5J 5J8, Canada, and such other locations as the Parties may agree in writing from time to time, subject
to Section 2.4(d). 

  

	(mm)	“FDA” has the meaning set forth in the License Agreement. 

  

	(nn)	“FD&C Act” means the United States Federal Food, Drug and Cosmetic Act, as amended from time to time. 

  

	(oo)	“Finished Product” means any Manufactured Product that has been Manufactured through completion of all Manufacturing stages, including filling, finishing, packaging, and release. 

 

	(pp)	“Fees” ***** 

  

	(qq)	“First Commercial Sale” has the meaning set forth in the License Agreement. 

  

	(rr)	“Force Majeure Event” has the meaning set forth in Section 12.2(a). 

  

	(ss)	“GLP” means the good laboratory practices regulations applicable to Manufacture that are promulgated by the Regulatory Authorities in the United States, or any other Regulatory Authorities designated in
the applicable SOW as the applicable Regulatory Authorities. 

  

	(tt)	“GMP” means the regulatory requirements for current good manufacturing practices promulgated by the FDA under the U.S. Food, Drug and Cosmetic Act and the regulations promulgated thereunder,
particularly 21 C.F.R. Parts 210 and 211, any applicable foreign equivalents thereof, and the quality guidelines of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), all
as may be amended from time to time. 

  

	(uu)	“GMP Batch” means a Batch that is intended to meet GMP requirements. 

  

	(vv)	“HAO1” means Hydroxyacid Oxidase (Glycolate Oxidase) 1, a gene transcribing for the protein 2-hydroxyacid oxidase 1. 

 

	(ww)	“IND” has the meaning set forth in the License Agreement. 

  

	(xx)	“Indemnified Party” has the meaning set forth in Section 9.3. 

  

	(yy)	“Indemnifying Party” has the meaning set forth in Section 9.3. 

  
 4 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

	(zz)	“Initial Deposit” has the meaning set forth in Section 6.1(b). 

  

	(aaa)	“Initiation Deposit” has the meaning set forth in Section 6.1(b). 

  

	(bbb)	“Initiating Party” has the meaning set forth in Section 7.4(e). 

  

	(ccc)	“Insolvent Party” has the meaning set forth in Section 11.3. 

  

	(ddd)	“Invention” means all technology and discoveries, innovations, developments, improvements, enhancements and Know-How conceived, or reduced to practice, including the intellectual property rights
embodying the foregoing, such as Patents, copyrights or trade secrets. 

  

	(eee)	“JDC” has the meaning set forth in Section 2.4(a). 

  

	(fff)	“Joint Invention” has the meaning set forth in Section 7.2(d). 

  

	(ggg)	“Joint Patent Infringement Action” has the meaning set forth in Section 7.4(d). 

  

	(hhh)	“Joint Patents” means Patents that cover Joint Inventions. 

  

	(iii)	“Know-How” has the meaning set forth in the License Agreement. 

  

	(jjj)	“License Agreement” means the License Agreement of even date hereof between the Parties. 

  

	(kkk)	“Licensed Intellectual Property” has the meaning set forth in the License Agreement. 

  

	(lll)	“Lipid Nanoparticle” has the meaning set forth in the License Agreement. 

  

	(mmm)	“LNP Technology” has the meaning set forth in the License Agreement. 

  

	(nnn)	“Losses” has the meaning set forth in Section 9.1. 

  

	(ooo)	“MAA” has the meaning set forth in the License Agreement. 

  

	(ppp)	“Manufacture” or “Manufacturing” has the meaning set forth in the License Agreement. 

  

	(qqq)	“Manufactured Product” means, for each Batch, the Product or Additional Formulation that is Manufactured in such Batch, as identified in the applicable SOW. 

 

	(rrr)	“Manufacturing Process” means any and all processes (or any step in any process) and analytical methods used or planned to be used by Protiva to Manufacture any Manufactured Product, excluding packaging
and labeling. 

  

	(sss)	“Master Batch Record” or “MBR” means the manufacturing and control instructions for the Manufacture of a specific Batch of Manufactured Product. 

 

	(ttt)	“Materials” means Protiva Materials and Dicerna Materials. 

  

	(uuu)	“NDA” has the meaning set forth in the License Agreement. 

  

	(vvv)	“New York Courts” has the meaning set forth in Section 12.7(c). 

  

	(www)	“Nonconforming Batch” has the meaning set forth in Section 4.11. 

  

	(xxx)	“Non-GMP Batch” means any Batch intended for non-clinical use, including those intended to meet the requirement for pre-clinical use pursuant to GLP requirements, such as, for example, a batch intended
for use in GLP toxicology studies. 

  
 5 

	(yyy)	“Non-Initiating Party” has the meaning set forth in Section 7.4(e). 

  

	(zzz)	“Party” means Dicerna or Protiva; and “Parties” means Dicerna and Protiva. 

  

	(aaaa)	“Patent” has the meaning set forth in the License Agreement. 

  

	(bbbb)	“Patent Infringement Action” has the meaning set forth in the License Agreement. 

  

	(cccc)	“Payload Joint Patent” has the meaning set forth in Section 7.3(b). 

  

	(dddd)	“Permitted Contractor” has the meaning set forth in the License Agreement. 

  

	(eeee)	“Person” has the meaning set forth in the License Agreement. 

  

	(ffff)	“PH1” means Primary Hyperoxaluria 1. 

  

	(gggg)	“Phase 3 Trial” means a clinical trial that is designed to gather further evidence of safety and efficacy of a Product in the Field (and to help evaluate its overall risks and benefits) and is intended
to support Regulatory Approval for a Product in the Field in one or more countries in the Territory. 

  

	(hhhh)	“Pivotal Trial” has the meaning set forth in the License Agreement. 

  

	(iiii)	“Product” has the meaning set forth in the License Agreement. 

  

	(jjjj)	“Product Composition Patent” has the meaning set forth in Section 7.2(e)(iii). 

  

	(kkkk)	“Production Plan” means a plan for Manufacturing the Manufactured Product during a specified period, which plan shall include Protiva’s requirements for Dicerna Materials and a production schedule,
including scheduled Manufacture dates, for the period covered by such plan. 

  

	(llll)	“Protiva” has the meaning set forth in the Preamble. 

  

	(mmmm)	“Protiva Indemnitees” has the meaning set forth in Section 9.2. 

  

	(nnnn)	“Protiva Intellectual Property” has the meaning set forth in the License Agreement. 

  

	(oooo)	“Protiva Materials” has the meaning set forth in the License Agreement. 

  

	(pppp)	“Protiva Rights and Technology” means Patents, rights to Patents, Know-How, Inventions and other intellectual property (including methods, processes, or compositions of matter) directed to Lipid
Nanoparticles. 

  

	(qqqq)	“Quality Agreement” means the quality agreement between the Parties to be entered into within ***** days of the Effective Date, which will govern the Parties’ respective quality and regulatory
responsibilities for the Manufacture of GMP Batches of Manufactured Product, including equipment cleaning, qualification, calibration and maintenance, testing, sample retention, records and record retention, regulatory inspections, quality audits,
out-of-specifications, deviations, investigations, recalls, voluntary withdrawals, and environmental monitoring. 

  

	(rrrr)	“Raw Material” means any component used in the Manufacture of any Manufactured Product. 

  

	(ssss)	“Record Retention Period” has the meaning set forth in Section 6.5. 

  
 6 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

	(tttt)	“Reimbursable Expenses” ***** 

  

	(uuuu)	“Regulatory Approval” has the meaning set forth in the License Agreement. 

  

	(vvvv)	“Regulatory Authority” has the meaning set forth in the License Agreement. 

  

	(wwww)	“Replacement Batch” has the meaning set forth in Section 4.11. 

  

	(xxxx)	“Run” means a single Manufacturing run of Manufactured Product at a Facility and progressing though quality testing and release. 

 

	(yyyy)	“Secondary CMO” means any one or more CMO(s) selected by Dicerna, its Affiliate or their Sublicensees as a back-up manufacturer of Product for commercial sales. 

 

	(zzzz)	“Services Forecast” means a non-binding, good faith, *****-month rolling forecast of Dicerna’s estimated requirements for all Services other than the Manufacture of GMP Batches and Non-GMP Batches,
during the *****-month period covered by such non-Batch Forecast. 

  

	(aaaaa)	“Shipping and Handling Procedures” means Dicerna’s procedures for packaging, preserving, monitoring and shipping any and all Dicerna property. 

 

	(bbbbb)	“Services” means the obligations to be performed by Protiva pursuant to this Supply Agreement. 

  

	(ccccc)	“Solvent Party” has the meaning set forth in Section 11.3. 

  

	(ddddd)	“SOP” means the duly authorized and documented standard operating procedure practiced by each of Dicerna and Protiva in the performance of a specified process. 

 

	(eeeee)	“Specifications” means the list of tests, test procedures, references to any analytical procedures, and appropriate acceptance criteria (i) to which any Manufactured Product at any stage of
Manufacture must conform to be considered acceptable for its intended use, or (ii) to which Raw Materials (including Materials) must conform to be considered acceptable for their intended use, in each case that are mutually approved by the
Parties, as such Specifications are amended or supplemented from time to time by mutual agreement of the Parties in writing, it being understood, however, that references herein to “Specifications” in the context of Non-GMP Batches shall
not imply that such Specifications conform with the standards of GMP, and, as such, Specifications for Non-GMP Batches shall be considered for regulatory and quality control purposes to be draft Specifications. As used in this Supply Agreement,
“Product Specifications” means the Specifications applicable to a particular Manufactured Product, “Finished Product Specification” means the Specifications applicable to a particular Finished Product, “ Raw
Materials Specifications” means the Specifications applicable to a particular Raw Material, and “Equipment Specifications” means the Specifications applicable to any part or whole of the Equipment. For clarity, the Product
Specifications and Finished Product Specifications will identify which Lipid Nanoparticle will be used in the Manufactured Product *****. 

  
 7 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

	(fffff)	“Statement of Work” or “SOW” means a statement of work or work order signed by both Parties that relates to the Services to be performed by either or both Parties. 

 

	(ggggg)	“Sublicensee” means a Third Party to whom Dicerna has granted a sublicense in a Sublicense Agreement pursuant to the terms of the License Agreement. 

 

	(hhhhh)	“Sublicense Agreement” has the meaning set forth in the License Agreement. 

  

	(iiiii)	“Supply Agreement” means this Development and Supply Agreement and all SOWs generated hereunder, together with all Exhibits attached hereto and to each SOW. 

 

	(jjjjj)	“Technical Transfer” means all or a portion of the transfer by Protiva to Dicerna or a Designated CMO of Protiva Intellectual Property and Protiva’s Confidential Information useful or necessary for
the Manufacture of Product, including analytical method transfer and qualification, equipment qualification and scale up engineering. 

  

	(kkkkk)	“Technical Transfer Plan” has the meaning set forth in Exhibit D. 

  

	(lllll)	“Term” has the meaning set forth in Section 11.1. 

  

	(mmmmm)	“Third Party” means any Person other than Protiva, Dicerna or any of their respective Affiliates. 

  

	(nnnnn)	“Third Party Claim” has the meaning set forth in Section 9.3. 

  

	1.2	Interpretation. 

 In this Supply Agreement unless otherwise specified: 

 

	(a)	“includes” and “including” shall mean respectively includes and including without limitation; 

  

	(b)	except where the context otherwise requires, the word “or” is used in the inclusive sense (and/or); 

  

	(c)	a Party includes its permitted assignees or their respective permitted successors in title to substantially the whole of its undertaking; 

 

	(d)	a statute or statutory instrument or any of their provisions is to be construed as a reference to that statute or statutory instrument or such provision as the same may have been or may from time to time hereafter be
amended or re-enacted; 

  

	(e)	words denoting the singular shall include the plural and vice versa and words denoting any gender shall include all genders; and 

  

	(f)	general words shall not be given a restrictive interpretation by reason of their being preceded or followed by words indicating a particular class of acts, matters or things; and 

 

	1.3	Conflict. 

  

	(a)	In the event of any conflict between this Supply Agreement and the License Agreement, the License Agreement shall prevail. 

  

	(b)	In the event of any conflict between this Supply Agreement, the Quality Agreement, and any SOW, the following agreements shall govern in the following priority: 

 

	 	(i)	this Supply Agreement; 

  
 8 

	 	(ii)	the Quality Agreement; and 

  

	 	(iii)	the applicable SOW; 

 unless the Quality Agreement or SOW expressly contemplates such conflict,
in which case the terms of such Quality Agreement or SOW shall control. 
 Article 2 DEVELOPMENT COLLABORATION 

 

	2.1	Responsibilities of Protiva under the Services. 

 Subject to the terms and conditions of this Supply
Agreement, Dicerna hereby appoints Protiva to provide the following services to Dicerna, its Affiliates and their Sublicensees: 
  

	(a)	design (i) a formulation of the Product for use in Development by Dicerna, its Affiliates or their Sublicensees, and (ii) the final formulated Product, subject to Dicerna approval, to be used as a clinical
development candidate; 

  

	(b)	Manufacture GMP and Non-GMP Batches of Manufactured Product for Dicerna, its Affiliate or their Sublicensees’ pre-clinical testing and development activities; 

 

	(c)	Manufacture GMP Batches of the Manufactured Product approved by Regulatory Authorities for use by Dicerna, its Affiliate or their Sublicensee in studies required to develop the Product for Regulatory Approval and for
all clinical trials up until such time as the completion of Technical Transfer in accordance with Exhibit D; provided, however, that any obligation of Protiva to continue Manufacture as provided herein will cease if Dicerna fails to perform
its obligations related to the Technical Transfer in accordance with the timing set forth in Section 2.1(e); 

  

	(d)	design stability study protocols, and perform stability studies, for all Batches of the Manufactured Product Manufactured by Protiva; 

 

	(e)	perform Technical Transfer to Dicerna or any Designated CMO pursuant to the timing mutually agreed by the Parties, provided that it must occur prior to the earlier of (i) initiation of a Phase 3 Trial or
(ii) the Manufacture of the Batches for the First Commercial Sale of the Product; 

  

	(f)	with respect to Regulatory Authorities: 

  

	 	(i)	grant (and hereby does grant) to Dicerna permission to provide Regulatory Authorities reference access to Protiva’s DMF(s) for the Manufactured Product and to other regulatory documentation of Protiva directed to
Lipid Nanoparticles or the Manufactured Product, solely for the purpose of enabling such Regulatory Authorities to examine the suitability of the Manufactured Product for Regulatory Approval; 

 

	 	(ii)	to the extent Regulatory Authorities make written demands for more detailed information than is available in Protiva’s DMF or other regulatory documentation of Protiva directed to Lipid Nanoparticles or the
Manufactured Product, update Protiva’s DMF or assist in the preparation of all Chemistry, Manufacturing and Control (CMC)-related regulatory documents necessary for any IND, CTA, NDA, MAA and other submissions to Regulatory Authorities;

  

	 	(iii)	assist Dicerna in responding to requests from Regulatory Authorities; and 

  

	 	(iv)	assist Dicerna in relevant filings with respect to the Product, including any IND or CTA, with Regulatory Authorities. 

  
 9 

	2.2	Technical Transfer. 

 With respect to Technical Transfer, the Parties have the rights and obligations set
forth on Exhibit D. 
  

	2.3	Statements of Work. 

 The Parties acknowledge that the performance of the Services may be implemented
through one or more SOWs executed by both Parties, and in accordance with the timelines set forth therein. The Parties agree to negotiate all SOWs and Change Orders in good faith and Protiva may not unreasonably withhold, delay or condition its
acceptance or execution of any SOW or Change Order proposed by Dicerna that is necessary for the implementation of the Services as described in Section 2.1. The process for proposal and execution of SOWs is further set forth in Sections 3.2,
3.3, 3.4 and 3.5 Attached hereto as Exhibits A, B and C are drafts of the initial three SOWs. The Parties shall use Commercially Reasonable Efforts to finalize such draft SOWs as promptly as practical after the Effective Date,
with a goal of finalizing them within ***** days after the Effective Date. 
  

	2.4	Joint Development Committee. 

  

	(a)	Within ***** days after the Effective Date, the Parties shall appoint a joint development committee (the “JDC”), consisting of an equal number of members appointed by each Party, which number of members
shall not exceed ***** from each Party, to oversee the performance of the Services and the Development and Manufacturing by Protiva of the Manufactured Product, subject to the terms set forth herein. Each member of the JDC shall have the appropriate
expertise to oversee the Parties’ performance of their respective obligations under this Supply Agreement. Each Party shall have the right, at any time and from time to time, to designate a replacement, on a permanent or temporary basis, for
any or all of its previously designated members of the JDC. After the JDC has been formed, it shall remain in existence until the earlier of the First Commercial Sale of the Manufactured Product or the successful completion of Technical Transfer.

  

	(b)	The JDC shall meet at least ***** per ***** on such dates and times as the Parties may agree. The Parties shall agree in advance on a written agenda for each meeting of the JDC. The regularly scheduled JDC meetings
shall take place in person or telephonically as determined by the Parties. The members of the JDC may also convene or be polled or consulted from time to time by means of telephone conference, video conference, electronic mail or correspondence and
the like, as the Parties deem necessary. The Parties will alternate (every other meeting) responsibility for drafting the minutes of the meeting of the JDC, which shall be promptly (and in any event within ***** days of the meeting) issued to the
Parties following each meeting. The Parties shall use Commercially Reasonable Efforts to agree as to the specific text of such minutes within ***** days after receipt. 

 

	(c)	The principal purposes of the JDC shall be to oversee and provide guidance and direction on the overall strategy for the Development and Manufacturing by Protiva of the Manufactured Product. Subject to the express
rights of the Parties as set forth herein, the functions of the JDC shall include: 

  

	 	(i)	reviewing the overall strategy regarding clinical and regulatory matters pertaining to the Manufactured Product; 

  
 10 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

	 	(ii)	acting as liaison between the Parties to ensure that they are informed of the ongoing progress of the Development of the Manufactured Product; 

 

	 	(iii)	overseeing creation of annual and long-range plans for Development of the Manufactured Product; 

  

	 	(iv)	reviewing and approving Specifications and SOPs; 

  

	 	(v)	agreeing to non-binding written Batch Forecasts and non-binding written Services Forecasts of anticipated Manufacturing and Service requirements during the applicable *****-month period covered by each such forecast, in
accordance with Section 3.1 below; and 

  

	 	(vi)	performing such other responsibilities as may be mutually agreed upon by the Parties from time to time. 

  

	(d)	The Parties shall use Commercially Reasonable Efforts to make all decisions in good faith by unanimous vote or unanimous written consent of both Parties, with each Party having, collectively among its respective
designees, one vote in all decisions; provided, however, that if the issue in question requires resolution prior to the date Dicerna could reasonably expect the issue to be resolved pursuant to this Supply Agreement, then subject to
the other provisions in, and obligations under, this Agreement (i) Protiva has final decision making authority (including regarding the implementation thereof), on: ***** (ii) the JDC shall continue to discuss the following items in good
faith, which may only be resolved by the unanimous vote or unanimous written consent of the JDC: ***** (iii) Dicerna has final decision making authority (including regarding the implementation thereof) on *****. 

 

	(e)	Each Party shall be responsible for the costs of its representatives on the JDC, including all travel and related costs and expenses for its members and approved invitees to attend meetings of, and otherwise participate
on, the JDC. 

  

	(f)	The JDC shall not have any power to amend, modify or waive compliance with this Supply Agreement. 

  
 11 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

	2.5	On-Site Participation of Dicerna Personnel at the Facilities. 

  

	(a)	Dicerna has the right to designate at its discretion up to ***** of its or its Designated CMO’s personnel to be on site at the applicable Facility, and such additional personnel in such numbers as may be agreed to
by the Parties or as otherwise required by Applicable Requirements, during normal business hours to (i) coordinate and observe the Runs and (ii) otherwise assist Dicerna and its Designated CMO to prepare for Technical Transfer and for any
future interactions or correspondence with the applicable Regulatory Authorities. 

  

	(b)	While at the Facilities, Dicerna’s representatives will have access to such areas as are reasonably related to the Manufacture of the Manufactured Products, food-service areas, designated office space and public
areas, or as otherwise authorized by Protiva, and shall comply (i) as agents of Dicerna with all confidentiality obligations owed by Dicerna hereunder and (ii) with applicable Protiva policies and procedures (including all Protiva security
policies and procedures) as provided to Dicerna in writing. 

  

	2.6	Acceptance of Final Formulated Product. 

 Protiva shall submit the final formulated Product developed by
Protiva pursuant to this Supply Agreement and as set forth in the applicable SOW to Dicerna for Dicerna’s evaluation, testing and approval. Protiva shall provide such assistance as Dicerna may reasonably require to conduct such evaluation and
testing. If Dicerna reasonably determines that the final formulated Product does not meet the agreed-upon Finished Product Specifications, then Dicerna shall provide Protiva with notice of the same. ***** Acceptance of the final formulated Product
does not waive any representation, warranty or other rights provided in this Supply Agreement. 
 Article 3 FORECASTING 

 

	3.1	Batch Forecasting. 

  

	(a)	The JDC shall use Commercially Reasonable Efforts to agree on non-binding written Batch Forecasts of anticipated Manufacturing requirements during the applicable *****-month period covered by each such forecast no later
than the ***** Business Day of each *****. 

  

	(b)	Dicerna’s JDC members shall initially propose a Batch Forecast to Protiva JDC members, which proposal shall specify the quantity of each GMP Batch and Non-GMP Batch of Manufactured Product, as applicable, and the
anticipated Manufacturing date for each Batch, specified as *****. Dicerna shall propose each such Batch Forecast in good faith based on its anticipated requirements for Manufactured Products. 

 

	(c)	 Within ***** days following Protiva’s JDC members receipt of each proposed Batch Forecast, the JDC shall agree upon a final forecast, and the JDC
shall deliver to Dicerna a 

  
 12 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

	 	
Production Plan covering the forecasted period and notify Dicerna by facsimile or electronic mail addressed to the attention of a JDC member of Dicerna to be designated by Dicerna, if Protiva
anticipates difficulties in meeting Dicerna’s requirements or timelines during the forecasted period, and the JDC shall thereafter negotiate a mutually achievable Production Plan. 

 

	(d)	The Parties acknowledge and agree that Protiva may not be able to provide Dicerna with Manufactured Product in excess of what is in a Batch Forecast due to Protiva’s use of the applicable Production Plan in
scheduling its materials procurement and in allocating its personnel. 

  

	3.2	Services Forecasting. 

  

	(a)	The JDC shall use Commercially Reasonable Efforts to agree on non-binding written Services Forecasts of anticipated Service requirements during the applicable *****-month period covered by each such forecast no later
than the ***** Business Day of each *****. 

  

	(b)	Dicerna’s JDC members shall initially propose a Services Forecast to Protiva JDC members, which proposal shall specify the nature of the Service and the anticipated date by which such Services shall be completed,
specified as *****. 

  

	(c)	Within ***** days following Protiva’s JDC members receipt of each proposed Services Forecast, the JDC shall agree upon a final forecast, and the JDC shall deliver to Dicerna a plan covering the forecasted
period and notify Dicerna by facsimile or electronic mail addressed to the attention of a JDC member of Dicerna to be designated by Dicerna, if Protiva anticipates difficulties in meeting Dicerna’s requirements or timelines during the
forecasted period, and the JDC shall thereafter negotiate a mutually achievable Services Forecast. 

  

	(d)	The Parties acknowledge and agree that Protiva may not be able to provide Dicerna with non-Manufacturing Services in excess of what is in the Services Forecast due to Protiva’s use of the Services Forecast in
allocating its personnel. 

  

	3.3	Lead Times for Manufacturing SOWs. 

  

	(a)	Other than for the initial SOWs attached hereto, Dicerna shall send a draft SOW for any desired Batch to be Manufactured at least: (A) ***** days prior to each Manufacturing date for each GMP Batch; and
(B) ***** days prior to each Manufacturing date for each non-GMP Batch (provided that Protiva shall use Commercially Reasonable Efforts to accommodate requests from Dicerna for Manufacturing with a shorter lead time), specifying:

 ***** 

  
 13 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

 ***** 
  

	(b)	Only one (1) Batch of Manufactured Product shall be ordered in each SOW. Each SOW shall be sent by facsimile or electronic mail to Protiva addressed to the attention of Director of Manufacturing and Supply Chain
(or such other Person as Protiva may designate from time to time in writing). 

  

	(c)	Within ***** Business Days of receipt of each draft SOW, Protiva shall respond by facsimile or electronic mail to Dicerna addressed to the attention of the Vice President of Business Development (or such other Person as
Dicerna may designate from time to time) specifying: 

 ***** 

Protiva may not reject a SOW for the Manufacture of a Batch if the same is consistent with the then-current Batch Forecast and Production
Plan. 
  

	3.4	Lead Times for all Other SOWs. 

  

	(a)	Other than for the initial SOWs attached hereto, Dicerna shall provide Protiva a draft SOW for any desired non-Manufacturing Services at least ***** days prior to the start of each desired Service (provided that Protiva
shall use Commercially Reasonable Efforts to accommodate requests from Dicerna for Services with a shorter lead time), specifying: 

***** 

  
 14 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

	    	***** 

  

	(b)	Within ***** Business Days of receipt of each draft SOW, Protiva shall respond by facsimile or electronic mail to Dicerna addressed to the attention of Vice President of Business Development (or such other Person as
Dicerna may designate from time to time) specifying: 

  

	    	***** 

 Notwithstanding the lead time specified in this Section 3.4, Dicerna is not required to issue a
SOW at least ***** days prior to a desired Service if shorter notice is provided by Regulatory Authorities to Dicerna. Provided that Dicerna shall have notified Protiva in writing within ***** Days of Dicerna’s receipt of any demand from a
Regulatory Authority, Protiva shall assist Dicerna in responding to queries and demands from Regulatory Authorities. 
  

	3.5	Binding SOWs and Change Orders. 

  

	(a)	Except as the Parties shall otherwise agree and without limiting Section 2.3, the Parties shall make Commercially Reasonable Efforts to mutually execute each SOW in sufficient time for all activities contemplated
in such SOW to be completed as scheduled in the applicable forecast. 

  

	(b)	Each SOW shall be governed by the terms of this Supply Agreement, and none of the terms of Dicerna’s purchase orders, Protiva’s acknowledgment forms, or any other form, shall apply. 

 

	(c)	If the scope of work of a SOW changes, then the applicable SOW may be amended as provided in this Section 3.5(c) (each a “Change Order”). If a required modification to a SOW is identified by either
Party, the identifying Party shall notify the other Party in writing as soon as reasonably possible to provide a description of the required modification(s). If Dicerna identifies a change, Protiva shall respond within ***** Days of receiving such
notice or within such time as may be required for Protiva to obtain necessary information from its Permitted Contractors, and shall indicate in writing to Dicerna (i) whether such Change Order is necessary or feasible, (ii) to what extent,
if any, such Change Order alters the time frame, or any other parameters of Protiva’s Manufacture of the applicable Batch or provision of the applicable Service, and (iii) what effect, if any, Protiva believes the implementation of such
Change Order would have on the Batch Price or Fees, and both Parties shall use Commercially Reasonable Efforts to timely execute a mutually agreeable Change Order. 

  
 15 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

	(d)	When contracting with Permitted Contractors, Protiva shall use Commercially Reasonable Efforts to minimize any rescheduling fees and cancellation fees charged by such Permitted Contractors, it being understood that any
Permitted Contractor that is already an existing contractor of Tekmira or Protiva have established rescheduling fees and cancellation fees, which fees shall be the responsibility of and paid by Dicerna in the event of an applicable rescheduling or
cancellation. 

  

	(e)	No Change Order shall be effective unless and until it has been signed by authorized representatives of both Parties. 

  

	(f)	Unless otherwise requested by Dicerna, Protiva shall continue to work on the existing SOW during any such negotiations, but in no event shall Protiva be obligated to commence work in accordance with the Change Order
unless and until it is signed by authorized representatives of both Parties. For clarity, if requested by Dicerna, Protiva will suspend all work under a SOW (and any related SOWs) until such time as a mutually accepted Change Order has been
executed. 

 Article 4 MANUFACTURING 
  

	4.1	Dicerna Materials. 

  

	(a)	Dicerna shall at its sole cost and expense (i) source, purchase and provide such quantities of Dicerna Materials as are set forth in each SOW, and (ii) notify Protiva of any changes to qualification procedures
for such vendors or suppliers or to any Raw Material release or Specification procedures applicable to any Dicerna Materials. 

  

	(b)	Dicerna retains title to and ownership of the Dicerna Materials at each and every stage of Manufacture and has sole responsibility, but not the obligation, to obtain and maintain insurance coverage for any loss or
damage to Dicerna Material. 

  

	(c)	Dicerna shall deliver Dicerna Materials to Protiva in accordance with Dicerna’s Shipping and Handling Procedures. Protiva shall receive Dicerna Materials in accordance with Protiva’s SOPs and shall visually
examine the packaging integrity of Dicerna Materials and ensure that damage has not occurred during transport. If Protiva visually detects any defect or damage in any Dicerna Materials or the packaging thereof, Protiva shall promptly notify Dicerna
with detailed information concerning the nature of the damage and seek instructions from Dicerna. 

  

	(d)	Dicerna will cause all Dicerna Materials to be delivered to Protiva for use in Non-GMP Batches to be released in accordance with the Raw Material Specifications for such Dicerna Materials. Dicerna shall provide all
Dicerna Materials and their Associated Documentation to Protiva not less than ***** days prior to the initiation of each Manufacturing campaign to enable Protiva to perform such Raw Material release testing on Dicerna Materials as specified in each
applicable SOW. 

  

	(e)	If, pursuant to any SOW, Protiva is to conduct full release testing of Dicerna Materials in accordance with the Raw Material Specifications, Dicerna shall provide all Dicerna Materials and their Associated Documentation
to Protiva not less than ***** days prior to the initiation of each Manufacturing campaign, and supply reasonably sufficient quantities of Dicerna Materials for the purposes of both raw material testing and Manufacturing. 

  
 16 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

	(f)	If Protiva is to conduct either a limited release or full release of the Dicerna Materials pursuant to a SOW, Protiva shall conduct such limited release or full release of the Dicerna Materials prior to introducing each
lot of Dicerna Materials into the Manufacture of Manufactured Product and shall provide Dicerna with copies of the analytical reports, raw data and any other relevant documentation in respect of each lot of Dicerna Materials tested, and notify
Dicerna of any deficiencies in respect of any lot of Dicerna Materials tested. 

  

	(g)	Dicerna acknowledges that the late delivery of sufficient quantity and quality of any Dicerna Materials or Associated Documentation may be a Delay Event resulting in a delay in Protiva’s performance of the
applicable SOW requiring such Dicerna Materials or Associated Documentation. In the event of Dicerna’s delivery of non-conforming Dicerna Materials or late delivery of any Dicerna Materials or Associated Documentation for which Protiva is not
responsible, Protiva shall notify Dicerna of any necessary change to such time line, and if changes to such time line are necessary the Parties shall negotiate in good faith to revise such time line by way of a Change Order. 

 

	4.2	Protiva Materials. 

  

	(a)	Protiva shall (i) source, purchase and provide such quantities of Protiva Materials as are reasonably required for each SOW, and (ii) qualify, monitor and audit the suppliers or vendors of Protiva Materials.
Protiva shall procure reasonably sufficient quantities of Protiva Materials for the purposes of both Raw Material testing and Manufacturing. 

  

	(b)	Protiva shall perform all testing and evaluation of the Protiva Materials to be used in the Manufacture of Batches as required by the Applicable Requirements, and otherwise in accordance with the Quality Agreement.
Protiva shall cause all Protiva Materials to be used in the Manufacture of Batches to be released in accordance with the Raw Material Specifications for such Protiva Materials prior to their use, including as set forth in the Quality Agreement, and
shall provide Dicerna with copies of the analytical reports, raw data and any other relevant documentation in respect of each lot of Protiva Materials tested. 

  

	4.3	Specification Changes. 

 Except as otherwise expressly set forth to the contrary in the Quality
Agreement, if Dicerna is required, or desires, to change the Specifications, Protiva shall: (a) accommodate any request for any changes required by any Regulatory Authority or Applicable Law; and (b) use Commercially Reasonable Efforts to
accommodate any other request; provided, however, that Dicerna shall promptly advise Protiva in writing of any such change(s), and provide information reasonably necessary for Protiva to evaluate the effect of such change(s), and Protiva shall
promptly advise Dicerna as to scheduling or Batch Price or Fee changes, if any, which may result from such change(s). The notification and approval procedure shall be in accordance with the Quality Agreement and SOPs (i.e., change
control procedures) agreed upon by the Parties from time to time. The Parties shall hold a JDC meeting in a timely manner with appropriate advisors invited to discuss such changes as appropriate. 

  
 17 

	4.4	Responsibility for Safe Use and Safe Keeping. 

  

	(a)	Protiva shall be responsible in accordance with Applicable Laws for implementing and maintaining health and safety procedures and for the handling of any materials or hazardous waste used in or generated by the
Manufacturing. Protiva, in consultation with Dicerna, shall develop safety and handling SOPs for Dicerna Materials and Manufactured Product (other than Additional Formulations). Dicerna shall have no responsibility for Protiva’s health and
safety program; except that Dicerna must deliver a current MSDS in the form agreed between the Parties from time to time for each of the Dicerna Materials supplied to Protiva. 

 

	(b)	Protiva shall (i) account for all Dicerna Materials and handle and store all Dicerna Materials in accordance with Applicable Requirements and instructions of Dicerna, (ii) not provide Dicerna Materials to any
person other than Protiva’s personnel and Permitted Contractors who require access to the Dicerna Materials in the performance of the Services without the express prior written consent of Dicerna, (iii) not use Dicerna Materials for any
purpose other than conducting the Services, including, not to analyze (except as necessary to perform Raw Material release testing), characterize, modify or reverse engineer any Dicerna Materials or take any action to determine the structure,
sequence or composition of any Dicerna Materials unless required pursuant to a signed SOW, (iv) destroy or return to Dicerna all unused quantities of Dicerna Materials according to Dicerna’s written directions, and (v) ensure that all
of Protiva’s personnel and Permitted Contractors having access to the Dicerna Material are made aware of and comply with the terms of this Supply Agreement, including the obligations of confidentiality respecting same contained herein. Protiva
shall return all Dicerna Materials to Dicerna following the completion of the Services contemplated in each SOW, unless otherwise agreed to in writing by both Parties. 

 

	(c)	Protiva acknowledges and agrees that Dicerna Materials are the property of Dicerna and that Dicerna shall retain all right, title and interest in and to Dicerna Materials, including all proprietary rights thereto.

  

	4.5	Manufacture. 

  

	(a)	Facilities. To the extent one or more Facilities are expressly identified in a SOW, Protiva shall perform the Manufacture only at the applicable Facilities. Protiva shall be responsible for ensuring that the
Facilities meet the Applicable Requirements at all relevant times. 

  

	(b)	Personnel. Protiva shall furnish all personnel and supervision necessary to perform the Manufacture of the Manufactured Products, and shall take all reasonable steps to ensure that such personnel are properly
trained and proficient in the Specifications, analytical methods and the Manufacturing Process and in handling the Equipment, Materials, and Manufactured Product. 

 

	(c)	 Equipment. Protiva shall supply, qualify, validate, calibrate, service and maintain all Equipment necessary for its Manufacture of Manufactured
Product, and comply with its own SOPs for the cleaning and maintenance of such Equipment. ***** 

  
 18 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

	    	***** 

  

	(d)	Licenses and Permits. Protiva shall be responsible for obtaining any licenses or permits and regulatory and government approvals necessary for the operation and use of its Facilities as pharmaceutical
manufacturing facilities generally and for Manufacture of the Manufactured Products and performance of the Services specifically. Where any such licenses, permits or approvals are required for the operation and use of the Facilities as
pharmaceutical manufacturing facilities generally, all expenses thereof will be at Protiva’s sole cost. Where any such licenses, permits or approvals are required specifically for the performance of the Services which would not otherwise be
required by Protiva, the expense thereof shall be treated as part of Protiva’s Reimbursable Expenses for purposes of determining the applicable Fees or Batch Price. 

 

	(e)	Production. Protiva shall be responsible for the preparation of the Master Batch Record and Executed Batch Record for all GMP Batches, and Protiva’s Quality personnel shall approve each MBR prior to
commencement of Manufacture and each Executed Batch Record following completion of Manufacture. Each MBR shall be assigned an identification number and any changes to an MBR shall be documented in sufficient detail for submission to Regulatory
Authorities as needed. 

  

	(f)	Records. In respect of GMP Batches, all MBRs and Executed Batch Records generated by Protiva or its Permitted Contractors for the Manufacture of Manufactured Product under this Agreement shall be made available
by Protiva to Dicerna, its Affiliate, their Sublicensee, any Designated CMO and Secondary CMO, as applicable, in accordance with the Quality Agreement but shall remain the property and Confidential Information of Protiva. Protiva shall maintain and
retain true and accurate books, records, test and laboratory data, reports and other information related to the Manufacture of the Manufacture Products, including all information required to be maintained under this Supply Agreement, the Quality
Agreement or Applicable Laws (including GMPs). Protiva will maintain all such information only in separate forms, notebooks and records to the extent possible (i.e., not commingled with other information) and will maintain all such information for
at least the period of time specified in the Quality Agreement or longer if required under Applicable Laws (including GMPs). Protiva shall make all such documentation available to Regulatory Authorities as set forth in the License Agreement.

  

	(g)	Audits. Dicerna may conduct audits to verify that Protiva is complying with this Supply Agreement, the Quality Agreement, any SOW and any Applicable Laws, as well as to verify invoices. Dicerna may conduct *****
per ***** and unlimited “for cause” audits. During such audits, personnel of Dicerna or its representatives will have access only to all public areas and those areas that are directly related to the performance of Protiva’s
obligations under this Supply Agreement. No more than a reasonable number of representatives will be permitted on Protiva’s premises for any such audit. Dicerna shall provide reasonable notice of such audit and perform such audit during normal
business hours. 

  
 19 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

	4.6	Testing and Release. 

  

	(a)	Protiva shall perform all Raw Material release testing, in-process testing and Finished Product release testing in accordance with the test parameters set forth in the applicable Specifications. If at any time during
the Raw Material release testing of Dicerna Materials, Protiva discovers that the whole or part of a Batch of Dicerna Materials does not meet the acceptance criteria set forth in the applicable Specifications, Protiva shall notify Dicerna in writing
by ***** to provide sufficient details to enable Dicerna to order replacement shipments of relevant Dicerna Materials. 

  

	(b)	All GMP Batches shall be released by Protiva’s Quality Assurance representative before shipment to Dicerna. 

  

	(c)	If Dicerna requests stability studies to be performed on a Manufactured Product by way of an SOW, Protiva shall design and Dicerna shall approve a study protocol and applicable SOPs to be used by Protiva.

  

	4.7	Storage, Packaging and Shipment. 

 Protiva shall store, package, label and ship the Manufactured Product
according to the Applicable Requirements and according to packaging SOPs mutually agreed upon by Dicerna and Protiva in writing. Protiva shall deliver all Batches within the delivery week for such Batches as set forth in the applicable SOW. Protiva
shall ensure all shipments of Batches contain Batch numbers and manufacture/expiry dates, are packaged using shipping containers agreed in writing between the Parties and are delivered to Dicerna, or to a location designated in writing by Dicerna.
All shipments of Batches by Protiva to Dicerna shall be EXWorks (Incoterms, 2010) Facility, freight collect, by a common carrier designated in writing by Dicerna, at Dicerna’s expense. Dicerna shall procure, at its cost, insurance covering
damage or loss to all Batches during shipping. 
  

	4.8	Inspection Upon Receipt. 

 Within ***** calendar days from the date of Dicerna’s receipt of a Batch
of Manufactured Product, Dicerna shall notify Protiva in writing if Dicerna discovers through visual inspection any shortage of or damage to such Batch, or to its packaging or any other obvious defect detectable by the naked eye. Protiva shall not
be responsible for any loss or damage to any Manufactured Product during transport provided Protiva has packaged all Manufactured Product in accordance with agreed packing SOPs. 

 

	4.9	Disputed Batch. 

 With each Batch of Manufactured Product, Protiva shall deliver to Dicerna samples for
testing in accordance with the Quality Agreement and the Applicable Requirements. Within ***** calendar days after the date of Dicerna’s receipt of a Batch of Manufactured Product, the test samples and its applicable Certificate of Analysis and
Certificate of Compliance, Dicerna shall determine whether such Batch conforms to the applicable Finished Product Specifications. If Dicerna believes any Batch of Manufactured Product does not meet the applicable Finished Product Specifications
(“Disputed Batch”), then Dicerna shall give Protiva written notice thereof as soon as practicable but in no event later than ***** days after the date of receipt of the Disputed Batch and shall, unless otherwise directed by Protiva,
return a portion of the 

  
 20 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

 
Disputed Batch for further testing by Protiva. Failure to provide such written notice within such *****-day period shall constitute an irrevocable acceptance by Dicerna of the Disputed Batch. If,
after conducting its own testing, Protiva agrees, or it is determined pursuant to Section 4.10, that the returned Disputed Batch fails to meet the applicable Finished Product Specifications, the provisions of Section 4.11 shall apply.
Acceptance of any Batch shall not limit any remedies otherwise available to Dicerna under this Supply Agreement. 
  

	4.10	Independent Laboratory. 

 If there is any dispute concerning whether a Batch of Manufactured Product
meets the applicable Finished Product Specifications as a result of Protiva’s negligence or breach of this Supply Agreement, the Parties shall designate an independent expert or independent laboratory (acting as an expert and not as an
arbitrator) to determine whether or not the Disputed Batch at issue meets the applicable Finished Product Specifications (or fails to meet the Specifications due to a non-conformity of, endotoxin in, impurity of, or adulteration of any Dicerna
Materials for which Raw Material release testing was not required by Dicerna as part of the Manufacture). The decision of such independent expert shall be in writing and shall be binding on both Protiva and Dicerna. The costs of such independent
expert shall be borne by the Parties equally; provided, however that the Party that is determined to be incorrect in the dispute shall be responsible for all such costs and shall indemnify the prevailing Party for its share of the costs incurred.
For clarity, Protiva shall be entitled to retain samples of any Batch of Manufactured Product Manufactured by Protiva for testing by independent experts or independent laboratories. 

 

	4.11	Replacement Batches. 

  

	(a)	In the event a Disputed Batch is determined to have failed the applicable Finished Product Specifications (“Nonconforming Batch”), the whole of such Nonconforming Batch shall be either returned to
Protiva or destroyed, at Dicerna’s option and, if returned pursuant to Section 4.11(b) or 4.11(d), at Protiva’s expense. 

  

	    	***** 

  
 21 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

	4.12	Non-GMP Batches. 

 Notwithstanding anything to the contrary contained herein, Sections 4.9 through 4.11
shall not apply to Non-GMP Batches (i) when such Batches include Dicerna Materials or Dicer Substrates that have not been previously used in a successful Manufacturing run by Protiva and (ii) for which a test Batch run has not been
conducted. 
 Article 5 REGULATORY MATTERS 
  

	5.1	Quality Agreement. 

 Within ***** days of the date hereof, the Parties shall negotiate in good faith and
enter into the Quality Agreement to govern the quality and regulatory responsibilities of the Parties in respect of the Manufacture of GMP-grade Product, which shall contain the following provisions (a) Manufacturing audits; (b) reporting
of complaints; (c) notification of regulatory correspondence, including warning letters, recalls, market withdrawals and corrections.; (d) responding to regulatory correspondence; (e) inspections; and (f) recalls, including
financial responsibility. 
 Article 6 FINANCIAL PROVISIONS 
  

	6.1	Invoicing. 

  

	(a)	Each SOW shall specify the Batch Price or Fees, as applicable, for the Services under such SOW. 

  

	(b)	For each Manufacturing SOW, Dicerna shall pay to Protiva in respect of such SOW: 

  

	 	    	***** 

  

	(c)	For all non-Manufacturing SOWs, unless otherwise set forth in the SOW, Protiva shall invoice Dicerna for the Fees ***** in arrears. 

  

	(d)	Protiva will include with each invoice reasonable documentary evidence for the Batch Prices and Fees. Protiva will also provide such additional documentary support or evidence regarding the Batch Prices and Fees as
reasonably requested by Dicerna. 

  
 22 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

	6.2	Rescheduling and Cancellation. 

  

	(a)	Dicerna reserves the right, upon written notice to Protiva, to reschedule or cancel any mutually executed SOW subject to Dicerna’s payment of the applicable actual Reimbursable Expenses caused by such rescheduling
or cancellation. 

  

	(b)	Notwithstanding anything in this Supply Agreement to the contrary, (i) Dicerna shall have no obligation to pay any Reimbursable Expenses caused by any rescheduling or cancellation if the need to so reschedule or
cancel is due to any act or omission by Protiva, its Affiliates or any Permitted Subcontractor, and (ii) Dicerna shall only be required to pay to Protiva ***** percent ***** of the total amount of any Reimbursable Expenses caused by any
rescheduling or cancellation if the need to so reschedule or cancel is due to any Force Majeure Event(other than rescheduling or cancellation when the need to so reschedule or cancel is due to a Force Majeure Event that delays delivery of Dicerna
Materials to Protiva). 

  

	6.3	Payment and Interest. 

  

	(a)	With the exception of the invoices for the Initial Deposit and Initiation Deposit, Dicerna shall pay all invoices within ***** days following Dicerna’s receipt of Protiva’s invoice, by wire transfer of
immediately available funds to a bank account designated in advance in writing by Protiva. 

  

	(b)	Any payments due from one Party to the other Party under this Article VI that are not paid by the date such payments are due shall bear interest from the date such unpaid payments are due until paid in full at the
lesser of: (i) ***** percent ***** per *****; or (ii) the highest amount of interest permitted by Applicable Law. The foregoing interest shall be in addition to any other remedies that either Party may have pursuant to this Supply
Agreement. 

  

	6.4	Payment Procedures and Tax. 

  

	(a)	Remittance of payments under this Article VI shall be made by means of wire transfer of immediately available funds to a bank account designated in advance in writing by Protiva. All amounts payable to Protiva under
this Supply Agreement shall be paid in United States Dollars. In those cases in which the amounts due in United States Dollars is calculated based on one or more currencies other than United States Dollars, such amounts shall be converted into
United States Dollars using the spot exchange rate for the relevant currency on the date of the applicable transaction, as such exchange rate is published by Wall Street Journal (or comparable publication if not available). 

 

	(b)	 Protiva is solely responsible for any sales, use, excise, value-added, services, consumption, or other similar tax that is assessed on the provision
of the Services, Batch Prices or Fees and shall either pay such payment directly or reimburse Dicerna for the same. Any withholding or other taxes that Dicerna or its Affiliates are required by Applicable Law to withhold or pay on behalf of Protiva
may be deducted from such 

  
 23 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

	 	
payments and paid to the appropriate tax authority contemporaneously with the remittance to Protiva, provided that (i) Dicerna promptly furnishes to Protiva proper evidence of the taxes so
paid and (ii) Dicerna cooperates with and furnishes to Protiva appropriate documents to secure application of the most favorable rate of withholding tax under Applicable Law (or exemption from such withholding tax payments, as applicable).
Dicerna and Protiva shall use Commercially Reasonable Efforts to cooperate to minimize any such taxes, assessments and fees to the extent permitted by Applicable Law. 

 

	6.5	Records and Audit. 

 Until the ***** anniversary of the date any book or record is created or such longer
period required by Applicable Law (the “Record Retention Period”), Protiva shall maintain and retain complete and accurate books of account and records covering all transactions relating to payment of amounts that may be due under
Article VI of this Supply Agreement. Upon the reasonable advance notice of Dicerna (of at least ***** days), Protiva shall make such books and records available for inspection and audit by Dicerna’s authorized representative (which shall be a
national certified public accounting firm designated by Dicerna), subject to reasonable precautions to protect the confidential information of Protiva. Dicerna may not audit Protiva’s books and records more than once in any *****-month period.
All audits must be conducted during normal business hours of Protiva and conducted in a manner so as to minimize the impact on the normal operations of Protiva. The accounting firming conducting any such audit must provide the report of its findings
of any audit to both Parties, may only identify in such report whether the amount of Batch Prices and Fees paid was correct and the actual amount of the Batch Prices and Fees payable and may not disclose any other Confidential Information of
Protiva. The auditor’s report and all other information disclosed to the auditor or generated by the auditor in such audit will be the Confidential Information of Protiva. Dicerna shall pay the cost of such audits unless it discovers that
Protiva has overcharged for Batch Prices or Fees during any year in the Record Retention Period by an amount of ***** percent ***** or more, in which case the costs of such audit shall be borne by Protiva. If an audit reveals an underpayment or
overpayment, the Party responsible for making payment shall promptly pay to the other Party the amount of the underpayment or overpayment discovered unpaid under this Section 6.5, subject to Section 6.3(b). 

Article 7 INTELLECTUAL PROPERTY 
  

	7.1	License Agreement. 

  

	(a)	The terms and conditions regarding Dicerna’s use and licensing of certain Patents, Know-How and technology of Protiva and Tekmira are set forth in the License Agreement. 

 

	7.2	Ownership. 

  

	(a)	Protiva is and shall at all times remain the sole and exclusive owner of Protiva’s Confidential Information. 

  

	(b)	Dicerna is and shall at all times remain the sole and exclusive owner of Dicerna’s Confidential Information. 

  
 24 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

	    	***** 

  

	(f)	All determinations of inventorship and authorship required by this Section 7.12 will be determined in accordance with United States Applicable Laws regarding intellectual property. 

 

	(g)	Each Party shall, and shall (i) cause its Affiliates and (ii) use Commercially Reasonable Efforts to cause its employees, agents and contractors to, take all further actions (including execution of written
documents) reasonably requested by the other Party for purposes of vesting ownership of Inventions with such other Party in accordance with this Section 7.2 and otherwise permit any such other Party to fully enjoy its rights in such Inventions.

  
 25 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

	7.3	Prosecution and Maintenance of Joint Patents and Product Composition Patents. 

  

	    	***** 

  

	7.4	Third-Party Infringement of Joint Patents and Product Composition Patents. 

  

	(a)	Each Party shall use Commercially Reasonable Efforts to promptly report in writing to the other Party during the Term any known or suspected commercially relevant infringement by a Third Party of any Joint Patents of
which such Party becomes aware and provide the other Party with all evidence supporting or relating to such infringement in its possession. 

  
 26 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

	    	***** 

  
 27 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

	    	***** 

 Article 8 CONFIDENTIAL INFORMATION AND PUBLICITY 

 

	8.1	Incorporation by Reference. 

 The provisions of Article VI of the License Agreement are herein
incorporated into this Supply Agreement, mutatis mutandis. 
 Article 9 INDEMNIFICATION AND INSURANCE 

 

	9.1	Protiva Indemnification. 

 Protiva agrees to indemnify Dicerna and its Affiliates, and their respective
agents, directors, officers, employees, representatives, successors and permitted assigns (the “Dicerna Indemnitees”) against and to hold each of them harmless from any and all losses, costs, damages, fees or expenses
(“Losses”) actually incurred or suffered by a Dicerna Indemnitee to the extent arising out of or in connection with any claim, suit, demand, investigation or proceeding brought by a Third Party based on: (a) any breach of any
representation, warranty or covenant by Protiva under this Supply Agreement; (b) Protiva’s, its Affiliates’ or its Permitted Contractors’ gross negligence, willful misconduct or violation of Applicable Law or (c) *****. The
foregoing indemnification shall not apply to the extent that any Losses are due to Dicerna’s, its Affiliates’ or its Sublicensees’ gross negligence or willful misconduct, or Dicerna’s breach of Section 12.1(d). 

 

	9.2	Dicerna Indemnification. 

 Dicerna agrees to indemnify Protiva and its Affiliates, and their respective
agents, directors, officers, employees, representatives, successors and permitted assigns (the “Protiva Indemnitees”) against and to hold each of them harmless from any and all Losses actually incurred or suffered by a Protiva
Indemnitee to the extent arising out of or in connection with any claim, suit, demand, investigation or proceeding brought by a Third Party based on: (a) any breach of any representation, warranty or covenant by Dicerna under this Supply
Agreement; (b) Dicerna’s, its Affiliates’ or its Sublicensees’ gross negligence, willful misconduct or violation of Applicable Law; or (c) *****. The foregoing indemnification obligations shall not apply to the extent that
any Losses are due to Protiva’s, its Affiliates or its Permitted Contractors’ gross negligence or willful misconduct. 

  
 28 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

	9.3	Tender of Defense; Counsel. 

 Any Person (the “Indemnified Party”) seeking
indemnification under this Article VII agrees to give prompt notice in writing to the other Party (the “Indemnifying Party”) of the assertion of any claim or the commencement of any action by any Third Party (a “Third Party
Claim”) in respect of which indemnity may be sought under this Article. Such notice shall set forth in reasonable detail such Third Party Claim and the basis for indemnification (taking into account the information then available to the
Indemnified Party). The failure to so notify the Indemnifying Party shall not relieve the Indemnifying Party of its indemnification and hold harmless obligations hereunder, except to the extent such failure shall have materially and adversely
prejudiced the Indemnifying Party. The Indemnifying Party shall be entitled to participate in the defense of any Third Party Claim and shall be entitled to control and appoint lead counsel reasonably satisfactory to the Indemnified Party for such
defense by written notice to the Indemnified Party within ***** calendar days after the Indemnifying Party has received notice of the Third Party Claim, in each case at its own expense; provided, however, that the Indemnifying Party must use
Commercially Reasonable Efforts to conduct the defense of the Third Party Claim in a manner designed to protect the rights of the Indemnified Parties, and otherwise conduct such defense actively and diligently, thereafter in order to preserve its
rights in this regard. The Indemnifying Party shall not be entitled to assume or maintain control of the defense of any Third Party Claim and shall pay the fees and expenses of one counsel retained by the Indemnified Party if: (a) the Third
Party Claim relates to or arises in connection with any criminal proceeding, action, indictment or allegation; (b) the Third Party Claim seeks an injunction or equitable relief against a Indemnified Party or any of its Affiliates; or
(c) the Indemnifying Party has failed or is failing to prosecute or defend vigorously the Third Party Claim. Each Indemnified Party shall obtain the prior written consent of the Indemnifying Party, such consent not to be unreasonably withheld,
delayed or conditioned, before entering into any settlement of a Third Party Claim. Notwithstanding the foregoing, the Indemnifying Party shall not be entitled to enter into or approve any settlement of a Third Party Claim without the consent of the
Indemnified Party (which may be withheld in its sole discretion), if the settlement (i) does not expressly unconditionally release all applicable Indemnified Parties and their Affiliates from all Losses with respect to such Third Party Claim,
(ii) imposes injunctive or other equitable relief against the Indemnified Party or any of its Affiliates, (iii) involves any admission of criminal or similar liability, or (iv) involves any monetary damages that may not be fully
covered by the Indemnifying Party. In the event that the Indemnifying Party fails to assume the defense of the Third Party Claim in accordance with this Section 9.3, (1) the Indemnified Party may defend against the Third Party Claim in any
manner it reasonably may deem appropriate, and (2) the Indemnifying Party shall remain responsible for any Losses of the Indemnified Party as a result of such Third Party Claim. In circumstances where the Indemnifying Party is controlling the
defense of a Third Party Claim in accordance with this Section 9.3, the Indemnified Party shall be entitled to participate in the defense of any Third Party Claim and to employ separate counsel of its choice for such purpose, in which case the
fees and expenses of such separate counsel shall be borne by such Indemnified Party. Notwithstanding anything herein to the contrary, in circumstances where there is a conflict of interest that would reasonably make it inappropriate under applicable
standards of professional conduct to have common counsel for the 

  
 29 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

 
Indemnifying Party and the Indemnified Party, the Indemnified Party shall be entitled to employ separate counsel, that is reasonably acceptable to the Indemnifying Party, and the Indemnifying
Party shall pay the reasonable fees and expenses of such separate counsel. Each Party shall cooperate, and cause their respective Affiliates to cooperate in all reasonable respects, in the defense or prosecution of any Third Party Claim and shall
furnish or cause to be furnished such records, information and testimony, and attend such conferences, discovery proceedings, hearings, trials or appeals, as may be reasonably requested in connection therewith, all at the expense of the Indemnifying
Party. 
  

	9.4	Insurance. 

 Each Party shall maintain insurance, including product liability insurance, with respect to
its activities under this Supply Agreement regarding the Product in such amount as such Party customarily maintains with respect to similar activities for its other products. Each Party shall maintain such insurance for so long as it continues its
activities under this Supply Agreement, the License Agreement or the Quality Agreement, and thereafter for so long as such Party customarily maintains insurance for itself covering similar activities for its other products. 

Article 10 EXPORT 
  

	10.1	General. 

 The Parties acknowledge that the exportation from the United States of materials, products and
related technical data (and the re-export from elsewhere of United States origin items) may be subject to compliance with United States export laws, including the United States Bureau of Export Administration’s Export Administration
Regulations, the Act and regulations of the FDA issued thereunder, and the United States Department of State’s International Traffic and Arms Regulations which restrict export, re-export, and release of materials, products and their related
technical data, and the direct products of such technical data. The Parties agree, under this Supply Agreement, to comply with all export Applicable Laws and to commit no act that, directly or indirectly, would violate any Applicable Laws relating
to the export, re-export, or release of any materials, products or their related technical data to which the United States adheres or with which the United States complies. 
  

	10.2	Delays and Assistance. 

  

	(a)	The Parties acknowledge that they cannot be responsible for any delays attributable to export controls which are beyond the reasonable control of either Party. 

 

	(b)	The Parties agree to provide reasonable assistance to one another in connection with each Party’s efforts to fulfill its obligations under this Article. 

Article 11 TERM AND TERMINATION 
  

	11.1	Term. 

 The term of this Supply Agreement, shall commence on the Effective Date and, unless earlier
terminated as provided herein, shall terminate upon the last to occur of: (a) five (5) years after the Effective Date; (b) the last date of expiry of any GMP Batch of Manufactured Product Manufactured by Protiva hereunder; or
(c) the completion of the activities set forth in Exhibits D. 

  
 30 

	11.2	Termination for Material Breach. 

 If either Party commits a material breach or material default in the
performance or observance of any of its obligations under this Supply Agreement, and such breach or default continues without cure for a period of ***** days after delivery by the other Party of written notice reasonably detailing such breach or
default, then the non-breaching or non-defaulting Party shall have the right to terminate this Supply Agreement, with immediate effect, by giving written notice to the breaching or defaulting Party. The Parties shall retain all rights and remedies
(at law or in equity) in respect of any breach hereof. 
  

	11.3	Rights in Bankruptcy. 

 Each Party (the “Insolvent Party”) shall promptly notify the
other Party (the “Solvent Party”) in writing upon the initiation of any proceeding in bankruptcy, reorganization, dissolution, liquidation or arrangement for the appointment of a receiver or trustee to take possession of the assets
of the Insolvent Party or similar proceeding under law for release of creditors by or against the Insolvent Party or if the Insolvent Party shall make a general assignment for the benefit of its creditors. To the extent permitted by Applicable Law,
if the applicable circumstances described above shall have continued for ***** days undismissed, unstayed, unbonded and undischarged, the Solvent Party may terminate this Supply Agreement upon written notice to the Insolvent Party at any time. 

 

	11.4	Termination of License Agreement. 

 In the event the License Agreement is terminated, this Supply
Agreement shall terminate upon the effective date of the termination of the License Agreement. 
  

	11.5	Consequences of Termination; Survival. 

  

	(a)	Termination of this Supply Agreement shall not relieve the Parties of any obligation accruing prior to or upon such expiration or termination, and the provisions of Article 1 (Definitions and Interpretation), Sections
4.5(e) (Records), 6.3 (Payment and Interest), 6.4 (Payment Procedures and Tax), 6.5 (Records and Audit), Article 7 (Intellectual Property), Article 8 (Confidential Information and Publicity), Article 9 (Indemnification and Insurance), Article 11
(Term and Termination), and Article 12 (General Provisions) shall survive any expiration or termination of this Supply Agreement and Exhibit D. 

  

	(b)	In the event of termination by Dicerna for Protiva’s uncured material breach of this Supply Agreement, Protiva, shall *****. 

  

	(c)	Upon the termination by either Party or both Parties of this Supply Agreement in its entirety, each Party shall promptly return to the other Party all physical manifestations of the other Party’s intellectual
property and Confidential Information, except to the extent that the Party has a license to such Intellectual Property or Confidential Information pursuant to the License Agreement. 

  
 31 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

	11.6	Remedies. 

 The Parties acknowledge and agree that, in the event of a breach or a threatened breach by
either Party of this Supply Agreement for which it shall have no adequate remedy at law, the other Party may suffer irreparable damage and, accordingly, may be entitled to injunctive and other equitable remedies to prevent or restrain such breach or
threatened breach, in addition to any other remedy they might have at law or at equity. In the event of a breach or threatened breach by a Party of any such provision, the other Party shall be authorized and entitled to seek from any court of
competent jurisdiction injunctive relief, whether preliminary or permanent, arising from such breach, which rights shall be cumulative and in addition to any other rights or remedies to which the other Party may be entitled in law or equity. 

Article 12 GENERAL PROVISIONS 
  

	12.1	Representation and Warranties. 

  

	(a)	Mutual Representations and Warranties by Protiva and Dicerna. Each Party hereby represents and warrants to the other Party as of the Effective Date that: 

 

	 	(i)	it is duly organized and validly existing under the laws of the jurisdiction of its incorporation or formation, and has all necessary power and authority to conduct its business in the manner in which it is currently
being conducted, to own and use its assets in the manner in which its assets are currently owned and used, and to enter into and perform its obligations under this Supply Agreement; 

 

	 	(ii)	the execution, delivery and performance of this Supply Agreement has been duly authorized by all necessary action on the part of such Party and its Board of Directors or other governing body and no consent, approval,
order or authorization of, or registration, declaration or filing with any Third Party or Governmental Authority is necessary for the execution, delivery or performance of this Supply Agreement; 

 

	 	(iii)	this Supply Agreement constitutes the legal, valid and binding obligation of such Party, enforceable against it in accordance with its terms, subject to (A) Applicable Laws of general application relating to
bankruptcy, insolvency and the relief of debtors, and (B) Applicable Laws governing specific performance, injunctive relief and other equitable remedies; and 

 

	 	(iv)	neither it nor any of its Affiliates or their employees have ever been (A) convicted of a crime for which a Person can be debarred under Section 306(a) or 306(b) of the Generic Drug Enforcement Act of 1992 or
under 42 U.S.C. Section 1320-7 or (B) sanctioned by, suspended, excluded or otherwise ineligible to participate in any federal health care program, including Medicare and Medicaid or in federal procurement or non-procurement programs. If
at any time this representation and warranty is no longer accurate, Protiva or Dicerna, as the case may be, shall immediately notify the other of such fact. 

  
 32 

	(b)	Protiva Representations, Warranties, and Covenants. Protiva hereby represents, warrants, and covenants to Dicerna that: 

  

	 	(i)	the Manufactured Product, at the time of delivery to Dicerna’s designated carrier, shall: (A) conform to the Specifications; (B) be Manufactured in compliance with the requirements of all Applicable Laws
(including GMP for GMP Batches); (C) comply with Protiva’s SOPs; and (D) be transferred free and clear of any liens, claims or encumbrances of any kind to the extent arising through or as a result of the acts or omissions of Protiva,
its Affiliates or their respective agents; 

  

	 	(ii)	no Manufactured Product constituting or being part of any shipment or other delivery now or hereafter made to Dicerna will be adulterated or misbranded within the meaning of the FD&C Act or would be an article
that could not, under the provisions of the FD&C Act, be introduced into interstate commerce; 

  

	 	(iii)	it owns, lawfully controls or has valid rights to use the Facilities and that the Facilities shall be maintained in such condition as will allow Protiva to Manufacture the Manufactured Product in compliance with and
conformance to all Applicable Requirements (including GMPs at the Facilities where GMP Batches are Manufactured); 

  

	 	(iv)	Protiva shall perform the Services in a diligent, careful, thorough, workmanlike and professional manner, using employees and Permitted Contractors having a level of skill, knowledge, qualifications and experience in
the area commensurate with the requirements of the Services; 

  

	 	(v)	Protiva shall perform the Services and its other obligations herein in compliance with all Applicable Laws; and 

  

	 	(vi)	the Services shall be conducted at and coordinated from the facilities of Protiva under the direction and supervision of a qualified program director employed by Protiva and approved by Dicerna. 

 

	(c)	Tekmira Representations, Warranties, and Covenants. Tekmira hereby represents, warrants, and covenants to Dicerna that: 

  

	 	(i)	as of the Effective Date, it is duly organized and validly existing under the laws of the jurisdiction of its incorporation or formation, and has all necessary power and authority to conduct its business in the manner
in which it is currently being conducted, to own and use its assets in the manner in which its assets are currently owned and used, and to enter into and perform its obligations under this Supply Agreement; 

 

	 	(ii)	as of the Effective Date, the execution, delivery and performance of this Supply Agreement has been duly authorized by all necessary action on the part of Tekmira and its Board of Directors and no consent, approval,
order or authorization of, or registration, declaration or filing with any Third Party or Governmental Authority is necessary for the execution, delivery or performance of this Supply Agreement; 

 

	 	(iii)	 as of the Effective Date, this Section 12.1(c) constitutes the legal, valid and binding obligation of Tekmira, enforceable against it in
accordance with its terms, 

  
 33 

	 	
subject to (A) Applicable Laws of general application relating to bankruptcy, insolvency and the relief of debtors, and (B) Applicable Law governing specific performance, injunctive
relief and other equitable remedies; 

  

	 	(iv)	as of the Effective Date, neither it nor any of its Affiliates or their employees have ever been (A) convicted of a crime for which a Person can be debarred under Section 306(a) or 306(b) of the Generic Drug
Enforcement Act of 1992 or under 42 U.S.C. Section 1320-7 or (B) sanctioned by, suspended, excluded or otherwise ineligible to participate in any federal health care program, including Medicare and Medicaid or in federal procurement or
non-procurement programs. If at any time this representation and warranty is no longer accurate, Tekmira shall immediately notify Dicerna of such fact; and 

  

	 	(v)	Tekmira shall cause Protiva to perform and to comply with the provisions of this Supply Agreement, and shall remain responsible for and guarantee the performance of Protiva under this Supply Agreement, and is liable to
Dicerna for any breach of this Supply Agreement by Protiva and for the actions and omissions of Protiva undertaken pursuant to this Supply Agreement as if taken by Tekmira itself. 

 

	(d)	Dicerna Representations, Warranties, and Covenants. Dicerna hereby represents, warrants, and covenants to Protiva that the Dicerna Materials, at the time of delivery to Protiva, shall (i) conform to all
applicable Raw Material Specifications; (ii) be Manufactured in compliance with the requirements of all Applicable Laws (including GMPs for Dicerna Materials to be used in GMP Batches); and (iii) comply with Dicerna’s SOPs.

  

	(e)	Warranty Disclaimer. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS SUPPLY AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTY OR CONDITIONS OF ANY KIND, EITHER EXPRESS OR IMPLIED, TO THE
OTHER PARTY WITH RESPECT TO ANY INTELLECTUAL PROPERTY, PRODUCTS, GOODS, RIGHTS OR OTHER SUBJECT MATTER OF THIS SUPPLY AGREEMENT AND HEREBY DISCLAIMS ALL IMPLIED CONDITIONS, REPRESENTATIONS, AND WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT OR VALIDITY OF PATENT RIGHTS WITH RESPECT TO ANY AND ALL OF THE FOREGOING. EACH PARTY HEREBY DISCLAIMS ANY REPRESENTATION OR WARRANTY THAT THE DEVELOPMENT, MANUFACTURE OR COMMERCIALIZATION OF ANY
PRODUCT PURSUANT TO THIS SUPPLY AGREEMENT SHALL BE SUCCESSFUL OR THAT ANY PARTICULAR SALES LEVEL WITH RESPECT TO ANY SUCH PRODUCT SHALL BE ACHIEVED. 

  

	12.2	Force Majeure and Delay Events. 

  

	(a)	 Except with respect to payment obligations, a Party shall neither be held liable or responsible to any other Party, nor be deemed to have defaulted
under or breached this Supply Agreement, for failure or delay in fulfilling or performing any term of this Supply Agreement to the extent, and for so long as, such failure or delay is caused by or results

  
 34 

	 	
from causes beyond the reasonable control of the affected Party, including fire, floods, embargoes, power shortage or failure, acts of war (whether war be declared or not), insurrections, riots,
terrorism, civil commotions, strikes, lockouts or other labor disturbances, acts of God or any acts, omissions or delays in acting by any Governmental Authority or any other Party (each a “Force Majeure Event”), and such affected
Party promptly begins performing under this Supply Agreement once such causes have been removed; provided that if Protiva experiences any such event that hinders its ability to Manufacture and supply Manufactured Product to Dicerna, Protiva shall
allocate resources and capacity to Manufacturing and supplying the Manufactured Products to Dicerna on a basis no less favorable to Dicerna than Protiva provides to its other customers or itself. 

 

	(b)	In the case of a Delay Event, Protiva shall be excused from performance hereunder for the period of time attributable to such delay, but only to the extent: (i) Protiva gives Dicerna notice of such Delay Event
promptly after Protiva becomes aware of the Delay Event; (ii) Protiva uses Commercially Reasonable Efforts to perform the applicable Service or other obligation given due regard equally to Protiva’s obligations to Dicerna, to
Protiva’s then-existing obligations to Third Parties and to Protiva’s own internal project timelines; (iii) the occurrence of such Delay Event is not due to an earlier or contemporaneous failure or delay by Protiva, its Affiliates or
Permitted Contractors; and (iv) such Delay Event actually prevents Protiva from the timely performance of the applicable Service or other obligation. 

  

	12.3	Consequential Damages. 

 UNDER NO CIRCUMSTANCES WILL ANY PARTY BE LIABLE TO ANY OTHER PARTY WITH RESPECT
TO THIS SUPPLY AGREEMENT, AND THE ACTIVITIES CONTEMPLATED HEREBY, FOR ANY CONSEQUENTIAL, INDIRECT, SPECIAL, PUNITIVE, INCIDENTAL OR SIMILAR DAMAGES, WHETHER FORESEEABLE OR UNFORESEEABLE AND REGARDLESS OF THE CAUSE OF ACTION FROM WHICH THEY ARISE,
EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES OCCURRING. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 12.3 IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OF A PARTY OR DAMAGES AVAILABLE FOR A PARTY’S BREACH
OF CONFIDENTIALITY OBLIGATIONS IN ARTICLE 8. 
  

	12.4	Assignment. 

 Neither Party shall assign any of its rights and obligations hereunder without the prior
written consent of the other Party, except (a) to a purchaser of all or substantially all of the assets or business of such Party to which this Supply Agreement relates, or to the successor resulting from any merger, acquisition, consolidation
or similar transaction with such Party and (b) to an Affiliate; provided, however, that (i) such assignment to an Affiliate shall not relieve such Party of its obligations herein, and (ii) in each case, the assigning
Party shall provide the other Party with written notice of such assignment. Any purported transfer or assignment in contravention of this Section 12.4 shall, at the option of the non-assigning Party, be null and void and of no effect. This
Supply Agreement shall be binding upon and inure to the benefit of the Parties and their permitted successors and assigns. 

  
 35 

	12.5	Notices. 

 Notices to Dicerna shall be addressed to: 

Dicerna Pharmaceuticals, Inc. 

480 Arsenal St., #120 

Watertown, MA 02472 

United States 

Attention: CEO and President 

With a copy to: 

Dicerna Pharmaceuticals, Inc. 

480 Arsenal St., #120 

Watertown, MA 02472 

United States 

Attention: Chief Financial Officer 

Notices to Protiva shall be addressed to: 

Protiva Pharmaceuticals Corporation 

100-8900 Glenlyon Parkway 

Burnaby, B.C. 

Canada V5J 5J8 

Attention: President & CEO 

Facsimile No.: (604) 630-5103 

Notices to Tekmira shall be addressed to: 

Tekmira Pharmaceuticals Corporation 

100-8900 Glenlyon Parkway 

Burnaby, B.C. 

Canada V5J 5J8 

Attention: President & CEO 

Facsimile No.: (604) 630-5103 

In each case with copy to: 

Orrick, Herrington & Sutcliffe LLP 

51 West 52nd Street 

New York, NY 10019 

Attention:         R. King Milling 

Facsimile No.: (212) 506-5151 

Any party hereto may change their address by giving notice to the other parties in the manner provided in this Section 12.5. Any notice required or
provided for by the terms of this Supply Agreement shall be in writing and shall be (a) sent by certified mail, return receipt requested, postage prepaid, (b) sent via a reputable international express courier service, or (c) sent by
facsimile transmission, with a copy by regular mail. The effective date of the notice shall be the actual date of receipt by the receiving party. 

  
 36 

	12.6	Independent Contractors. 

 It is understood and agreed that the relationship between the Parties is that
of independent contractors and that nothing in this Supply Agreement shall be construed as authorization for either Party to act as the agent for the other Party. 
  

	12.7	Governing Law; Dispute Resolution Arbitration. 

 This Supply Agreement shall be governed and interpreted
in accordance with the substantive laws of the State of New York, excluding its conflicts of laws principles. 
  

	(a)	The Parties and Tekmira recognize that a bona fide dispute as to certain matters may from time to time arise during the Term that relate to a Party or Tekmira’s rights or obligations hereunder. In the event of the
occurrence of any Dispute, the Parties and Tekmira shall first have such Dispute referred to their respective executives designated below for attempted resolution by good faith negotiations within ***** calendar days after such notice is received.
If either Party or Tekmira desires to pursue arbitration under Section 12.7(b) below to resolve any such Dispute, unless expressly provided for otherwise herein, a referral to such executives under this Section 12.7(a) shall be a mandatory
condition precedent. Said designated executives as of the Effective Date are as follows. 

 For Dicerna: Douglas Fambrough,
Ph.D., President and CEO 
 For Protiva: Mark Murray, President and CEO 

For Tekmira: Mark Murray, President and CEO 

In the event that they shall be unable to resolve the Dispute by consensus within such *****-day period, the Dispute shall be finally settled
by binding arbitration as provided below. 
  

	(b)	 Except as expressly otherwise provided in this Supply Agreement, in the event of any dispute arising out of or relating to the interpretation of any
provision of this Supply Agreement or the failure of either Party or Tekmira to perform or comply with any obligation of such party pursuant to this Supply Agreement or the breach, termination or validity hereof (a “Dispute”), such
Dispute will be finally settled by arbitration in accordance with the commercial arbitration rules of the American Arbitration Association, then in force and the Federal Arbitration Act, 9 U.S.C. § 1 et seq., by three (3) arbitrators (the
“Arbitrators”); provided that the appointed arbitrators shall have appropriate experience in the pharmaceutical industry. Dicerna shall appoint one Arbitrator and Protiva and Tekmira, collectively, shall appoint one
Arbitrator, and such two Arbitrators shall jointly appoint the third Arbitrator. If any party is not able to appoint its Arbitrator or the two initial Arbitrators are not able to appoint the third Arbitrator within a reasonable amount of time after
the initiation of such process, the applicable Arbitrator or Arbitrators will be appointed in accordance with the above identified commercial arbitration rules. The place of arbitration will be New York, New

  
 37 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

	 	
York, and the Arbitrators must decide the Dispute in accordance with the substantive laws of the State of New York. The Arbitrators, by accepting their appointment, undertake to conduct the
process such that the award is rendered within ***** months of their appointment and is final and binding upon all parties participating in such arbitration. The judgment rendered by the Arbitrators may, at the Arbitrator’s discretion,
include costs of arbitration, reasonable attorneys’ fees and reasonable costs for any expert and other witnesses. Judgment upon the award may be entered in any court having jurisdiction, or application may be made to such court for judicial
acceptance of the award or an order of enforcement as the case may be. Any period of limitations or survival period that would otherwise expire between the initiation of the procedures described in this Section 12.7 and the conclusion of such
procedures will be extended until ***** days following the conclusion of such procedures. This Section 12.7 does not prohibit a Party or Tekmira from seeking preliminary injunctive relief in aid of arbitration from a court of competent
jurisdiction. 

  

	(c)	The Parties and Tekmira consent to (i) the exclusive jurisdiction of the Federal courts and the State courts of the State of New York, in each case, located in the borough of Manhattan, City of New York (the
“New York Courts”) for (A) any action referenced in Section 12.7(d) and (B) any action in aid of arbitration, for provisional relief of the status quo or to prevent irreparable harm prior to the appointment of the
Arbitrators in Section 12.7(d) above, and (ii) the non-exclusive jurisdiction of the New York Courts for any action to enter or enforce any arbitral award entered in connection with this Supply Agreement. THE PARTIES AND TEKMIRA HEREBY
IRREVOCABLY WAIVE, AND AGREE TO CAUSE THEIR RESPECTIVE AFFILIATES TO WAIVE, THE RIGHT TO TRIAL BY JURY IN SUCH ACTIONS. 

  

	(d)	Unless agreed by the Parties, the foregoing alternative dispute resolution procedures shall not be used with respect to any claim by one Party against another regarding the validity, infringement, misappropriation or
violation of a Patent, copyright, trade secret or trademark. 

  

	12.8	Severability. 

 In the event that any provision of this Supply Agreement is held by a court of competent
jurisdiction to be unenforceable because it is invalid or in conflict with any law of the relevant jurisdiction, the validity of the remaining provisions shall not be affected and the rights and obligations of the Parties and Tekmira shall be
construed and enforced as if this Supply Agreement did not contain the particular provisions held to be unenforceable, provided that the Parties and Tekmira, shall negotiate in good faith a modification of this Supply Agreement with a
view to revising this Supply Agreement in a manner which reflects, as closely as is reasonably practicable, the commercial terms of this Supply Agreement as originally signed. 

 

	12.9	No Implied Waivers. 

 The waiver by either Party or Tekmira of a breach or default of any provision of
this Supply Agreement by the other Party or Tekmira shall not be construed as a waiver of any succeeding breach of the same or any other provision, nor shall any delay or omission on the part of either Party or Tekmira to exercise or avail itself of
any right, power or privilege that it has or may have hereunder operate as a waiver of any right, power or privilege by such Party or Tekmira. 

  
 38 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

	12.10	Headings. 

 The headings of articles and sections contained this Supply Agreement are intended solely for
convenience and ease of reference and do not constitute any part of this Supply Agreement, or have any effect on its interpretation or construction. 
  

	12.11	Entire Agreement; Amendment. 

 This Supply Agreement, the License Agreement and the Quality Agreement
contain the entire understanding of the Parties with respect to the subject matter hereof and thereof and supersede and replace any and all previous arrangements and understandings, whether oral or written, between the Parties with respect to the
subject matter hereof and thereof. This Supply Agreement may be amended only by a writing signed by each of the Parties. 
  

	12.12	Time of the Essence. 

 Protiva acknowledges that time is of the essence with respect to Protiva’s
obligations in each SOW for which any specified performance period, delivery date or other temporal requirement is identified, including all timetables and milestones, and is strictly required for Dicerna in light of its schedules and commitments;
provided, however, that this Section 12.12 shall not apply to any SOW that is not consistent with the current Batch Forecast. 
  

	12.13	Waiver of Rule of Construction. 

 Each Party and Tekmira has had the opportunity to consult with counsel
in connection with the review, drafting and negotiation of this Supply Agreement. Accordingly, the rule of construction that any ambiguity in this Supply Agreement shall be construed against the drafting party shall not apply. 

 

	12.14	No Third Party Beneficiaries. 

 Except as expressly contemplated herein, no Third Party, including any
employee of either Party or Tekmira, shall have or acquire any rights by reason of this Supply Agreement. 
  

	12.15	Further Assurances. 

 Each Party and Tekmira shall provide such further documents or instruments required
by the other Party or Tekmira as may be reasonably necessary or desirable to give effect to the purpose of this Supply Agreement and carry out its provisions. 
  

	12.16	Performance by Affiliates. 

 Either Party may use one or more of its Affiliates to perform its
obligations and duties hereunder, and Affiliates of a Party are expressly granted certain rights herein; provided that each such Affiliate shall be bound by the corresponding obligations of such Party and the relevant Party shall
remain liable hereunder for the prompt payment and performance of all their respective obligations hereunder. 

  
 39 

	12.17	Counterparts. 

 This Supply Agreement may be executed in any number of counterparts in original or by
facsimile or PDF copy, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument. 
  

	12.18	Non-Solicitation of Employees. 

 Each Party agrees that from the Effective Date until the expiration of
***** after the expiration of the Term of this Supply Agreement, it shall not, except upon the express prior written consent of the other Party in each instance, directly or indirectly employ in any capacity (whether as a full or part time employee
or as a consultant or contractor) any individual who is then employed by such other Party and has worked in any capacity related to this Supply Agreement, the License Agreement or the Quality Agreement. This provision shall not apply to or prohibit
general solicitations, such as job postings though public media, not focused on or directed specifically to the personnel of the other Party or hiring or employing any individual who is hired by a Party in response to those general solicitations.

  
  

  
 40 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

 IN WITNESS WHEREOF, authorized representatives of the Parties have executed and delivered this Supply
Agreement effective as of the Effective Date. 
  

									
	PROTIVA BIOTHERAPEUTICS INC.				DICERNA PHARMACEUTICALS INC.
					
	By:		 /s/ B. Cousins
				By:		 /s/ Douglas Fambrough

					
	Name:		 B. Cousins
				Name:		 Douglas Fambrough

					
	Title:		 EVP & CFO
				Title:		 CEO & President

					
	By:		 /s/ Paul Brennan
						
					
	Name:		 Paul Brennan
						
					
	Title:		 SVP Business Development
						
			
	TEKMIRA PHARMACEUTICALS CORPORATION				DICERNA PHARMACEUTICALS INC.
					
	By:		 /s/ B. Cousins
				By:		 /s/ James E. Dentzer

					
	Name:		 B. Cousins
				Name:		 James E. Dentzer

					
	Title:		 EVP & CFO
				Title:		 Chief Financial Officer

					
	By:		 /s/ Paul Brennan
						
					
	Name:		 Paul Brennan
						
					
	Title:		 SVP Business Development
						

 Development and Supply Agreement 

 Exhibit A 

SOW #1 
 See attached. 

 SOW NUMBER: D001 

***** 

  
 A -2 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

 ***** 

  
 A -3 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

 ***** 

  
 A -4 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

 ***** 

  
 A -5 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

 ***** 

  
 A -6 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

 Exhibit B 

SOW #2 
 See attached. 

 SOW NUMBER: D002 

***** 

  
 B -2 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

 ***** 

  
 B -3 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

 ***** 

  
 B -4 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

 ***** 

  
 B -5 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

 ***** 

  
 B -6 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

 Exhibit C 

SOW #3 
 See attached. 

 SOW NUMBER: D003 

***** 

  
 C -2 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

 ***** 

  
 C -3 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

 ***** 

  
 C -4 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

 ***** 

  
 C -5 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

 ***** 

  
 C -6 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

 ***** 

  
 C -7 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

 Exhibit D 

Technical Transfer 
 ***** 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. 

 ***** 

  
 D -2 

THE COMPANY HAS REQUESTED AN ORDER FROM THE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO
SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}]]